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Abstract 
 
Strong adaptive evolutionary forces shape the interactions between pathogens 
and their hosts and typically lead to a stable co-existence. In this process of co-
evolution, mammals have developed restriction factors that limit retrovirus 
infectivity, replication or assembly and narrow the spectrum of potential host 
species. These restriction factors are either constitutively expressed, such as 
APOBEC3 proteins, cytidine deaminases that interfere with reverse transcription, 
or form part of the type I interferon-induced innate immunity, such as TRIM5, a 
member of the tripartite motif protein family that induces degradation of 
retroviral capsid, blocks reverse transcription, or tetherin (BST-2, CD317), which 
inhibits release of nascent viral particles from infected cells. Conversely, viruses 
have evolved antagonists of restriction factors or proteins that limit IFN-induced 
gene expression, thus evading immune surveillance. The interaction between 
host and viral components is delicately balanced and has a significant impact on 
disease outcome. 
Feline immunodeficiency virus (FIV), a lentivirus closely related to human 
immunodeficiency virus (HIV), is a recent introduction into domestic cats and 
causes an immunodeficiency syndrome analogous to human AIDS. Interestingly, 
non-domestic cats such as lion or pumas have co-existed with lentiviruses for 
prolonged periods of time and FIV infections are largely benign. Although plasma 
viral and proviral loads are high in both domestic and non-domestic cats, in vitro 
studies have shown that FIV infection of non-domestic cat T lymphocytes is 
significantly less efficient than that of domestic cat T cells. Thus, this thesis 
tests the hypothesis that the differential disease outcome of FIV infections in 
felids is caused by differences in lentiviral restriction factor activities or their 
sensitivities to FIV restriction factor antagonists. 
Data presented in this study show for the first time that feline APOBEC3 
proteins are expressed in tissues and cell types relevant for FIV infection. The 
APOBEC3 proteins A3H and A3CH exhibited a high antiviral activity against FIV 
lacking the APOBEC3 antagonist Vif in single-cycle replication assays, with no 
difference in activity being detected between domestic and non-domestic cat 
proteins. However, domestic cat A3CH was significantly more sensitive to 
antagonism by FIV Vif than lion or puma A3CH, which would allow efficient viral 
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replication in domestic cat T lymphocytes and subsequently lead to T cell loss 
and immunodeficiency.  
Furthermore, this thesis provides evidence that felid tetherins can 
prevent FIV particle release from producer cells in single-cycle replication 
assays; however, stable expression of domestic and non-domestic cat tetherins 
in feline cell lines did not abrogate FIV replication. Indeed, syncytium formation 
indicative of viral cell-to-cell spread was significantly enhanced in type I 
interferon-treated feline cells infected with CD134-independent strains of FIV 
which often arise in chronic (late) stages of FIV infections in vivo.  
Finally, this work reports the generation of a synthetic domestic cat 
TRIM5α-cyclophilin A fusion protein which was highly efficient at preventing FIV 
pseudotype and productive infection. This novel feline restriction factor 
represents a potent antiviral defence agent with very low potential for toxicity 
and could in future be used in gene therapy approaches to treat FIV-infected 
cats. 
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 Introduction 1
 
1.1 Retroviruses 
 
Viruses are obligate intracellular pathogens that are dependent on the cellular 
transcriptional machinery to replicate their genomes and on a wide array of host 
factors to express viral proteins and to assemble viral particles (virions). Virions 
are the extracellular forms of viruses that are suited for transmission to target 
cells. They are 15 to 400 nm in size and contain the viral nucleic acid enclosed in 
a capsid. In the case of enveloped viruses the capsid is surrounded by the inner 
shell of the particle, located just underneath the lipid membrane (Gomez and 
Hope, 2005). 
Viruses can employ different kinds of replication strategies dependent 
on the nature of their genomes (single or double-stranded RNA or DNA) and the 
mode of replication. However, all viral proteins are expressed through 
messenger RNA (Baltimore, 1971). Retroviruses are enveloped viruses whose 
genetic information is encoded on two single-stranded positive sense RNA 
molecules. Members of the Retroviridae virus family differ from other positive-
stranded RNA viruses by using a replication strategy termed reverse transcription 
(Abbink and Berkhout, 2007). Reverse transcription is a process catalysed by the 
viral enzyme reverse transcriptase (RT) that converts the viral RNA genome into 
a double-stranded DNA copy which is inserted into the host genomic DNA as a 
provirus. Integrated proviral DNA then serves as a template for the transcription 
of viral genes (Nisole and Saib, 2004; Wu, 2004). 
 
1.1.1 Overview 
 
Retroviruses are pathogens of vertebrates that often possess a high degree of 
specificity for their respective hosts. We distinguish between the two 
subfamilies Orthoretrovirinae and Spumaretrovirinae. They are further 
categorised into simple and complex retroviruses according to the complexity of 
their genomes. Simple retroviruses possess the three open reading frames (ORFs) 
gag (group-specific antigen), pol (polymerase) and env (envelope). Gag encodes 
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the structural proteins, pol RT and other enzymes indispensable for replication 
and env the envelope glycoprotein (Env) responsible for cell entry and as such a 
major determinant for host cell tropism. This group is subdivided into the genera 
Alpha-, Beta- and Gammaretrovirus. Complex retroviruses encode a variable 
number of additional regulatory and accessory genes. This group is subdivided 
into the genera Deltaretrovirus, Lentivirus and Spumavirus.  
The infectious property of retroviruses was first discovered in 1904 by 
Vallée and Carré, who showed that equine infectious anemia virus (EIAV) could 
be transmitted between horses with a filtrate (Vallee and Carre, 1904). EIAV is 
transmitted by blood-feeding insects, and clinical signs include recurrent febrile 
episodes, anaemia, thrombocytopenia, oedema, diarrhoea, and lethargy (Leroux 
et al., 2004; Craigo et al., 2005). The first oncogenic retrovirus, avian leukosis 
virus (ALV), was described in 1908 (Ellermann and Bang, 1908). Another 
oncovirus of the Alpharetrovirus genus is the Rous sarcoma virus, the causative 
agent of sarcomas in chickens, which was discovered in 1911 by Rous (Rous, 
1911). In 1936, the mouse mammary tumour virus (MMTV), a member of the 
Betaretrovirus genus, was the first virus shown to cause tumour formation in 
mammals. It can be transmitted vertically from mothers with breast cancer to 
pups in the form of a DNA provirus integrated in the DNA of milk lymphocytes 
(Bittner, 1942). Gammaretroviruses include murine leukaemia virus (MLV) and 
feline leukaemia virus (FeLV). Clinical signs of infection are diverse and include 
immunosuppression and both proliferative and non-proliferative haematopoeitic 
disorders. 
The first human retrovirus to be isolated was human T lymphotropic 
virus type 1 (HTLV-1), a deltaretrovirus, which causes leukaemias and 
lymphomas in mature T cells (Poiesz et al., 1981). Human immunodeficiency 
virus type 1 (HIV-1) was discovered by Montagnier and Gallo in 1983 (Barre-
Sinoussi et al., 1983; Gallo et al., 1984). Human immunodeficiency virus type 2 
(HIV-2) was first described in Senegal, West Africa, in 1985 (Barin et al., 1985). 
Due to the definition of HIV as the cause of human acquired immunodeficiency 
syndrome (AIDS) retrovirology became the most intensively studied field in 
virology. HIV is considered pandemic by the World Health Organization, infecting 
33.4 million people with approximately 2.7 million new infections and 2 million 
deaths per year (World Health Organization, 2008). FIV was discovered in 1987 
(Pedersen et al., 1987). FIV infection of domestic cats causes an AIDS-like 
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syndrome characterised by recurrent gingivitis-stomatitis, cachexia, 
neuropathology and increased incidence of tumour development (Pedersen et 
al., 1987; Hosie et al., 1989; Sparger et al., 1989; Yamamoto et al., 1989; 
Ackley et al., 1990; Torten et al., 1991; Callanan et al., 1992; Callanan et al., 
1996). FIV infects approximately 0.5 million cats in the UK alone and is therefore 
an important veterinary pathogen. Moreover, FIV is a valuable animal model for 
HIV infection in humans for investigating common principles of AIDS progression 
and is used for the development of vaccines for the prevention of lentiviral 
infection. Other lentiviruses of veterinary importance infect cattle (bovine 
immunodeficiency virus; BIV), goats (caprine arthritis/encephalitis virus; CAEV), 
horses (EIAV) and non-human primates (simian immunodeficiency virus; SIV). 
 
1.1.2 Genome organisation 
 
As mentioned above, the genome of simple retroviruses, such as FeLV, contains 
the three ORFs gag, pol and env (Fig. 1-1). These functional genes are flanked N-
terminally by the 5’ long-terminal repeat (5’ LTR) and C-terminally by the 3’ 
long-terminal repeat (3’ LTR). The LTRs contain transcription and regulatory 
elements (Pecon-Slattery et al., 2008a). Signals for gene expression found in 
LTRs include enhancer, promoter, transcription initiation, transcription 
termination and polyadenylation signals. Both the host cell transcriptional 
machinery and virus-encoded proteins, which enhance or modulate LTR activity 
and subsequently the expression of viral RNA and proteins, interact with the 
LTRs (Krebs et al., 2001). Gag encodes for the capsid proteins matrix (MA), 
capsid (CA) and nucleocapsid (NC). Pol encodes for the viral enzymes protease 
(PR), reverse transcriptase (RT) and integrase (IN), and env encodes for the 
envelope glycoprotein (Env), which consists of surface (SU) and transmembrane 
(TM) regions. 
Complex retroviruses, such as the feline foamy virus (FeFV), HIV or FIV 
possess additional regulatory and accessory genes. The regulatory proteins help 
achieve optimal viral replicative efficiency (Emerman and Malim, 1998) and the 
accessory proteins ensure viral persistence, replication, dissemination and 
transmission by supporting the evasion from and the manipulation of the host 
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adaptive and innate immunity or by antagonising host restriction factors (Malim 
and Emerman, 2008). 
FeFV is a member of the genus Spumavirus and encodes for three 
additional genes (Winkler et al., 1997). The two bel genes are located between 
env and the 3’ LTR of the FeFV provirus (Winkler et al., 1997). The Bel1/Tas 
protein of foamy viruses is a transactivator of LTR-directed gene expression 
(Mergia et al., 1990; Keller et al., 1991); (Rethwilm et al., 1991; Keller et al., 
1992; Lee et al., 1992; Lochelt et al., 1993; Zou and Luciw, 1996; Winkler et al., 
1997) and absolutely required for viral gene expression (Lochelt et al., 1991; 
Baunach et al., 1993; Yu and Linial, 1993; Winkler et al., 1997; Wagner et al., 
2000). Bel2 and a protein called Bet are essential for efficient virus production 
(Alke et al., 2001; Lochelt et al., 2005; Munk et al., 2008; Perkovic et al., 2009). 
Bet is generated by a splice event fusing the N-terminal shared domain of bel1 
to the coding sequence of bel2 (Muranyi and Flugel, 1991; Bodem et al., 1998). 
Bel2 is fully contained in Bet. Both bel and bet genes are expressed from an 
internal promoter (IP) located between env and the 3’ LTR (Lochelt et al., 1993; 
Lochelt, 2003). A third ORF corresponding to the human foamy virus (HFV) bel3 
gene (Weissenberger and Flugel, 1994) is not present in FeFV (Winkler et al., 
1997). 
HIV-1 possesses the most complex genome amongst the retroviruses. It 
encodes for the six regulatory/accessory proteins Tat, Rev, Vpr, Vif, Vpu and Nef 
(Emerman and Malim, 1998). Tat, Rev and Vpr are of importance to achieve an 
optimal viral replication efficiency (Emerman and Malim, 1998). Tat 
(transactivator of transcription) regulates high-level HIV-1 transcription from 
proviral DNA, which enables the virus to sustain persistent infections in vivo 
despite a very short half-life of infected cells (Wei et al., 1995; Perelson et al., 
1996). Rev (regulator of virus gene expression) (Zou et al., 1997; Lockridge et 
al., 1999; Miller et al., 2000) is a critical factor for virus replication (Pecon-
Slattery et al., 2008a) as it permits nuclear export of the unspliced viral 
transcripts in infected cells (Malim et al., 1989c; Pollard and Malim, 1998). Vpr 
(viral protein R) acts in a complementary (but mechanistically distinct) fashion 
to Rev and facilitates nuclear import of viral DNA (Emerman and Malim, 1998). 
Another function of Vpr is to delay or arrest infected cells in the G2 phase of the 
cell cycle. Because the HIV-1 LTR is more active in G2 than in any other phase 
(Goh et al., 1998) transcription is maximised which can be an important 
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selective advantage for the virus. The vif (virus infectivity factor) gene is 
present in all known lentiviruses except for EIAV. Vif enhances viral infectivity 
(Fisher et al., 1987; Strebel et al., 1987; Gabuzda et al., 1992; Kishi et al., 1992; 
Von Schwedler et al., 1993; Kao et al., 2003) and is essential for productive 
infection in cells such as primary peripheral blood lymphocytes and macrophages 
and in some immortalised T-cell lines (Gabuzda et al., 1992; Von Schwedler et 
al., 1993). Vpu (viral protein U) and Nef (negative factor) down-regulate the 
primary receptor for HIV-1, CD4. CD4 binds to nascently synthesised HIV-1 Env 
protein in the endoplasmic reticulum (ER) (Crise et al., 1990). Vpu also binds to 
CD4 in the ER and targets it for proteolysis (Schubert et al., 1998), thereby 
decreasing the ability of Env to transit to the cell surface (Willey et al., 1992b). 
 
 
 
Figure 1-1 Genome organisation of simple and complex retroviruses. Feline 
leukaemia virus (FeLV) is a simple retrovirus belonging to the Gammaretrovirus 
genus and possesses three open reading frames, as well as 5’ and 3’ long 
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terminal repeats (LTRs). Feline foamy virus (FeFV), human immunodeficiency 
virus type I (HIV-1) and feline immunodeficiency virus (FIV) belong to the complex 
retroviruses and have an additional suite of accessory genes. Gag, group-specific 
antigen; pol, polymerase; env, envelope glycoprotein; MA, matrix; CA, capsid; NC, 
nucleocapsid; PR, protease; RT, reverse transcriptase; DU, dUTPase; IN, 
integrase; nef, negative factor; orf2, open reading frame A; rev, regulator of virus 
gene expression; tat, transactivator of transcription; vif, virus infectivity factor; vpu, 
viral protein U. 
 
In contrast to Vpu, Nef acts to remove CD4 that is already located on the cell 
surface by endocytosis (Greenberg et al., 1997; Le Gall et al., 1998; Piguet et 
al., 1998). The rationale for this is that CD4-Env interactions on the cell surface 
could reduce virion release or inhibit the incorporation of Env into virions, which 
is prevented by Nef-initiated CD4 endocytosis (Lama et al., 1999; Ross et al., 
1999). Both Vpu and Nef also downregulate the expression of the major 
histocompatibility complex I (Schwartz et al., 1996; Kerkau et al., 1997; Collins 
et al., 1998; Roeth and Collins, 2006), which potentially helps to avoid host 
immune surveillance. 
Tat, Vpr, Vpu and Nef are absent from the FIV genome. However, it 
encodes for the proteins OrfA (also called Orf2) and deoxyuridine triphosphate 
nucleotidohydrolase (dUTPase). OrfA is a transactivator necessary for productive 
FIV replication in primary T lymphocytes as well as in some feline T cell lines 
(Phillips et al., 1990; Sparger et al., 1992; Tomonaga et al., 1993; Sparger et al., 
1994; Waters et al., 1996; de Parseval and Elder, 1999). OrfA deletion mutants 
have been associated with decreased viral replication and pathogenicity (Sparger 
et al., 1994; Inoshima et al., 1996; Inoshima et al., 1998b; Norway et al., 2001; 
Gemeniano et al., 2003; Gemeniano et al., 2004). In addition, it has been shown 
that OrfA induces G2 cell cycle arrest (Gemeniano et al., 2004) and down-
regulates cell surface expression of the FIV primary binding receptor, CD134 
(Hong et al., 2010). Studies also suggested that OrfA can affect later steps of 
virus replication, such as particle formation or release, and possibly early steps, 
such as binding and entry (Gemeniano et al., 2003). Overall, it seems that OrfA 
is exhibiting multiple functions homologous to HIV Vpr, Vpu, Tat, or Nef (Malim 
and Emerman, 2008). dUTPase is encoded specifically in non-primate lentivirus 
genomes and forms part of the pol gene (Payne and Elder, 2001). dUTPase 
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prevents uracil misincorporations during viral replication (Elder et al., 1998; 
Inoshima et al., 1998a) and dUTPase-defective FIV cannot replicate in feline 
macrophages (Lerner et al., 1995).  
 
1.1.3 Replication cycle 
 
In general, the retrovirus life cycle can be divided into early and late stages. The 
early stages comprise the attachment of virions to the target cell and their 
fusion with the target cell membrane, uncoating of the viral core and reverse 
transcription of viral RNA into DNA, nuclear import of the viral DNA and its 
integration into the target cellular genome. The late stages of the retrovirus life 
cycle include virus replication, assembly and egress.  
Because the HIV-1 life cycle (Fig. 1-2) has been studied in far greater 
detail than the FIV life cycle, all life cycle stages mentioned in this chapter refer 
to HIV-1 rather than FIV, unless otherwise stated. 
 
1.1.3.1 Cellular entry 
 
HIV transmission between individuals occurs mainly through exchange of blood or 
other bodily fluids but vertical transmission through breast milk has also been 
described. FIV is transmitted between cats through deep bite wounds and 
scratches caused by fighting. HIV targets T lymphocytes, macrophages and, to 
some extent, dendritic cells (DCs). Its cell tropism is determined by the cell 
surface receptors required for target cell attachment and entry. HIV uses CD4 as 
its primary cell entry receptor (Dalgleish et al., 1984; Klatzmann et al., 1984; 
Maddon et al., 1986; Clapham and McKnight, 2001; Clapham and McKnight, 2002) 
and the chemokine receptors CCR5 (Alkhatib et al., 1996; Deng et al., 1996; 
Dragic et al., 1996; Trkola et al., 1996) and CXCR4 (Choe et al., 1996; Feng et 
al., 1996; Oberlin et al., 1996; Bleul et al., 1997) as co-receptors. Co-receptor 
usage is strain-dependent. R5 strains of HIV-1 use CCR5 and are able to enter 
macrophages, DCs and T lymphocytes, whereas X4 strains of HIV-1 use CXCR4 
and can infect CD4+ T lymphocytes only (Doms and Trono, 2000). In early stages 
of infection, CCR5-tropic HIV-1 strains dominate and infect CCR5-expressing 
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immune cells of the mucosa (de Roda Husman and Schuitemaker, 1998; Clapham 
and McKnight, 2002); (Miller and Shattock, 2003; Davis and Doms, 2004; Moore et 
al., 2004; Wilflingseder et al., 2005). Mucosal macrophages and DCs migrate to 
draining lymph nodes where they infect susceptible T lymphocytes (Clapham and 
McKnight, 2002; Davis and Doms, 2004; Moore et al., 2004; Wilflingseder et al., 
2005). Mucosal DCs can capture viral particles via interactions between HIV-1 
Env and the C-type mannose binding lectins DC-SIGN (DC-specific intercellular 
adhesion molecule-grabbing non-integrin) and DC-SIGNR (DC-SIGN-related) 
(Geijtenbeek et al., 2000; Pohlmann et al., 2001) and promote HIV-1 
internalisation, allowing the virus to remain infectious until it can be presented 
to T lymphocytes (van Kooyk and Geijtenbeek, 2003). HIV-1 is capable of 
switching its co-receptors in vivo. In about 50% of untreated HIV-1 infections the 
evolution of R5X4- and X4-tropic viral variants can be observed (Connor et al., 
1997). This is accompanied by a change in target cell tropism from macrophages 
to T lymphocytes and the progression to AIDS (Nielsen et al., 1993). R4-tropic 
viruses display a broader T lymphocyte tropism than R5-tropic viruses (Bleul et 
al., 1997; Clapham and McKnight, 2002). In addition to CCR5 and CXCR4, HIV-2 
can also use CCR1, CCR2b and CCR3 as co-receptors in vitro (Maddon et al., 
1986; Sattentau et al., 1988; Alkhatib et al., 1996; Deng et al., 1996; Clapham 
and McKnight, 2002). Both HIV-1 and HIV-2 can use the chemokine receptor D6 
to infect astrocytes in the brain (Neil et al., 2005).  
FIV and HIV display a similar cell tropism; however, because feline CD4 is 
expressed only in T lymphocytes but is absent from macrophages or DCs (Ackley 
et al., 1990), CD4 was excluded as primary receptor for FIV (Willett et al., 1991; 
Hosie et al., 1993; Norimine et al., 1993). Instead, primary strains of FIV use the 
feline homologue of OX40 (CD134), a member of the tumour necrosis factor 
receptor/nerve growth factor receptor (TNFR/NGFR) superfamily (Shimojima et 
al., 2004). CD134 is expressed in activated CD4+ T lymphocytes (Paterson et al., 
1987; Mallett et al., 1990; de Parseval et al., 2004; Joshi et al., 2005) and at low 
levels in activated CD8+ T lymphocytes (Baum et al., 1994; Al Shamkhani et al., 
1996), macrophages and activated B cells (Durkop et al., 1995). CD134-
dependent infection requires co-expression of CXCR4 (Shimojima et al., 2004). 
Interestingly, during late (chronic) stages of FIV infections, CD134-independent 
strains of FIV can arise that can enter the cell via CXCR4 only, enabling them to 
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also target CD8+ T lymphocytes and B cells (Willett et al., 1997a; Willett et al., 
1997b; Hosie et al., 1998).  
The adsorption of HIV-1 to target cells prior to receptor engagement is 
aided by host cell surface molecules like heparin sulphate proteoglycan (Mondor 
et al., 1998), LFA-1 (Fortin et al., 1998) and nucleolin (Nisole et al., 1999). The 
retrovirus-receptor interactions that lead to cell entry require a series of steps 
that have been particularly well studied for HIV-1 (Nisole and Saib, 2004). HIV-1 
envelope glycoproteins are organised into trimeric spikes displayed on the 
surface of the viral particle. Each spike comprises a trimer of three 
transmembrane gp41 (TM) subunits non-covalently bound to a trimer of three 
exterior gp120 (SU) subunits (Kowalski et al., 1987). Gp120 consists of variable 
(V1-V5) and conserved regions (Starcich et al., 1986). V1 to V4 form surface-
exposed loops, and the conserved regions are involved in interactions with gp41 
and the viral receptors (Starcich et al., 1986).  
In a first step, the HIV-1 Env gp120 subunit engages CD4. The binding 
reaction induces a conformational change in gp120, namely the repositioning of 
V1/V2 and V3, which exposes the co-receptor binding site (Kwong et al., 1998; 
Rizzuto et al., 1998; Doms, 2000; Rizzuto and Sodroski, 2000). Co-receptor 
binding in turn leads to a conformational rearrangement of gp41, which triggers 
fusion of Env with the host cell membrane and entry of the viral core into the 
host cell cytoplasm (Kwong et al., 1998). In addition to receptor-mediated cell 
entry, HIV-1 uses clathrin-mediated endocytosis (McClure et al., 1988; Marsh and 
Pelchen-Matthews, 2000; Fredericksen et al., 2002; Vidricaire et al., 2003) 
(Daecke et al., 2005; Wei et al., 2005) for cell entry; however, particles entering 
by endocytosis are not infectious as they are degraded by the proteasome 
(Schwartz et al., 1998). 
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Figure 1-2 HIV-1 replication cycle. (1) Virions bind to the primary cell-entry 
receptor CD4 (CD134 for FIV) on the surface of target cells. Receptor binding 
causes a conformational change in the viral envelope glycoprotein (Env) that 
enables co-receptor binding. The main co-receptors for HIV-1 are the chemokine 
receptors CCR5 and CXCR4 (FIV uses CXCR4 only). (2) Virions enter the target 
cell by fusion between viral and cellular membranes. Viral cores are released into 
the cytoplasm. (3) The viral cores interact with the cellular microtubule and actin 
network (not shown) and are rapidly routed to the nuclear membrane where they 
bind to nuclear pore complexes. Within intact cores reverse transcription 
complexes (RTCs) are formed. These are HIV-1 complexes that undergo reverse 
transcription, the conversion of the single-stranded, positive-sense RNA viral 
genome into double-stranded DNA (Arhel, 2010). Upon completion of reverse 
transcription, uncoating of viral cores (the loss of capsid proteins) is initiated and 
RTCs mature into pre-integration complexes (PICs). (4) Nuclear localisation 
signals in integrase (IN), matrix (MA) and HIV-1 viral protein R (Vpr) and the 
central DNA flap in the viral cDNA enable PICs to enter the nucleus in the absence 
of cell division. (5) IN catalyses the integration of the viral cDNA into the host cell 
genome. (6) The integrated viral cDNA is transcribed along with host genes and 
newly synthesised viral RNA is exported into the cytoplasm with the help of the 
regulator of viral gene expression protein (Rev). (7) Viral proteins are translated in 
the cytoplasm and are, together with viral RNA, transported to lipid rafts in the host 
cell plasma membrane, where (8) assembly of viral particles and their budding 
from the host cell occur. (9) The nascent viral particles then mature and are now 
infectious for target cells. Figure adapted from Arhel et al. (2007). 
 
1.1.3.2 Uncoating and reverse transcription 
 
Once inside the cytoplasm, viral particles undergo uncoating and reverse 
transcribe their single-stranded, positive sense RNA genomes into double-
stranded cDNA capable of integrating into the host genome. In order to be 
transported from the plasma membrane to the nuclear membrane viral particles 
interact with cellular cytoskeleton components such as cortical actin 
(Bukrinskaya et al., 1998; Ploubidou and Way, 2001) or the microtubule network 
(McDonald et al., 2002).  
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 There has been a lot of controversy about the timing of uncoating (the 
rapid disassembly of the viral capsid) and reverse transcription (Arhel, 2010). It 
has been thought previously that capsid disassembly and loss of CA occurs shortly 
after cell entry (Dvorin and Malim, 2003; Bukrinsky, 2004; Lehmann-Che and 
Saib, 2004; Suzuki and Craigie, 2007) and that complete uncoating is required for 
reverse transcription complex (RTC) formation and the initiation of reverse 
transcription (Mortuza et al., 2004). RTCs are viral complexes containing MA, PR, 
RT, IN, Vif, Vpr and two copies of the single-stranded plus-sense RNA genome as 
well as numerous cellular proteins (Bukrinsky et al., 1993b; Peterlin and Trono, 
2003), in which reverse transcription occurs (Telesnitsky and Goff, 1997; Basu et 
al., 2008). However, uncoating may be a gradual process which is still ongoing 
while reverse transcription has already been initiated (Warrilow et al., 2009; 
Hulme et al., 2011). In this scenario molecular rearrangements during reverse 
transcription may trigger conformational changes and a stepwise disassembly of 
the viral capsid (Arhel, 2010). Current data suggest a third model that proposes 
that uncoating occurs in close proximity to nuclear pores in the nuclear 
membrane upon completion of reverse transcription (Dismuke and Aiken, 2006; 
Arhel et al., 2007; Schaller et al., 2011). The role of an intact capsid structure 
may be to concentrate RT enzyme near the target RNA (Klarmann et al., 1993). 
While it was thought originally that uncoating was a prerequisite for the 
initiation of reverse transcription, this third model implies that completion of 
reverse transcription is essential for uncoating to occur (Arhel, 2010).  
The regulation of the timing of reverse transcription and uncoating is 
crucial for successful nuclear import (Forshey et al., 2002; Dismuke and Aiken, 
2006; Iordanskiy et al., 2006; Arhel et al., 2007; Yamashita et al., 2007). In the 
process of reverse transcription the enzyme reverse transcriptase (RT) catalyses 
the conversion of single-stranded plus-sense RNA to double-stranded DNA. The 
first step of reverse transcription is the synthesis of minus-strand strong-stop 
DNA at the primer binding site (PBS) at the 5’ end of the RNA genome using a 
lysine tRNA (tRNALys; contained within the virion) as a primer (Wain-Hobson et 
al., 1985; Guyader et al., 1987). The minus-strand strong-stop DNA is then 
transferred to the 3’ end of the RNA genome and anneals to a complementary 
sequence in the R (repeated) region of the LTR and the synthesis of the minus-
strand DNA is completed. RNase H activity of reverse transcriptase degrades the 
RNA matrix. Plus-strand DNA synthesis is initiated from two RNA regions that are 
34 
 
 
resistant to RNase H digestion because they contain a unique poly purine tract 
(PPT) sequence (Charneau et al., 1992; Charneau et al., 1994; Telesnitsky and 
Goff, 1997). Lentiviruses initiate plus-strand DNA synthesis from the central and 
3’ PPT (cPPT and 3’ PPT, respectively). DNA is copied into the PBS of the lysine 
tRNA molecule, and the tRNA is degraded by RNase H. The PBS on the plus-
strand DNA is now exposed so that plus-strand DNA can anneal to the PBS at the 
3’ end of the minus-strand DNA in a second strand transfer event. This strand 
transfer leads to the formation of a circular structure. Both plus-sense and 
minus-sense DNA syntheses are completed at the central termination sequence 
(CTS) in the centre of the genome. The downstream strand is displaced over 99 
nucleotides creating the central DNA flap (Charneau et al., 1994). Reverse 
transcription generates pre-integration complexes (PICs) which contain MA, PR, 
RT, IN and Vpr (Farnet and Haseltine, 1991; Bukrinsky et al., 1993b; Miller et al., 
1997; Iordanskiy et al., 2006; Suzuki and Craigie, 2007) but are lacking CA 
proteins (Farnet and Haseltine, 1991; Miller et al., 1997). PICs also contain many 
cellular factors such as the high mobility group protein HMG-I (Y) (Miller et al., 
1997) and LEDGF/p75 (lens epithelium-derived growth factor/transcriptional co-
activator p75) (Llano et al., 2004; Maertens et al., 2004) which may aid the 
association of the PIC with chromatin or integration (Miller et al., 1997; Ciuffi et 
al., 2005; Emiliani et al., 2005).  
 
1.1.3.3 Nuclear import and integration 
 
The next step in the retrovirus life cycle is nuclear import and integration of the 
viral DNA into the host cell genome. Nuclear import of most retroviruses is cell 
cycle-dependent and requires the breakdown of the nuclear membrane during 
mitosis (Roe et al., 1993; Lewis and Emerman, 1994). Lentiviruses have the 
unique ability to replicate in metabolically active non-dividing cells (Gartner et 
al., 1986; Weinberg et al., 1991; Lewis et al., 1992) such as terminally 
differentiated macrophages or quiescent T lymphocytes as a result of active 
nuclear import of their genomes across the nuclear membrane (Bukrinsky et al., 
1992). Nuclear pore complexes (NPCs) are known to mediate transport of 
macromolecules of up to 39 nm in diameter (Pante and Kann, 2002; Tran and 
Wente, 2006) from the cytoplasm into the nucleoplasm through a central nuclear 
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pore channel (Fried and Kutay, 2003). Curiously, the stokes diameter of the HIV-
1 PIC has been determined to be 56 nm (Yamashita and Emerman, 2004) so that 
passive transport through nuclear pores cannot take place. Instead, nuclear 
localisation signals (NLS) in IN (Gallay et al., 1997; Bouyac-Bertoia et al., 2001), 
MA (Bukrinsky et al., 1993a; Bukrinsky et al., 1993b; Von Schwedler et al., 1994; 
Dubrovsky et al., 1995; Jenkins et al., 1998; Peterlin and Trono, 2003) and Vpr 
(Heinzinger et al., 1994; Fouchier et al., 1998; Popov et al., 1998; Vodicka et 
al., 1998; de Noronha et al., 2001; Le Rouzic et al., 2002) enable signal-
mediated nuclear import via interactions with nucleocytoplasmic shuttling 
receptors of the karyopherin β family. The nuclear impact factors transportin-3 
(TNPO3) (Christ et al., 2008; Goff, 2008; Lee et al., 2010), importins α, β (Fried 
and Kutay, 2003) and 7 (Zaitseva et al., 2009) as well as nucleoporins (Woodward 
et al., 2009) are required for infection of both dividing and non-dividing cells. 
Furthermore, the central DNA flap in the viral cDNA has been shown to 
enhance nuclear localisation of HIV-1 PICs (Charneau et al., 1992; Hungnes et 
al., 1992; Charneau et al., 1994; De Rijck et al., 2005). Stable integration of 
viral cDNA into the host cell genome is catalysed by IN. It was previously thought 
that HIV-1 integration would occur at random sites. Recently however, it has 
been shown that integration is influenced by chromatin structure (Pryciak et al., 
1992) and that HIV-1 prefers gene-rich regions of the genome and actively 
transcribed genes (Schroder et al., 2002; Wu et al., 2003).  
 
1.1.3.4 Transcription and translation  
 
Once integration of HIV-1 into the host genome has occurred, the provirus 
behaves like any human gene and transcription is initiated at the 5’ end of the 
proviral genomic DNA and terminated at its 3’ end (Jones and Peterlin, 1994). In 
the early stages of viral transcription, host RNA polymerase II interacts with 
cellular transcription factors and the proviral LTR. The LTR contains promoter 
elements and enhancer sequences. The core promoter contains the initiator (Inr) 
and a TATA box (Berkhout and Jeang, 1992; Jones and Peterlin, 1994). Upstream 
of Inr are three Specificity Protein 1 (SP1) transcription factor binding sites 
(Berkhout and Jeang, 1992; Jones and Peterlin, 1994). Together, these elements 
position RNA polymerase II on the proviral DNA to initiate transcription. Further 
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upstream is the enhancer, which can bind the transcription factors nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-kB) and nuclear factor 
of activated T cells (NFAT) (Jones and Peterlin, 1994), which ensure that virus 
replication proceeds at high levels. Downstream of Inr lays a regulatory element 
known as transactivation response (TAR) element. Low levels of basal 
transcription drive the synthesis of HIV-1 transcription factor Tat transcripts. Tat 
is then translated in the cytoplasm and shuttled back into the nucleus with the 
help of its NLS. In a second phase of viral transcription, Tat and its cellular co-
factor, positive transcription elongation factor B (P-TEFb), interact with TAR to 
allow RNA polymerase II to generate full-length viral transcripts (Berkhout et al., 
1989; Dingwall et al., 1989; Wei et al., 1998; Isel and Karn, 1999; Kao et al., 
2003; Raha et al., 2005) and to increase transcription from the HIV-1 LTR several 
hundred-fold (Taube et al., 1999).  
FIV lacks a tat gene and TAR but it encodes for OrfA, which transactivates 
transcription at low levels and is essential for productive FIV replication in 
primary T lymphocytes (Phillips et al., 1990; Sparger et al., 1992; Tomonaga et 
al., 1993; Sparger et al., 1994; de Parseval and Elder, 1999).  
During HIV-1 transcription, three classes of transcripts are synthesised 
that give rise to approximately 30 different viral transcripts generated by 
alternative splicing (Bohne et al., 2005). These include unspliced, 9-kb mRNA 
species that encode for the Gag/Pol polyprotein (Kim et al., 1989; Arrigo et al., 
1990; Schwartz et al., 1990; Neumann et al., 1994), singly spliced, 4-kb mRNAs 
that encode Vif, Vpr, Vpu and Env (Arrigo et al., 1990), and multiply-spliced 
mRNA species that encode for Tat, Rev and Nef (Robert-Guroff et al., 1990; 
Schwartz et al., 1990). Nuclear export of intron-containing mRNAs is inhibited by 
cellular commitment factors in the nucleus (Legrain and Rosbash, 1989; Cullen, 
2003b) and HIV-1 is dependent on Rev to transport unspliced and singly spliced 
RNA species out of the nucleus (Malim et al., 1989a; Malim et al., 1989c). Rev 
binds directly to a RNA secondary structure present within the 3’ end intron 
region of all incompletely spliced HIV-1 mRNAs called RRE (Rev Responsive 
Element) (Chang and Sharp, 1989; Malim et al., 1989b; Zapp and Green, 1989; 
Hope et al., 1990). Rev multimerises upon RRE binding which initiates a complex 
with the cellular exportin-1 (CRM-1) and the GTPase Ran (Fornerod et al., 1997; 
Askjaer et al., 1998). CRM-1 targets the complex to the nuclear pore (Fornerod 
et al., 1997; Neville et al., 1997; Cullen, 2003a). After translocation to the 
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cytoplasm, Ran-GTP is converted into Ran-GDP, and Ran, exportin-1 and Rev 
dissociate from the viral RNA. Rev is then recycled back into the nucleus by 
importin β from which it dissociates in the nucleoplasm through interaction with 
Ran-GTP (Henderson and Percipalle, 1997; Askjaer et al., 1998; Fischer et al., 
1999; Cullen, 2003a). Incompletely spliced viral RNA is now available for splicing 
and translation on ribosomes or packaging into virions.  
 
1.1.3.5 Particle assembly and egress 
 
The retrovirus life cycle is completed with the assembly of viral particles and 
their release from the producer cell. Virion assembly is driven by retroviral Gag 
precursor polyprotein (Pr55Gag) which is translated on the cytoplasm on free 
polysomes (Spearman, 2006). In fact, HIV-1 Pr55Gag expression alone is sufficient 
for the production of virus-like particles (VLPs) that are morphologically 
indistinguishable from immature viral particles (Gheysen et al., 1989).  
The HIV-1 Pr55Gag contains three major domains that play a critical role in 
the assembly process: a membrane binding domain (M), a Gag-Gag interaction 
domain (I) and a late domain (L). The M domain lays within MA and is important 
for targeting of Pr55Gag to the inner leaflet of the plasma membrane and for the 
recruitment of viral envelope glycoproteins into virions (Freed and Martin, 1995; 
Freed and Martin, 1996; Freed, 1998). HIV-1 Env precursors are synthesised on 
endoplasmic reticulum-bound ribosomes and transported to the plasma 
membrane through the secretory pathway (Spearman, 2006). In the trans-Golgi 
network, the Env precursor gp160 is proteolytically cleaved into gp41 (TM) and 
gp120 (SU) (Decroly et al., 1994) and Env trimers are incorporated into the 
forming viral particle. The membrane-targeting activity of the M domain in MA 
relies on myristoylation of the MA N-terminus and a patch of basic amino acids 
(Yuan et al., 1993; Freed et al., 1994; Spearman et al., 1994; Zhou et al., 1994; 
Hill et al., 1996; Dalton et al., 2007).  
The I domain is located in the C-terminus of CA and the N-terminus of the 
NC region of Pr55Gag and mediates Pr55Gag monomer 
interactions/multimerisation, RNA binding and formation of preassembled virion 
complexes (Rein et al., 1998; Burniston et al., 1999; Cimarelli et al., 2000) 
(Sandefur et al., 2000; Derdowski et al., 2004). Encapsidation of full-length HIV-
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1 RNA depends on binding of NC to the RNA packaging signal Ψ (Aldovini and 
Young, 1990; South and Summers, 1993; Dannull et al., 1994; Tsukahara et al., 
1996; Dorman and Lever, 2000) and coincides with packaging of Vif (Liu et al., 
1995; Karczewski and Strebel, 1996). Pr55Gag multimerisation and RNA 
recruitment is followed by the formation of Gag/Gag-Pol complexes, which are 
also targeted to the plasma membrane.  
The L domain is on the N-terminus of HIV-1 p6 (FIV p2) and is essential for 
viral budding. A PTAP (Pro-Thr-Ala-Pro) motif in p6 recruits the cellular protein 
Tsg101 (Garrus et al., 2001; Martin-Serrano et al., 2001; VerPlank et al., 2001; 
Carter, 2002; Freed, 2003). P6 binding to Tsg101 recruits the endosomal sorting 
complex required for transport (ESCRT) machinery (Babst et al., 2000; Katzmann 
et al., 2001; Bache et al., 2003; Pornillos et al., 2003). This machinery, which is 
normally involved in intracellular sorting of membrane proteins and membrane 
scission, is hijacked by retroviruses to exit infected cells (Gomez and Hope, 
2005). P6 also recruits HIV-1 Vpr into the viral particle.  
HIV-1 buds from lipid rafts in the plasma membrane. These are detergent-
resistant plasma membrane regions enriched in glycosphingolipids, 
sphingomyelin, cholesterol and glycosylphophatidylinositol (GPI)-linked proteins 
(Brown, 2002). Release of HIV-1 from infected cells can be directional with virus 
being released to sites of cell-cell contact (termed infectious synapses; (Jolly et 
al., 2004)) to facilitate infection of target cells (McDonald et al., 2003). After 
budding of the immature virion, the radially arranged Pr55Gag molecules within 
the virions are dismantled and viral protease (PR) cleaves Pr55Gag into MA, which 
coats the inner leaflet of the viral membrane; CA, which forms a cone-shaped 
core that contains two copies of genomic viral RNA; and NC, which is bound to 
genomic RNA, to create a mature, infectious viral particle. 
 
1.2 Immunology of FIV infections of the domestic cat 
 
FIV infection of domestic cats (Felis catus) leads to the development of a severe 
immunodeficiency similar to AIDS in humans. Like HIV, FIV targets and depletes 
CD4+ T lymphocytes and causes an inversion of the CD4+/CD8+ ratio. Therefore, 
FIV infections are not only studied as an important global veterinary pathogen 
but also serve as a small animal model for HIV infections. FIV was isolated in 
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1986 from a domestic cat exhibiting multiple opportunistic infections and AIDS-
like signs (Pedersen et al., 1987).  
 
1.2.1 Course of FIV infections 
 
The course of disease in FIV and HIV infections is strikingly similar (Fig. 1-3). It 
can be divided into three stages: a relatively short acute phase (four to eight 
weeks), a prolonged period of clinical latency (several years) and a terminal 
phase (several months for FIV; two to three years for HIV).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 Schematic course of a FIV infection. The graph shows infection 
stage-dependent changes in peripheral CD4+ T lymphocyte counts, plasma 
viraemia and anti-FIV antibody concentration. Figure adapted from Weiss (1993). 
 
Following infection of a cat with FIV the primary stage of disease is 
characterised by increasing viral loads associated with mild signs such as febrile 
episodes, weight loss, lymphadenopathy and neutropenia. Because the virus 
targets CD4+ T lymphocytes the number of T lymphocytes in the peripheral blood 
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sharply decreases. This acute phase is followed by a period of clinical latency in 
which cats are usually asymptomatic. Virus production in the peripheral blood is 
limited by the onset of robust humoural and cellular antiviral immune responses 
(see Section 1.2.2) (English et al., 1993; Dean et al., 1996). However, the 
number of CD4+ T lymphocytes gradually declines (Yamamoto et al., 1988; 
English et al., 1994; Bendinelli et al., 1995). Once it falls below a certain 
threshold the feline immune system becomes severely impaired and cats suffer 
from chronic upper respiratory tract and intestinal infections, skin and ear 
diseases, neurological signs and secondary infections. Plasma viral loads increase 
(Goto et al., 2002). Moreover, the broadened FIV cell tropism in later disease 
stages (B and CD8+ T lymphocytes as well as CD4+ T lymphocytes and 
macrophages can be infected; [Novotney et al., 1990; English et al., 1993; Dean 
et al., 1996]) contributes to the immunodeficiency. 
Early after infection virus can be detected in the central nervous system, 
thymus and mesenteric lymph nodes (Toyosaki et al., 1993; Beebe et al., 1994; 
Dua et al., 1994; Rogers and Hoover, 1998; Obert and Hoover, 2002). Virus 
replication in peripheral blood mononuclear cells (PBMCs) can be observed 
several days post-infection (p.i.) (English et al., 1993; Lawson et al., 1993; Dean 
et al., 1996; Obert and Hoover, 2002). In later stages of the disease FIV 
replicates mainly in lymphoid tissue; however, infected cells can also be found 
in the bone marrow, intestine, kidneys and liver (Beebe et al., 1994; Park et al., 
1995; Bishop et al., 1996; Rogers and Hoover, 1998; Obert and Hoover, 2000a; 
Obert and Hoover, 2000b). 
 
1.2.2 Humoural and cellular antiviral immune responses 
 
The transition between acute infection and clinical latency is mediated by 
substantial humoural and cell-mediated antiviral immune responses (Bendinelli 
et al., 1995; Burkhard and Dean, 2003). Cats raise antibodies against Gag and 
Env epitopes from as early as two to four weeks p.i., which persist throughout 
the course of infection (Yamamoto et al., 1988; Egberink et al., 1992; English et 
al., 1994). Neutralising antibodies directed against the V3 loop in Env are 
produced but their presence does not correlate with virus clearance (Lombardi 
et al., 1993; Tozzini et al., 1993). However, the absence of detectable titres of 
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neutralising antibodies leads to a more rapid progression to immunodeficiency 
(Hohdatsu et al., 1993).  
The early stages of infection are accompanied by a rapid expansion of 
circulating CD8+ T lymphocytes (Ackley et al., 1990; Tompkins et al., 1991; 
Willett et al., 1993; English et al., 1994). These CD8+ T lymphocytes mediate 
both cytotoxic (Song et al., 1992; Song et al., 1995; Beatty et al., 1996; 
Burkhard et al., 2001; Flynn et al., 2002) and non-cytotoxic antiviral activities 
(Hohdatsu et al., 1993; Bucci et al., 1998; Gebhard et al., 1999) that result in a 
reduction of viraemia (Flynn et al., 1995; Beatty et al., 1996). Anti-FIV Gag-
specific CD8+ cytotoxic T lymphocytes (CTLs) have been detected in peripheral 
blood from two weeks p.i. to about 21 weeks p.i. (Beatty et al., 1996). In the 
asymptomatic phase of disease classic CTLs disappear from the peripheral blood 
but anti-FIV Gag and anti-FIV Env precursor CTLs (pCTLs) are present in lymph 
nodes (Beatty et al., 1996; Flynn et al., 2002) and spleen (Song et al., 1992; 
Song et al., 1995; Flynn et al., 2002). In addition to cytotoxic CD8+ T cells, non-
cytotoxic CD8+ T lymphocytes can be found in blood, lymph nodes and thymus 
that suppress viral replication in CD4+ T lymphocytes in a non-cytotoxic, non-
MHC (major histocompatibility complex) restricted manner (Bucci et al., 1998; 
Hohdatsu et al., 1998; Hohdatsu et al., 2000; Flynn et al., 2002). Their activity 
can be either contact-dependent (Bucci et al., 1998; Gebhard et al., 1999) or 
contact-independent (Hohdatsu et al., 1993; Levy et al., 1996; Choi et al., 
2000). Contact-independent, non-cytotoxic CD8+ T cell activity involves the 
secretion of soluble factors such as chemokines (Hohdatsu et al., 1993; Levy et 
al., 1996; Flynn et al., 1999; Choi et al., 2000). 
 
1.2.3 FIV-induced immune dysregulation 
 
Despite these early and robust antiviral immune responses virus cannot be 
cleared and infected cats will develop a progressive immunodeficiency. The 
immunodeficiency is first characterised by the loss of response to viral antigens 
and recall antigens (anergy), followed by the loss of mitogen responses (Clerici 
et al., 1989; Barlough et al., 1991; Torten et al., 1991) and cell-mediated 
immune responses to secondary pathogens (Davidson et al., 1993; Dean et al., 
1998). While the occurrence of secondary infection can be attributed to a 
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decline in CD4+ T lymphocyte numbers and the resulting decrease in pro-
inflammatory cytokines such as interleukin-2 (IL-2) and IFN-γ, an immune 
dysfunction develops early in infection before CD4+ T cells numbers begin to 
decline (Clerici et al., 1989; Barlough et al., 1991; Torten et al., 1991; Davidson 
et al., 1993). This immune dysfunction may be induced by a range of 
mechanisms (reviewed in: Tompkins and Tompkins [2008] and Burkhard and Dean 
[2003]) such as cytokine dysregulation (Clerici and Shearer, 1993), immunologic 
anergy and increased apoptosis (programmed cell death) (Miedema, 1992) as 
well as an inappropriate activation of immune regulatory cells (Ascher and 
Sheppard, 1990).  
PBMCs of FIV-infected cats show an altered cytokine production profile in 
response to mitogen stimulation (Lawrence et al., 1995). Elevated levels of IL-
10, IL-6, TNFα (tumor necrosis factor alpha) and IFN-γ and decreased levels of 
IL-2 and IL-12 were found in macrophages (Ritchey et al., 2001; Avery and 
Hoover, 2004) and lymph nodes (Levy et al., 1998; Levy et al., 2004) of FIV-
infected cats. The increased IL-10 to IL-12 ratio in infected cats (IL-10 is known 
to suppress IL-12 production by DCs) limits their ability to mount a primary 
immune response to protozoal (Levy et al., 1998; Levy et al., 2004) and 
bacterial (Dean et al., 1998) pathogens.  
Immunologic anergy and apoptosis of CD4+ T lymphocytes in lymphoid 
tissues contribute to the progressive loss of T cell immune function observed in 
of FIV-infected cats (Guiot et al., 1993; Sarli et al., 1998). Immunologic anergy is 
defined as inability of CD4+ T lymphocytes to produce IL-2 and proliferate in 
response to recall antigens (Tompkins and Tompkins, 2008). Lack of IL-2 drives 
stimulated cells into a programmed cell death. In T lymphocytes apoptosis is 
induced by the engagement of the cell surface receptors CD28 or CTLA4 with the 
co-stimulatory molecules B7.1 (CD80) and B7.2 (CD86). Members of the B7 family 
are usually found on professional antigen-presenting cells (APCs). CD28 is 
constitutively expressed on T lymphocytes, and CTLA4 expression is upregulated 
upon T cell activation. Interaction of B7 with CD28 on T lymphocytes stimulates 
IL-2 production and T cell proliferation, whereas interaction of B7 with CTLA4 
suppresses IL-2 production (Bluestone, 1997). Because the affinity of B7 for 
CTLA4 is several logs higher than for CD28, termination of a response would 
dominate over T cell activation. In FIV infections, however, B7 is also expressed 
on activated CD4+ and CD8+ T lymphocytes due to chronic antigenic stimulation 
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(Ranheim and Kipps, 1994; Folzenlogen et al., 1997).  B7+CTLA4+ T cells were 
shown to be anergic and to undergo spontaneous apoptosis in lymph nodes and 
PBMCs of FIV-positive cats (Tompkins et al., 2002). The B7-CTLA4 induced 
downregulation of IL-2 production contributes to the cytokine dysregulation 
described earlier.  
Inappropriate activation of immune regulatory cells has also been described 
in FIV-infected cats. CD4+ T lymphocytes with regulatory function (Tregs) are 
thymus-derived and develop during T cell maturation (Bluestone and Abbas, 
2003). They are long-lived and eliminate autoimmune cells. Tregs are usually 
anergic (Maloy and Powrie, 2001). Upon activation, however, they migrate to 
peripheral lymphoid tissues (Bluestone and Abbas, 2003), inhibit the 
proliferation of activated CD4+ and CD8+ T lymphocytes and induce their 
apoptosis (Thornton and Shevach, 1998; Shevach et al., 2001), which could 
prevent an effective immune response to FIV and secondary pathogens. 
 
1.3 FIV infections of non-domestic felids 
 
FIV is endemic in nine free-ranging species of Felidae which have been shown to 
harbour antibodies reactive to FIV (Troyer et al., 2005). Species-specific FIV 
strains have been described for the domestic cat (Felis catus), African lions 
(Panthera leo), North American pumas (Puma concolor), Pallas’s cats 
(Otocolobus manul), bobcats (Lynx rufus), jaguarundi (Herpailurus 
yagouaroundi), cheetahs (Acinonyx jubatus), leopards (Panthera pardus), ocelots 
(Leopardis pardalis) and spotted hyenas (Crocuta crocuta). These FIV strains are 
termed FIV-Fca, FIV-Ple (or lion lentivirus; LLV), FIV-Pco (or puma lentivirus; 
PLV), FIV-Oma, FIV-Lru, FIV-Hya, FIV-Aju, FIV-Ppa, FIV-Lpa and FIV-Ccr, 
respectively (Rigby et al., 1993; Brown et al., 1994; Langley et al., 1994; 
Carpenter et al., 1996; Barr et al., 1997; Carpenter et al., 1998; Nishimura et 
al., 1999; VandeWoude and Apetrei, 2006; Troyer et al., 2008).  
Interestingly, while FIV infection in domestic cats leads to the 
development of a severe immunodeficiency, FIV infection of non-domestic cats 
is usually not associated with disease (Brown et al., 1994; Langley et al., 1994; 
Osborne et al., 1994; Carpenter and Obrien, 1995; Barr et al., 1997; Packer et 
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al., 1999). This resembles the correlation between pathogenic HIV infections in 
humans and asymptomatic SIV infections in non-human primates.  
 
1.3.1 Seroprevalence of FIV in the Felidae and Hyaenidae 
 
The determination of the seroprevalence of FIVs in non-domestic cats relies 
greatly on domestic cat-, lion- and puma-based Western blot analyses 
(VandeWoude et al., 2002; VandeWoude et al., 2003; Troyer et al., 2005). Anti-
FIV antibodies in other species can be detected using a multistrain-antigen 
Western blot approach (Ostrowski et al., 2003; Troyer et al., 2005). The 
seroprevalence of FIVs varies by species and geographic location (reviewed in: 
VandeWoude and Apetrei [2006]). Table 1-1 summarises the results of several 
studies that have investigated FIV seroprevalence and pathogenicity in free-
ranging animals from the nine species of Felidae and from spotted hyenas in 
which species-specific FIVs have been identified. 
In summary, African lions and leopards, pumas and Pallas’ cats show very 
high seroprevalence rates. Interestingly, FIV infection is more prevalent in 
African and American populations than in Asian populations. It can be assumed 
that population densities in Asia are too low to support effective intra-species 
transmission. Cross-species FIV transmission events are rare and have been 
documented primarily for captive non-domestic felids (Carpenter et al., 1996; 
Nishimura et al., 1999; Troyer et al., 2005). This suggests that the artificially 
close contact in captivity settings contributed to the opportunity for cross-
species transmission events to occur, strengthening the concept of species-
specific FIV strains. 
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Table 1-1 FIV prevalence in Felidae and Hyenidae species (adapted from VandeWoude and Apetrei [2006]). 
 
Common name (species) Geographic location Virus Seroprevalence (%) Pathogenicity References 
Domestic cat (Felis catus) Worldwide FIV-Fca 1-35 AIDS 
(Sukura et al., 1992; Peri et al., 1994; Lin 
et al., 1995; Carpenter et al., 1998; Dorny 
et al., 2002; Lee et al., 2002; Maruyama 
et al., 2003; Troyer et al., 2005) 
Lion (Panthera leo) 
Africa (Serengeti, 
Ngorongor Crater, Lake 
Manyara, Kruger 
National Park) 
FIV-Ple 
(LLV) 
80-90 
No association with 
increased morbidity 
in Serengeti lions 
(Olmsted et al., 1992a; Spencer et al., 
1992; Brown et al., 1994; Carpenter et al., 
1996; Hofmann-Lehmann et al., 1996; 
Troyer et al., 2004) 
 Namibia  0  (Lutz et al., 1992; Brown et al., 1994) 
 Botswana  26  (Osofsky et al., 1996) 
 Asia  0  
(Lutz et al., 1992; Spencer et al., 1992; 
Brown et al., 1994) 
Puma, mountain lion or 
cougar (Puma concolor) 
North, Central and 
South America 
FIV-Pco 
(PLV) 
25 
Possible CD4
+
 T 
lymphocyte 
depletion; no 
association with 
increased morbidity 
in Midwestern 
cougars 
(Olmsted et al., 1992b; Langley et al., 
1994; Carpenter et al., 1996; Troyer et al., 
2005) 
 Wyoming, Montana  58  (Biek et al., 2003) 
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 Washington  25  (Evermann et al., 1997) 
 Florida (Florida panther)  15-76  (Miller et al., 2006) 
Pallas cat (Otocolobus 
manus) 
Mongolia FIV-Oma >80 None detected (Barr et al., 1997; Troyer et al., 2005) 
Bobcat (Lynx rufus) California FIV-Lru 0-30 None detected (Riley et al., 2004; Troyer et al., 2005) 
Jaguarundi (Herpailurus 
yagouaroundi) 
Central/South America FIV-Hya Ca. 20 None detected (Langley et al., 1994; Troyer et al., 2005) 
Cheetah (Acinonyx jubatus) Africa FIV-Aju <10 None detected 
(Olmsted et al., 1992b; Osofsky et al., 
1996; Munson et al., 2004; Troyer et al., 
2005) 
Leopard (Panthera pardus) Botswana, Africa FIV-Ppa 16, ca. 50 None detected (Osofsky et al., 1996; Troyer et al., 2005) 
 Asia  0  (Troyer et al., 2005) 
Ocelot (Leopardus pardalis) Central/South America FIV-Lpa 10 None detected (Langley et al., 1994; Troyer et al., 2005) 
Spotted hyena (Crocuta 
crocuta) 
Masai Mara National 
Reserve (Serengeti) 
FIV-Ccr 10-30 None detected (Harrison et al., 2004; Troyer et al., 2005) 
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1.3.2 Pathogenicity of FIV in non-domestic cats 
 
The most striking observation to be made from the studies of FIV infections in 
non-domestic felids is that FIV seems to be apathogenic and infections are 
mostly benign (Lutz et al., 1992; Carpenter and Obrien, 1995; Packer et al., 
1999). This is in stark contrast to FIV infections in domestic cats, which lead to 
the development of immunodeficiency. 
FIV infections of lions and pumas have been examined both on a systemic 
and on a cellular basis. The findings have been compared to those in domestic 
cats in order to determine differences in viral cell and tissue tropism, viral 
pathogenicity and host immune responses to FIV infection. FIV-seropositive lion 
and puma populations were monitored for a potential impact of FIV infection on 
survival, fecundity or susceptibility to secondary infections (Hofmann-Lehmann 
et al., 1996; Biek et al., 2006a; Biek et al., 2006b). In free-ranging animals, no 
correlation between FIV infection and a reduction in fitness was found (Biek et 
al., 2006b; Biek et al., 2006c). However, proviral and plasma viral loads of FIV-
Pco infected pumas were comparable with those of FIV-positive domestic cats 
(Poss et al., 2008). Additionally, there are several reports that FIV infection 
causes CD4+ T lymphocyte depletion in pumas and to a larger extent in lions 
(Roelke et al., 2006; Roelke et al., 2009). In a population of Botswana lions, a 
decreased CD4+/CD8+ ratio correlated with lymphadenopathy, gingivitis and 
papillomas (Roelke et al., 2009).  
Alterations in T cell numbers may not result in terminal-stage feline AIDS 
but could render these animals susceptible to opportunistic infections. A canine 
distemper virus (CDV) outbreak has been reported in FIV-positive (but not FIV-
negative) lion populations in the Serengeti in 1994 which caused significant 
mortality (Roelke-Parker et al., 2010). Moreover, a number of FIV-positive 
Florida panthers died in a recent FeLV outbreak (M. Cunningham, unpublished 
data). 
 
1.3.3 Infectivity of lion and puma lentiviruses for domestic cats 
 
Experimental infection of domestic cats with either FIV-Ple or FIV-Pco leads to 
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the development of persistent cell-associated viraemia, transient plasma 
viraemia and lymphadenopathy, and seroconversion in the absence of disease 
(VandeWoude et al., 1997a; VandeWoude et al., 1997b; VandeWoude et al., 
2002; VandeWoude et al., 2003; TerWee et al., 2005). Moreover, CD4+/CD8+ 
ratios were unaltered compared to uninfected control animals (VandeWoude et 
al., 1997a). These findings indicate that immunodeficiency in domestic cats is 
not primarily caused by a direct viral cytopathic effect (TerWee et al., 2005). 
However, it should be noted that the FIV-Ple and FIV-Pco isolates used in these 
studies had been propagated and amplified in the feline lymphoma cell line 3201 
for a considerable length of time prior to inoculation into cats, which could have 
resulted in their attenuation. Remarkably, infection of domestic cats with non-
pathogenic FIV-Pco prevented CD4+ T lymphocyte depletion upon subsequent 
superinfection with virulent FIV-Fca (VandeWoude et al., 2002; TerWee et al., 
2008). This resistance to superinfection was not mediated by acquired immunity 
but correlated with an increase in IFN-γ expression (TerWee et al., 2008).  
 
1.3.4 Growth of lion and puma lentiviruses in feline cells 
 
To assess the cell tropism of FIV-Ple and FIV-Pco in vitro, feline cell lines and 
primary cells such as feline lymphoma 3201 cells, a feline adherent lymph node 
cell (LNC) line as well as cat, lion and puma PBMCs were infected with these 
viruses (VandeWoude et al., 1997b). Cell-free FIV-Ple was able to infect cat 
PBMCs and to a lesser extent lion PBMCs, but not LNCs. Cell-free FIV-Pco did not 
infect cat or puma PBMCs. Cell-associated FIV-Pco (PBMCs from a seropositive 
puma from British Columbia) caused a low-titre infection in cat PBMCs and a 
high-titre infection in puma PBMCs. All three viruses replicated best in 3201 cells 
(VandeWoude et al., 1997b). Interestingly, infection of cat 3201 cells and PBMCs 
with FIV-Pco imparted resistance to FIV-Fca superinfection (VandeWoude et al., 
2002). 
Similar infection assays were performed in our laboratory. The IL-2 
dependent feline T cell line Mya-1 (Miyazawa et al., 1989) and primary lion T 
lymphocytes were infected with different strains of FIV-Fca, FIV-Ple and FIV-Pco 
(Fig. 1-4).  
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Figure 1-4 FIV cell tropism. The IL-2 dependent feline T cell line Mya-1 (A) and 
primary T lymphocytes obtained from an Angolan lion (B) were infected with 
divergent FIV-Fca strains GL8, B2542 and CPG, FIV-Ple and FIV-Pco. Virus 
production was determined on day 0, 3, 5 and 10 post-infection using a lentiviral 
RT assay. Whereas virus grew readily in Mya-1 cells, lion T lymphocytes were 
resistant to virus infection.  
 
Curiously, we observed that all viruses grew readily in Mya-1 cells, whereas lion 
T lymphocytes were resistant to infection (unpublished data). The inability of 
different FIVs (including FIV-Ple) to productively infect lion T lymphocytes is 
somewhat surprising given the fact that FIV-Ple infected lions show a high 
viraemia (Poss et al., 2008). Because the FIV-Ple isolate used in our study was 
obtained from groups that had passaged the virus for a long period of time in 
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3201 cells (VandeWoude et al., 1997a; VandeWoude et al., 1997b; VandeWoude 
et al., 2002; VandeWoude et al., 2003; TerWee et al., 2005), it is possible that 
the virus was attenuated. It would be interesting to determine if primary 
isolates of FIV-Ple can indeed infect lion T lymphocytes. This would point 
towards a selective restriction of FIV-Fca growth in lion T cells. In fact, the 
study presented here aims at elucidating the molecular bases for the differential 
disease outcome seen in FIV infections of domestic and non-domestic cats and 
the differences in the susceptibility of cat and lion T lymphocytes to lentiviral 
infection. 
 
1.4 Co-evolution between the Felidae and FIV   
 
The apparent lack of pathogenicity of FIV in non-domestic cats may be a 
consequence of prolonged periods of host-virus co-evolution that resulted either 
in an increased ability of the non-domestic cat immune systems to restrict FIV 
replication or in a decreased virulence of non-domestic cat FIV strains, or both. 
In contrast, FIV may be a relatively recent introduction into the domestic cat 
lineage resulting in the absence of host-virus co-adaptation and in a fatal disease 
outcome. Evidence for this hypothesis emerges from studies on the evolutionary 
history of the Felidae and on FIV evolution dynamics in feline populations. 
 
1.4.1 Evolutionary history of the Felidae 
 
Modern felids arose from a common ancestor during the late Miocene (ca. 10.8 
MYA) in Asia (Johnson et al., 2006). They diverged within a relatively short 
period of time (10.8 MYA to 6.2 MYA) into eight distinct evolutionary lineages 
comprising a total of 38 feline species (Johnson et al., 2006). The radiation of 
modern felids began with the divergence of the Panthera lineage followed by 
the split of the bay cat (9.4 MYA), the caracal (8.5 MYA) and the ocelot (8 MYA) 
lineages from the ancestor of more recent lineages. The divergence of the lynx 
lineage (7.2 MYA) was closely followed by the emergence of the puma lineage 
(6.7 MYA) and the more recently derived leopard and domestic cat lineages (6.2 
MYA) (Johnson et al., 2006). Within-lineage species differentiations took place 
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during the late Miocene/early Pliocene (6.4 MYA to 2.9 MYA) and during the late 
Pliocene/Pleistocene (3.1 MYA to 0.7 MYA).  
Of the feline species relevant to this study the puma is the oldest species 
and arose approximately 4.5 MYA (Pecon-Slattery et al., 2004; Johnson et al., 
2006). African lion species arose 2 MYA and the domestic cat evolved as a unique 
felid lineage circa 0.99 MYA (Johnson et al., 2006). Lineage and species 
differentiation events were facilitated by multiple intercontinental migration 
movements starting from Asia. Early migration of a progenitor of the caracal 
lineage to Africa occurred around 8.5 MYA to 5.6 MYA. Another migration event 
translocated a common ancestor of the ocelot, lynx, puma, leopard and 
domestic cat lineages across the then present Bering Strait land bridge to North 
America (8.5 MYA to 8 MYA) (Johnson et al., 2006). The leopard and domestic 
cat lineages either diverged from ancestors that had remained in Asia or from 
North American ancestors that had crossed the Bering Strait land bridge back to 
Asia. Additionally, Asiatic Panthera species migrated to America (jaguars, lions) 
and to Africa (lions, leopards) during the late Pliocene/early Pleistocene 
(Johnson et al., 2006). 
The recent evolutionary history and phylogeography of North American 
pumas and African lions have been studied in detail. North American pumas were 
extirpated from North America during the last ice age of the late Pleistocene but 
re-emerged from Brazil about 10,000 to 12,000 years ago (Culver et al., 2000). 
At present, they inhabit Western continental regions of the United States of 
America including Arizona, Texas, Colorado and Wyoming (Carpenter et al., 
1996; Culver et al., 2000; Biek et al., 2006a). The most recent ancestor of 
modern lion populations arose about 325,000 years ago from Eastern and 
Southern African lions and subsequently migrated into Central and North Africa 
and into Eurasia about 100,000 years ago (Antunes et al., 2008). These 
population expansions were followed by population reductions. At present, there 
are eleven lion populations in East Africa (Uganda, Kenia, Serengeti National 
Park, Ngorongoro Crater) and South Africa (Kruger National Park, Botswana, 
Namibia) and in Asia (Gir Forest, India) (Fig. 1-5) (Antunes et al., 2008). 
Interestingly, the Serengeti National Park accommodates three distinct lion 
populations that admixed recently.  
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Figure 1-5 Geographic location of extant lion (Panthera leo) populations. 
Analysis of microsatellite and sequencing data of 357 lions from Africa and the Gir 
forest in India revealed the existence of eleven distinct lion populations that cluster 
geographically (Antunes et al., 2008). These lion population (red circles) can be 
found in East Africa (Uganda, UGA; Kenia, KEN; Serengeti National Park, SER; 
Ngorongoro Crater, NGC), in South Africa (Kruger National Park, KRU; Botswana, 
BOT; Namibia, NAM) and in India (Gir Forest, GIR). Botswana and the Serengeti 
National Park accommodate two or three distinct lion populations (BOT-I and 
BOT-II, and SER-I, SER-II and SER-III, respectively). Furthermore, Antunes et al. 
(2008) included lions from Zimbabwe (ZBW), Angola (ANG) and the Atlas 
mountains in Morocco (ATL) into their study (green squares). These lions were 
representative of isolated, endangered or depleted populations.  
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1.4.2 Phylogeny of FIV and FIV population dynamics in the 
Felidae 
  
Based on the widespread occurrence of FIV and other lentiviruses in Africa 
together with large FIV interspecies divergences, which point towards a long FIV 
residence time within these species, an ancestral origin of FIV in Africa followed 
by interspecies transmission events and a global dissemination of FIV has been 
proposed (Pecon-Slattery et al., 2008b). The global dissemination of FIV from 
Africa occurred as a consequence of felid transcontinental migration movements 
into Eurasia and the Americas. Such a migration event across the Bering Strait 
land bridge took place around 4.5 MYA and lead to the introduction of FIV into 
seven species of the ocelot lineage, into cheetahs, pumas and jaguarundi (puma 
lineage) and into four modern species of the lynx lineage (Johnson et al., 2006). 
Subsequently, FIV was disseminated from North America to Central and South 
America (Johnson et al., 2006).  
Phylogenetic analyses of the genetic variation in the conserved pol and 
gag genes and the very diverse env gene of FIV demonstrated that FIV lineages 
are highly divergent but are monophyletic and species-specific (Phillips et al., 
1990; Olmsted et al., 1992b; Carpenter et al., 1996; Carpenter et al., 1998; 
Troyer et al., 2005). FIV-Pco can be divided into two major clades (A and B) and 
eight distinct viral lineages (Biek et al., 2006a). The two clades are highly 
divergent and appear to be paraphyletic as a consequence of two separate 
introductions of FIV into the puma lineage (Troyer et al., 2008). Clade A viruses 
can be found in Florida and California and clade B viruses in other parts of North 
America, Central America and Brazil. FIV-Pco lineages lack broad geographic 
associations consistent with recent and frequent FIV-Pco transmission events 
between puma populations in different locations (Carpenter et al., 1996).  
FIV-Ple diverges into six clades (A-F) that are endemic in distinct 
geographic areas (see Fig. 1-5) (Brown et al., 1994; Troyer et al., 2004; O'Brien 
et al., 2006; Antunes et al., 2008). Subtype A is present in the Serengeti 
National Park, the Kruger National Park and Botswana. Subtype B is endemic in 
lion populations in Uganda, the Serengeti National Park, the Ngorongoro Crater 
and Botswana. Subtypes C and D can be found in the Serengeti and in the Kruger 
National Parks, respectively. Subtype E is present in Botswana and subtype F in 
Kenya (Brown et al., 1994; Troyer et al., 2004; O'Brien et al., 2006; Antunes et 
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al., 2008). The three lion populations in the Gir forest in India, in southern 
Botswana and in Namibia are not infected with FIV (Brown et al., 1994; O'Brien 
et al., 2006). Reasons for the absence of FIV in these populations may be their 
physical separation from infected populations (for example by the Kalahari 
desert) or that FIV transmission cannot occur due to too low population 
densities.  
FIV-Fca falls into the five clades A-E with a majority of viruses belonging 
to either clade A or B (Sodora et al., 1994; Kakinuma et al., 1995; Sodora et al., 
1995; Pecoraro et al., 1996; Elder et al., 1998). Clade A and B viruses show a 
worldwide distribution; however, clade A viruses are predominant in the western 
part of the United States of America, northern Japan, Germany and South Africa, 
whereas clade B viral isolates are predominant in eastern Japan, Italy, Portugal 
and in eastern and central parts of the United States of America (Sodora et al., 
1994; Nishimura et al., 1998). Clades C, D and E viruses are rarer. Clade C 
viruses are present in northern Taiwan (Sodora et al., 1994; Inada et al., 1997; 
Uema et al., 1999), clade D isolates in western Japan (Nishimura et al., 1998) 
and clade E viruses in Argentina (Pecoraro et al., 1996). 
In general, pathogenic lentiviral infections are characterised by rapid 
virus evolution, high intrahost diversity and positive selection on several virus 
genes (Coffin, 1995; Crandall et al., 1999; Rambaut et al., 2004). In non-
pathogenic lentivirus infections, however, there is purifying selection on the 
virus, which usually shows a slower rate of evolution and high interhost diversity 
(Coffin, 1995; Crandall et al., 1999; Poss et al., 2008). Phylogenetic analyses of 
the FIV-Fca, FIV-Ple and FIV-Pco genome sequences showed a greater nucleotide 
diversity within FIV-Pco and FIV-Ple than within FIV-Fca (Brown et al., 1994; 
Burkala and Poss, 2007). The divergence between FIV-Pco clades A and B is high 
(20-27%) and comparable to that observed between FIV-Ple clades and 
significantly higher than that between FIV-Fca clades (Poss et al., 2008). The 
sequence variation between FIV-Pco lineages within FIV-Pco clades A and B is 
also very high (up to 24% in clade B) and comparable to the interclade diversity 
seen for domestic cat FIV clades (13-17%) (Poss et al., 2008). However, the 
intrahost diversity of FIV-Pco per gene in pumas is lower than 1%. The genome 
diversity within and between FIV-Ple clades is large, too. In contrast, FIV-Fca 
isolates exhibit only minimal interclade and intraclade genetic variation (Poss et 
al., 2008).   
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Furthermore, FIV-Pco shows slower evolutionary rates compared to FIV-Fca 
or HIV-1 and purifying selection is the predominant force changing the gene 
sequences (Poss et al., 2008); (Biek et al., 2003). However, a significant degree 
of positive selection can be seen in the FIV-Fca genome (Burkala and Poss, 
2007). These findings suggest that FIV infection of pumas was the most ancient 
event (Pecon-Slattery et al., 2008b; Poss et al., 2008), followed by FIV 
transmission to lions (Brown et al., 1994; Carpenter and Obrien, 1995). The low 
degree of FIV-Fca divergence points towards a recent emergence in combination 
with rapid viral diversification within the domestic cat (Pecon-Slattery et al., 
2008b). It is very likely that the extended periods of endemic lentiviral infection 
in pumas and lions have improved the restrictive ability of the puma and lion 
immune system to FIV infection and reduced the pathogenicity of FIV-Pco and 
FIV-Ple (Carpenter and Obrien, 1995; Burkala and Poss, 2007). In contrast, the 
relationship between the domestic cat and FIV-Fca seems to be unbalanced, thus 
allowing disease to progress.  
 
1.5 Antiretroviral intrinsic immunity 
 
The reduced pathogenicity of FIV infections in non-domestic felids combined 
with the restriction of FIV replication seen in lion T lymphocytes can best be 
explained by the presence of potent antiretroviral immune effector molecules in 
these cells that inhibit FIV growth at a post-entry stage of the lentiviral life 
cycle. The mammalian intrinsic immunity, a specific arm of the innate 
immunity, is the first line of defence against pathogens (Bieniasz, 2004; Goff, 
2004). The intrinsic immunity acts intracellularly and comprises so-called 
restriction factors. Restriction factors are proteins that block viral replication at 
different stages of the viral life cycle. They are either constitutively expressed 
or their expression can be upregulated by pattern recognition receptor (PPR)-
mediated innate immune signalling cascades, which upon detection of viral 
genomes initiate the transcription of genes encoding for restriction factors, 
among others.. The cell-type and species-specific expression and activity of 
restriction factors control the viral host spectrum and may impose a barrier to 
cross-species transmission events (Troyer et al., 2008). Well-studied examples of 
such host restriction factors are TRIM5α, an E3 ubiquitin ligase that binds 
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incoming retroviral capsids in the cytoplasm via its C-terminal PRY/SPRY (B30.2) 
domain and targets them for proteasomal degradation (Reymond et al., 2001; 
Stremlau et al., 2004), and APOBEC3 proteins, cytidine deaminases that induce 
hypermutations and impair viral reverse transcription (Teng et al., 1993; Sheehy 
et al., 2002; Mangeat et al., 2003; Zhang et al., 2003). Tetherin (BST-2, CD317) 
is a transmembrane protein that potently inhibits the release of nascent 
retrovirus particles in single-cycle replication assays (Neil et al., 2008; Van 
Damme et al., 2008). In order to efficiently replicate and evade immune 
surveillance, retroviruses have to overcome this line of defence and, thus, have 
evolved proteins that antagonise the actions of restriction factors or mechanisms 
to avoid them. Lentiviral Vif proteins (Sheehy et al., 2002; Sheehy et al., 2003; 
Munk et al., 2008) and spumaviral Bet proteins (Lochelt et al., 2005; Russell et 
al., 2005; Perkovic et al., 2009) counteract APOBEC3 proteins whereas HIV-1 and 
certain SIV Vpus, HIV-2 and SIV Envs, and SIV Nefs counteract tetherins (Neil et 
al., 2007; Neil et al., 2008; Van Damme et al., 2008; Gupta et al., 2009b; Jia et 
al., 2009; Le Tortorec and Neil, 2009; Sauter et al., 2009; Zhang et al., 2009a; 
Yang et al., 2010). The permanent conflict between host restriction factors and 
viral restriction factor antagonists has led to a rapid positive selection on both 
groups of proteins (Sawyer et al., 2004; McNatt et al., 2009; Ortiz et al., 2009).  
 
1.5.1 Innate interferon response  
 
Restriction factors are effector molecules of the interferon immune signalling 
pathways. Interferon signalling is triggered by pattern recognition. Several 
families of pattern recognition receptors are involved in the detection of 
pathogen-associated molecular patterns (PAMPs) such as the viral genome 
(Barbalat et al., 2011). Members of the Toll-like receptor (TLR) family have been 
identified as sensors of viral nucleic acid. Signalling through TLRs results in the 
production of type I IFNs (especially IFN-α and IFN-β) and inflammatory 
cytokines such as IL-6 and IL-12, and stimulates DC maturation and the 
establishment of antiviral innate immunity (reviewed in: (Medzhitov and 
Janeway, 1997; Akira et al., 2001; Janeway and Medzhitov, 2002; Takeda et al., 
2003; Iwasaki and Medzhitov, 2004)). A second group of viral nucleic acid sensors 
are cytosolic retinoic acid-inducible gene I (RIG-I)-like RNA helicases (Yoneyama 
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et al., 2004; Yoneyama and Fujita, 2007). The expression of these two classes of 
PPRs is cell-type specific, and they induce IFN production via distinct signalling 
pathways.  
TLRs that detect the presence of viruses include TLR3, TLR7 and TLR9, all 
of which can be found exclusively in endosomal compartments. TLR3 is localised 
in intracellular vesicles in conventional DCs (cDCs) (Matsumoto et al., 2003; 
Iwasaki and Medzhitov, 2004; Sousa, 2004) and responds to viral double-stranded 
RNA (dsRNA) (Alexopoulou et al., 2001). TLR3-dependent immune signalling is 
initiated by phagocytosis of apoptotic bodies of infected or dsRNA-containing 
cells by cDCs, which induces the maturation of these cDCs and type I IFN 
production (Schulz et al., 2005). DC maturation and secreted IFN promote cross-
priming of T lymphocytes leading to antigen-specific CD4+ and CD8+ T cell 
responses (Schulz et al., 2005). TLR7 and TLR9 are highly expressed in 
plasmacytoid DCs (pDCs) (Iwasaki and Medzhitov, 2004; Sousa, 2004). They 
recognise nucleic acids of viruses that are taken up by pDCs and are subjected to 
proteolytic degradation in the endosomal compartment. TLR7 can be activated 
by single-stranded RNA (ssRNA) rich in guanosine or uridine from viruses such as 
HIV and influenza (Diebold et al., 2004; Heil et al., 2004; Lund et al., 2004). 
TLR9 recognises viral single-stranded DNA (dsDNA) containing unmethylated 
cytidine-phosphate-guanosine (CpG) DNA motifs (Hemmi et al., 2003). TLR7 and 
TLR9-dependent signalling in pDCs leads to the synthesis of large amounts of 
type I IFN, in particular of IFN-α (Liu, 2005). Upon agonist binding, TLRs signal 
via adaptor molecules to phosphorylate and activate latent transcription factors 
which then translocate to the nucleus to regulate the expression of IFNs. TLR3 
signals via TRIF (Toll/IL-1 receptor domain-containing adaptor inducing IFN-β) 
(Yamamoto et al., 2002; Yamamoto et al., 2003), which interacts with the 
kinases TBK-1 (Tank-binding kinase 1) and IKKε (IkappaB kinase epsilon) to 
phosphorylate the transcription factors IRF3 (IFN-regulatory factor 3) and IRF7 
(Fitzgerald et al., 2003). This signalling cascade leads primarily to the 
production of IFN-β. Alternatively, TRIF can activate the transcription factors 
ATF2 (activating transcription factor 2)/c-Jun and NF-κB, which stimulates 
production of type I interferon and inflammatory cytokines (Gohda et al., 2004). 
In pDCs, TLR7 and TLR9 signal via the adaptor molecule MyD88 (myeloid 
differentiation primary response gene 88), the kinase IRAK1 (IL-1 receptor-
associated kinase 1) and TRAF6 (TNF receptor-associated factor 6) to 
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phosphorylate the transcription factor IRF7 (Hoshino et al., 2002; Hemmi et al., 
2003; Akira and Takeda, 2004; Honda et al., 2004; Kawai et al., 2004; Uematsu 
and Akira, 2007). IRF7 induces type I IFN production in pDCs. In cell types other 
than pDCs this pathway is non-functional and TLR7/TLR9 stimulation couples 
TRAF6 to the activation of ATF2/c-Jun and NF-κB (Akira and Takeda, 2004). In 
this case, expression of cytokines such as IL-6, IL-12 and TNF is triggered (Akira 
and Takeda, 2004). 
RIG-I-like RNA helicases are cytosolic PPRs, which detect dsRNA produced 
during viral replication. RIG-I itself is expressed in cDCs, fibroblasts and 
epithelial cells (Kato et al., 2005; Wilkins and Gale, 2010) and can signal for 
IRF3, IRF7 (Fitzgerald et al., 2003) and NF-κB activation (Balachandran et al., 
2004), which leads to the induction of type I IFNs (Yoneyama et al., 2004; 
Onoguchi et al., 2007). ISP-1 (IFN-β promoter stimulator-1) serves as adaptor 
mediating between RIG-I and the transcription factors (Kawai et al., 2005; 
Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005).  
Subsequently, secreted IFNs bind and activate the type I IFN receptor 
(IFNAR), which is a common cell-surface receptor. IFNAR is composed of two 
distinct chains, IFNAR1 and IFNAR2, which are associated with the Janus 
activated kinases (JAKs) TYK2 (tyrosine kinase 2) and JAK1, respectively 
(Silvennoinen et al., 1993). Binding of IFNs to IFNAR induces the JAK-STAT 
signalling pathway (Fu et al., 1992; Schindler et al., 1992; Silvennoinen et al., 
1993) through JAK-mediated tyrosine phosphorylation of the transcription factors 
STAT1 (signal transducer and activator of transcription 1) and STAT2. This then 
leads to the formation of STAT1/STAT2/IRF9 complexes, which are also known as 
ISGF3 (IFN-stimulated gene factor 3) complexes (Levy et al., 1988; Levy et al., 
1989; Kessler et al., 1990). These complexes translocate to the nucleus and bind 
to IFN-stimulated response elements (ISREs) (Israel et al., 1986; Levy et al., 
1988) present in promoters of certain genes (so-called IFN-stimulated genes, 
ISGs) to initiate their transcription (Der et al., 1998). ISGs have antiviral, 
antiproliferative or immunomodulatory properties. Additionally, type I and type 
II (IFN-γ) IFNs can cause the formation of STAT homodimers or heterodimers, 
which can also enter the nucleus to stimulate transcription of genes containing 
GAS (IFN-γ-activated site) elements in their promoters.  
Among the hundreds of ISGs that have been identified (Der et al., 1998) 
are the host restriction factors whose expression leads to the induction of a 
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heightened antiviral state. TRIM, APOBEC3 and tetherin genes contain ISREs in 
their promoters (Asaoka et al., 2005; Tanaka et al., 2006; Carthagena et al., 
2009). TRIM5α is expressed in the absence of IFNs but their presence increases 
TRIM5α expression (Asaoka et al., 2005; Sakuma et al., 2007; Carthagena et al., 
2008). Type I IFNs induce APOBEC3s in resting T lymphocytes, macrophages and 
DCs (Chen et al., 2006; Peng et al., 2006; Wang et al., 2008). Tetherin is 
constitutively expressed in pDCs (Blasius et al., 2006). In CD4+ T lymphocytes 
and macrophages, tetherin expression is upregulated by cellular activation and 
maturation but further enhanced by type I IFNs (Neil et al., 2008; Miyagi et al., 
2009). 
 
1.5.2 TRIM5α  
 
TRIM5α is the longest (alpha) isoform of the host protein TRIM5, a member of the 
tri-partite motif (TRIM) family of proteins (Reymond et al., 2001; Stremlau et 
al., 2004). This family is large, with at least 68 intact members in the human 
genome, which are involved in diverse cellular processes such as cell 
proliferation, differentiation, development, oncogenesis or apoptosis (Nisole et 
al., 2005). Some TRIM proteins, including TRIM1 (Yap et al., 2004), TRIM5α 
(Hatziioannou et al., 2004b; Keckesova et al., 2004; Perron et al., 2004; 
Stremlau et al., 2004; Yap et al., 2004), TRIM19 (Turelli et al., 2001) and TRIM22 
(Tissot and Mechti, 1995) form part of the host antiretroviral intrinsic immunity. 
TRIM5α was identified as the factor responsible for the previously reported Lv1 
(lentivirus susceptibility factor 1) and Ref1 (resistance factor 1) antiretroviral 
activities in rhesus monkey and human cells, respectively (Hatziioannou et al., 
2004b; Keckesova et al., 2004; Perron et al., 2004; Stremlau et al., 2004; Yap et 
al., 2004). It mediates a species-specific, early post-entry block to retroviral 
infection. 
 
1.5.2.1 Domain structure of TRIM proteins 
 
TRIM proteins typically comprise a RING domain with E3-ubiquitin ligase activity 
capable of auto-ubiquitination, a B-box 2 domain and a coiled-coil domain 
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RING Bb2 CC B30.2 
necessary for TRIM oligomerisation, referred to collectively as the RBCC 
(Reymond et al., 2001). Some TRIM proteins, including TRIM5α (Fig. 1-6), 
possess a C-terminal B30.2 (PRY/SPRY) domain that is thought to mediate 
binding of TRIM proteins to the incoming capsid of restriction-sensitive 
retroviruses (Mische et al., 2005; Sebastian and Luban, 2005; Stremlau et al., 
2006).  
 
 
 
 
 
 
Figure 1-6 Schematic representation of the TRIM5α domain topology. 
Members of the TRIM family comprise an N-terminal RING domain (RING) with 
E3-ubiquitin ligase activity, followed by a B-box 2 (Bb2) and a coiled-coil (CC) 
domain important for protein multimerisation. TRIM5α also possesses a C-terminal 
B30.2 (PRY/SPRY) domain (B30.2) involved in the binding of retroviral capsid.  
 
1.5.2.2 Mechanism of the antiretroviral activity of TRIM5α 
 
TRIM5α leads to a block in reverse transcription in most non-permissive cells 
(Stremlau et al., 2004); Keckesova et al., 2004). Evidence suggests that TRIM5α 
binds directly to the retroviral capsid lattice in the cytoplasm with the help of 
its B30.2 (PRY/SPRY) domain (Mische et al., 2005; Sebastian and Luban, 2005; 
Stremlau et al., 2006). The RING domain then catalyses the ubiquitination of the 
capsid/TRIM5α complex and targets it for a rapid proteasome-mediated 
degradation so that the virus cannot complete reverse transcription (Diaz-
Griffero et al., 2006a; Towers, 2007). While inhibition of the proteasome 
prevents degradation of the viral core and enables reverse transcription to 
proceed, virus remains non-infectious and the process of infection does not 
complete (Anderson et al., 2006; Wu et al., 2006; Campbell et al., 2008), 
indicating an additional proteasome-independent antiviral function for TRIM5α. 
Accelerated uncoating of the viral capsid from the incoming virion may underlie 
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this proteasome-independent restriction activity (Stremlau et al., 2006; Perron 
et al., 2007). 
 
1.5.2.3 Specificity of the TRIM5α-capsid interaction 
 
Human and non-human primate TRIM5α variants display significant differences in 
their specificity to lentiviral capsids which govern the species tropism of 
lentiviruses and prevent their cross-species transmission. Non-human primates 
can be grouped into apes, Old World monkeys such as guenons (Cercopithecus 
spp.), macaques (Macaca spp.), members of the genus Chlorocebus and white-
eyelid mangabeys (Cercocebus spp.), and New World monkeys such as squirrel 
monkeys (Saimiri spp.) and night or owl monkeys (Aotus spp.).  
Human TRIM5α (huTRIM5α) potently inhibits pre-integration stages of 
murine leukaemia virus N-strain (MLV-N) replication (Hatziioannou et al., 2004b; 
Perron et al., 2004; Yap et al., 2004) but shows only weak antiviral activity 
against HIV-1 and SIV of Old World rhesus macaques (Macaca mulatta; SIVmac) 
(Stremlau et al., 2004; Perez-Caballero et al., 2005; Sawyer et al., 2005; 
Stremlau et al., 2005; Yap et al., 2005). HIV-2 replication is moderately reduced 
in human cells (Ylinen et al., 2005). In contrast, Old World rhesus macaque and 
African green monkey (Chlorocebus sabaeus) TRIM5α (rhTRIM5α and agmTRIM5α, 
respectively) restrict HIV-1 and HIV-2 infectivity, but not that of MLV-N 
(Hatziioannou et al., 2004b; Keckesova et al., 2004; Stremlau et al., 2004; Yap 
et al., 2004; Ylinen et al., 2005). Moreover, agmTRIM5α is able to inhibit 
SIVmac, whereas its rhesus macaque homologue is not (Hatziioannou et al., 
2004b; Keckesova et al., 2004; Stremlau et al., 2004; Nakayama et al., 2005). 
Most New World monkey cells block SIVmac, but not HIV-1 or HIV-2 (Hofmann et 
al., 1999; Ylinen et al., 2005). Owl monkey (Aotus trivirgatus) kidney (OMK) 
cells are unusual among New World monkey cells in that they allow SIVmac 
infection but restrict HIV-1 infection (Hofmann et al., 1999). 
The antiviral specificity of TRIM5α has been mapped to residues in the 
B30.2 (PRY/SPRY) domain that are involved in lentiviral capsid recognition 
(Stremlau et al., 2004; Nakayama et al., 2005; Perez-Caballero et al., 2005; 
Sawyer et al., 2005; Sebastian and Luban, 2005; Song et al., 2005; Stremlau et 
al., 2005; Yap et al., 2005; Perron et al., 2006; Kono et al., 2009). Interestingly, 
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introduction of certain point mutations into the B30.2 (PRY/SPRY) domain of 
TRIM5αs can change their antiviral properties and their lentiviral specificities. 
For example, mutation of arginine residue 332 in the B30.2 (PRY/SPRY) domain 
of huTRIM5α to a proline present in the rhTRIM5α (Arg332Pro) enables the human 
variant to restrict HIV-1 (Stremlau et al., 2005; Yap et al., 2005). Similarly, 17 
amino acid residues and a 20 amino acid duplication in agmTRIM5α are essential 
for its ability to inhibit SIVmac (Nakayama et al., 2005). 
The retroviral determinants for susceptibility to TRIM5α lie within the N-
terminal domain of the capsid (CAN) as demonstrated by site-directed 
mutagenesis and the use of HIV-1/SIV capsid chimeras (Owens et al., 2003; 
Hatziioannou et al., 2004b; Owens et al., 2004; Song et al., 2007; Kratovac et 
al., 2008). Lentiviral capsid proteins are well conserved in terms of both amino 
acid sequence and structure. Non-conserved residues have been found to cluster 
into surface-exposed loops of CAN (Owens et al., 2003; Hatziioannou et al., 
2004b) and are the targets for inhibition by TRIM5α variants from different 
primates. One of these loops constitutes the cyclophilin A-CA binding site 
(Hatziioannou et al., 2004b) (see Section 1.5.3). Replacement of HIV-1 CA by 
SIVmac CA rendered HIV-1 sensitive to huTRIM5α and New World squirrel monkey 
TRIM5α (Owens et al., 2003; Hatziioannou et al., 2004b) and resistant to 
rhTRIM5α and owl monkey TRIM5α (Owens et al., 2003). Conversely, 
replacement of the SIVmac CA by that of HIV-1 caused SIVmac to become 
moderately sensitive to huTRIM5α, very sensitive to rhTRIM5α and owl monkey 
TRIM5α and resistant to squirrel monkey TRIM5α (Owens et al., 2003). 
 
1.5.2.4 TRIM5α in the Felidae 
 
In a previous study we have shown that domestic cat TRIM5α (feTRIM5α) bears a 
stop codon in its B30.2 (PRY/SPRY) domain (McEwan et al., 2009). This 
premature stop codon leads to a truncation of feTRIM5α, which ablates its 
antiviral activity. Interestingly, this truncation was found to be conserved among 
members of the Feliformia (McEwan et al., 2009). Because feline cells display a 
TRIM5α-null phenotype they are sensitive to infection by lentiviral pseudotype 
particles that express the vesicular stomatitis virus glycoprotein (VSV-G) to 
enable cell entry. It should be noted that FIV is highly sensitive to restriction by 
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TRIM5α proteins from rhesus macaques, African green monkeys and to some 
degree from humans (Saenz et al., 2005). These findings suggest that HIV-1 and 
FIV capsids pose similar targets for TRIM5α (Diaz-Griffero et al., 2007).  
 
1.5.3 The role of cyclophilin A in retroviral replication  
 
Another host factor, which has been implicated in early post-entry events and 
impacts on retroviral infectivity, is cyclophilin A (CypA). CypA is a 18-kDa, 
abundantly expressed cytosolic petidyl-prolyl isomerase. It is packaged into HIV-
1 virions in producer cells via an interaction with unprocessed Gag polyprotein, 
Pr55Gag (Luban et al., 1993; Franke et al., 1994; Thali et al., 1994). Target cell 
CypA also interacts with incoming HIV-1 capsid. In human cells, the specific 
binding of CypA to HIV-1 CA, especially that in target cells, is required for viral 
infectivity and disruption of the CypA-CA interaction impairs HIV-1 replication 
(Braaten et al., 1996a; Braaten et al., 1996b; Yin et al., 1998; Sokolskaja et al., 
2004; Hatziioannou et al., 2005). Paradoxically, in Old World monkey cells, 
disruption of the CypA-CA interaction leads to an enhancement of HIV-1 
infectivity and it is believed that CypA binding to HIV-1 CA renders HIV-1 more 
susceptible to Old World monkey TRIM5αs (Berthoux et al., 2005; Keckesova et 
al., 2006; Sokolskaja et al., 2006; Stremlau et al., 2006). 
 
1.5.3.1 Cyclophilin A-capsid interactions 
 
CypA is recruited to capsids of HIV-1, SIV of African green monkeys (SIVagm) and 
FIV (Luban et al., 1993; Franke et al., 1994; Thali et al., 1994; Lin and 
Emerman, 2006; Zhang et al., 2006); Diaz-Griffero et al., 2006b). In contrast, 
the capsids of most HIV-2 strains, SIVmac and MLV-N do not bind CypA (Franke et 
al., 1994,Braaten, 1996 #841; Yoo et al., 1997; Lin and Emerman, 2006). CypA 
binds to viral capsids via an interaction between its catalytic hydrophobic 
pocket, which contains aromatic residues, and a nine amino acid long, surface-
exposed proline-rich loop between alpha-helices 4 and 5 of CAN (Luban et al., 
1993; Franke et al., 1994; Thali et al., 1994; Gamble et al., 1996). Upon capsid 
binding, CypA catalyses the cis-trans isomerisation around the Gly89-Pro90 
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peptide bond within the CAN proline-rich loop (Bosco et al., 2002; Bosco and 
Kern, 2004). The CypA-CA interaction can be experimentally disrupted by 
mutational inactivation of the CypA binding site within CAN (Gly89Ala/Val, 
Pro90Ala) (Luban et al., 1993; Thali et al., 1994), by the immunosuppressive 
drug cyclosporine A (CsA) or non-immunosuppressive CsA analogues that 
compete with CA for CypA binding (Takahashi et al., 1989; Rosenwirth et al., 
1994; Ptak et al., 2008), or by knock-down of CypA using RNA interference 
(RNAi) (Berthoux et al., 2005; Keckesova et al., 2006).  
As mentioned earlier, prevention of CypA binding to CAN in target cells 
impacts negatively on HIV-1 infectivity in human cells and promotes HIV-1 
growth in Old World monkey cells. However, disruption of the CypA-CA 
interaction has no impact on SIVmac because its capsid does not bind CypA 
(Towers et al., 2003; Berthoux et al., 2005; Keckesova et al., 2006). 
 
1.5.3.2 Impact of cyclophilin A on capsid stability during viral 
uncoating 
 
The Gly89-Pro90 peptide bond in HIV-1 CA exists as a mixture of cis and trans 
isomers with 14% of CA molecules being in the cis and the remainder in the trans 
conformation (Gitti et al., 1996). CypA catalyses this cis-trans isomerisation 
(Bosco et al., 2002; Bosco and Kern, 2004). Alteration of the Gly89-Pro90 bond 
can induce conformational changes within and adjacent to the proline-rich, 
CypA-binding loop in HIV-1 CAN (Bosco et al., 2002; Bosco and Kern, 2004), which 
influence capsid stability. It has therefore been hypothesised that CypA may be 
critical for the temporal regulation of HIV-1 capsid disassembly (Braaten et al., 
1996a; Braaten et al., 1996b; Bosco et al., 2002; Howard et al., 2003; Bosco and 
Kern, 2004; Luban, 2007; Li et al., 2009; Ylinen et al., 2009).  
As discussed earlier, the regulation of the timing of uncoating is crucial 
for reverse transcription and successful nuclear import of viral cDNA. If 
uncoating is delayed or prevented, the PIC will fail to enter the nucleus. If 
instead uncoating is accelerated, reverse transcription will be inhibited. In fact, 
a decreased stability of HIV-1 CA in certain CA mutants was associated with 
defects in infectivity (Franke et al., 1994; Forshey et al., 2002; Brun et al., 
2008). It is unclear whether the enzymatic activity of CypA is essential for capsid 
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stability or if simple binding of CypA to HIV-1 CAN is sufficient to promote HIV-1 
infectivity (Luban, 2007).   
 
1.5.3.3 Modulation of Old World monkey TRIM5α activity by the 
cyclophilin A-capsid interaction 
 
The impact of CypA on HIV-1 CA stability explains the reduced HIV-1 infectivity 
in human cells upon inhibition of the CypA-CA interaction. Importantly, the 
positive effect of CypA on HIV-1 replication is independent of huTRIM5α 
(Keckesova et al., 2006; Sokolskaja et al., 2006). In the absence of CypA binding 
to CAN, the susceptibility of HIV-1 to huTRIM5α was unaltered and RNAi-
mediated knock-down of huTRIM5α did not rescue HIV-1 infectivity (Keckesova et 
al., 2006; Sokolskaja et al., 2006).  
In contrast, CypA has been shown to impact on Old World monkey (OWM) 
TRIM5α-mediated HIV-1 restriction (Berthoux et al., 2005; Keckesova et al., 
2006; Sokolskaja et al., 2006; Lin and Emerman, 2008). Prevention of CypA 
binding to HIV-1 CAN in OWM cells relieves the restriction of HIV-1 by OWM 
TRIM5αs (Berthoux et al., 2005; Keckesova et al., 2006; Stremlau et al., 2006). 
In fact, HIV-1 infectivity increased to the same extent that it increased upon 
knock-down of OWM TRIM5αs (Berthoux et al., 2005). Furthermore, CsA 
treatment did not lead to enhanced HIV-1 replication in OWM cells lacking OWM 
TRIM5αs (Keckesova et al., 2006). These data indicate that in OWM cells CypA is 
required for OWM TRIM5α activity, but to date the exact mechanism of the CA-
CypA-TRIM5α interplay is not known. It has been suggested that structural 
changes induced by cis-trans isomerisation of the HIV-1 CAN Gly89-Pro90 bond 
are better recognised by OWM TRIM5α (Berthoux et al., 2005; Keckesova et al., 
2006; Stremlau et al., 2006). Alternatively, CypA binding to CAN in the absence 
of catalysis may be sufficient to promote TRIM5α activity. Binding of CypA might 
lead to conformational changes in CAN that could expose the TRIM5α binding site 
(Berthoux et al., 2005). 
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1.5.3.4 Cyclophilin A and FIV 
 
It has been shown that FIV capsid binds to CypA (Lin and Emerman, 2006). A 
previous study in our group demonstrated that FIV CAN binds to feline CypA with 
almost the same affinity with which HIV-1 CAN binds to human CypA (dissociation 
constants of 6.2 µM and 5.3 µM, respectively) and that inhibition of the CypA-CA 
interaction reduces FIV infectivity in feline cells (McEwan, 2009). McEwan (2009) 
further solved the crystal structures of FIV CAN and feline CypA and used 
structure-guided models to hypothesise that binding between the two proteins is 
most likely mediated via a proline-rich loop in FIV CAN and a hydrophobic pocket 
in feline CypA. Mutagenesis of amino residues arginine 89 (Arg89) and Pro90 in 
FIV CAN ablated capsid binding to CypA. While in HIV-1 CAN the Gly89-Pro90 bond 
exists as cis-trans isomers, the corresponding Arg89-Pro90 bond in FIV CAN does 
not (Leo James, personal communication). Thus, cis-trans isomerisation around 
this bond cannot contribute to the effect of feline CypA on FIV core stability or 
the timing of FIV uncoating. Given the fact that feTRIM5α is non-functional, it 
can be excluded that the interaction between feline CypA and FIV CA protects 
FIV from feTRIM5α. It remains unclear what causes the reduction in FIV 
infectivity seen upon CypA inhibition. 
 
1.5.4 TRIM5-cyclophilin A fusion proteins  
 
Cells of the New World owl monkey Aotus trivirgatus restrict HIV-1 but not 
SIVmac, and the antiviral activity of owl monkey TRIM5α is overcome by 
interruption of CypA-CA binding (Towers et al., 2003; Nisole et al., 2004; Sayah 
et al., 2004). Both observations are explained by the discovery that owl monkey 
cells express a CypA-TRIM5α fusion protein (omTRIMCyp) (Nisole et al., 2004; 
Sayah et al., 2004). The CypA ORF replaces the B30.2 (PRY/SPRY) domain of 
TRIM5α and no owl monkey TRIM5α transcript could be detected in OMK cells 
(Nisole et al., 2004; Sayah et al., 2004). The CypA domain of omTRIMCyp 
specifically targets HIV-1 CA and enables the TRIM5α RING domain to 
ubiquitinate CA, which leads to its proteasomal degradation and an accelerated 
uncoating of the virus. HIV-1 determinants for sensitivity to omTRIMCyp map to 
the CypA binding site (Kootstra et al., 2003; Towers et al., 2003; Berthoux et 
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al., 2004; Hatziioannou et al., 2004a) so that disruption of the CypA-CA 
interaction affects both CypA and TRIMCyp (Sayah et al., 2004). In addition to 
HIV-1, omTRIMCyp inhibits SIVagm and FIV infection, whereas SIVmac is not 
restricted (Diaz-Griffero et al., 2006b). OmTRIMCyp has arisen by 
retrotransposon-mediated insertion of a processed CypA pseudogene within 
intron 7 of the TRIM5 gene (Fig. 1-7B) (Nisole et al., 2004; Brennan et al., 2008; 
Newman et al., 2008; Wilson et al., 2008; Ylinen et al., 2010). The CypA 
insertion generated a 15-nt duplication of the insertion site sequence (target 
site duplication; TSD) (Fig. 1-7). The CypA sequence does not contain any introns 
and is flanked by 5’ untranslated region (UTR), 3’ UTR and poly-A tail sequences. 
The 5’ UTR sequence of CypA contributes eleven amino acids to omTRIMCyp, 
which link the TRIM5α RBCC domain and the CypA domain (not shown) (Nisole et 
al., 2004).   
Soon after the isolation and characterisation of omTRIMCyp, a TRIMCyp 
protein was found in about 17% of rhesus macaques (Macaca mulatta) (Newman 
2008), which has arisen independently of omTRIMCyp (Newman et al., 2008; 
Wilson et al., 2008). In contrast to omTRIMCyp the rhesus TRIMCyp (rhTRIMCyp) 
is expressed by trans-splicing of a CypA pseudogene, which lies downstream of 
the rhTRIM5 gene locus, onto the rhTRIM5α RBCC transcript (Fig. 1-7). All rhesus 
macaques which express rhTRIMCyp are either heterozygous or homozygous for a 
G-to-T substitution in the 3’ splice acceptor site upstream of exon 7 of the 
TRIM5α gene (Newman et al., 2008). This splice site mutation (AG to AU) reduces 
(in the case of heterozygote animals) or prevents (in the case of homozygote 
animals) the splicing of exon 6 of the TRIM5α gene onto exon 7 and thereby the 
expression of full-length TRIM5α. Instead, a splice acceptor site immediately 
upstream of CypA is used to generate rhTRIMCyp. In heterozygous animals, 
RhTRIMCyp is expressed alongside a full-length TRIM5α and both proteins show 
different spectra of antiviral specificities (Wilson et al., 2008). Whereas 
rhTRIM5α can restrict M and O group HIV-1, HIV-2 and FIV, rhTRIMCyp cannot 
inhibit M group HIV-1. The activity of rhTRIMCyp is abolished upon prevention of 
the CypA-CA interaction. It is assumed that at endogenous expression levels both 
factors restrict in a co-dominant way (Wilson et al., 2008). CypA-TRIM5 gene 
fusions have further been detected in pig-tailed macaques (Macaca nemestrina) 
(Brennan et al., 2008; Newman et al., 2008; Virgen et al., 2008; Ylinen et al., 
2010) and in crab-eating macaques (Macaca fascicularis) (Ylinen et al., 2010). 
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Figure 1-7 Exon organisation and splicing of TRIM5 and TRIMCyp variants.   
Non-coding exons in the TRIM5 and TRIMCyp genes are marked by a dotted line 
and coding exons by a solid line. The colour coding indicates which of the coding 
exons encode for the RING, B-box 2, coiled-coil and B30.2 (PRY/SPRY) domains 
in rhesus macaque (Macaca mulatta) TRIM5α and the CypA domains in rhesus 
macaque and owl monkey (Aotus trivirgatus) TRIMCyps (rhTRIMCyp and 
omTRIMCyp, respectively). In rhesus macaques, a CypA pseudogene is located 
downstream of the rhTRIM5 gene locus. A percentage of animals is either 
heterozygous or homozygous for a splice acceptor site mutation immediately 
upstream of TRIM5 exon 7. In these animals, a CypA mRNA is trans-spliced 
directly onto the rhTRIM5α RBCC transcript (encoded by exons 2 to 6) to give rise 
to rhTRIMCyp. OmTRIMCyp CypA is encoded by a CypA cDNA located within 
intron 7 of the omTRIM5 gene. The CypA cDNA is flanked by a duplicated 
insertion site sequence (target site duplication; TSD), a fragment of the CypA 5’ 
untranslated region (UTR), and the CypA 3’ UTR and polyadenylation (CypA poly-
A tail) sequences. The CypA 5’ UTR contributes eleven amino acids to 
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omTRIMCyp. The CypA transcript is spliced onto the transcript encoded by exons 
2 to 7 and replaces the B30.2 (PRY/SPRY) domain of omTRIM5α in the mature 
omTRIMCyp protein. In contrast to rhesus macaques, owl monkeys do not 
express a TRIM5α with intact B30.2 (PRY/SPRY) domain. 
 
1.5.5 APOBEC3 proteins 
 
The antiviral activity of APOBEC3 (apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like) proteins was discovered through the study of the HIV-
1 accessory protein Vif (viral infectivity factor) (Wolf and Goff, 2008), which was 
shown to be dispensable for viral replication in certain permissive cell lines such 
as CEM-SS and SupT1, but required in non-permissive cells such as primary CD4+ 
T cells, monocyte-derived macrophages, and some T cell leukaemia lines such as 
CEM (Fisher et al., 1987; Strebel et al., 1987; Gabuzda et al., 1992; Sakai et al., 
1993; Sova and Volsky, 1993). The human APOBEC3G protein (huA3G; initially 
called CEM-15) was identified as the responsible cellular factor whose expression 
renders human cells non-permissive for infection by HIV-1 strains devoid of the 
vif gene, but not by vif-proficient HIV-1 strains (Sheehy et al., 2002).  
 
1.5.5.1 Domain structure of APOBEC proteins 
 
HuA3G belongs to a large family of cytidine deaminases (reviewed in Harris and 
Liddament [2004], Aguiar and Peterlin [2008], Goila-Gaur and Strebel [2008]) 
that catalyse the hydrolysis of cytidines to uracils. A3 proteins and other 
APOBECs possess a characteristic domain structure. A short alpha-helical domain 
is followed by a catalytic domain (CD), a short linker peptide and a 
pseudocatalytic domain (PCD) (Fig. 1-8) (Jarmuz et al., 2002). In certain A3 
proteins, such as the human A3 proteins A3B, A3DE, A3F and A3G, the entire unit 
is duplicated and adapts the form helix 1-CD1-linker 1-PCD1-helix 2-CD2-linker 2-
PCD2 (Jarmuz et al., 2002). Each catalytic domain contains the conserved 
His/Cys-X-Glu-X23-28-Pro-Cys-X2-4-Cys motif in which the histidine and cysteine 
residues coordinate zinc ions and the glutamate residue is required for proton 
shuttling during the deamination reaction (Harris et al., 2002; Jarmuz et al., 
2002). In double-deamination domain APOBECs one catalytic domain is generally 
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Single-deamination-
domain APOBEC 
Double-deamination-
domain APOBEC 
Helix CD PCD Linker 
catalytically active whereas the second catalytic domain is involved in nucleic 
acid binding and virus encapsidation (Hache et al., 2005; Navarro et al., 2005; 
Newman et al., 2005; Iwatani et al., 2006; Opi et al., 2006). 
 
 
 
 
 
 
 
 
 
 
Figure 1-8 Schematic representation of the APOBEC domain topology. The 
domain organisation of single-deamination-domain APOBECs and double-
deamination-domain APOBECs is shown. Members of the APOBEC family 
comprise an N-terminal alpha-helix followed by a catalytic domain (CD), a short 
linker peptide and a pseudocatalytic domain (PCD). In double-deamination-domain 
APOBECs this domain structure is duplicated. Each catalytic domain contains the 
conserved cytidine-deamination motif His/Cys-X-Glu-X23-28-Pro-Cys-X2-4-Cys. 
Figure adapted from Harris and Liddament (2004). 
 
1.5.5.2 Mechanism of the antiretroviral activity of APOBEC3 
proteins 
 
In order to carry out its antiviral activity, huA3G has to be packaged into Vif-
deficient virions as they are formed in producer cells (Sheehy et al., 2002; Harris 
et al., 2003; Lecossier et al., 2003; Mangeat et al., 2003; Zhang et al., 2003). 
The N-terminal, catalytically inactive catalytic domain of huA3G is able to 
interact with viral RNA (Jarmuz et al., 2002; Yu et al., 2004a; Khan et al., 2005; 
Iwatani et al., 2006; Khan et al., 2007; Tian et al., 2007; Wang et al., 2007) and 
the NC domain of Pr55Gag (Alce and Popik, 2004; Cen et al., 2004; Schafer et al., 
Helix 1 CD1 Linker 1 PCD1 Helix 2 CD2 Linker 2 PCD2 
His/Cys-X-Glu-X23-28-Pro-Cys-X2-4-Cys 
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2004; Zennou et al., 2004). HuA3G is then carried to the target cell, where, 
upon initiation of reverse transcription, it deaminates cytidine residues in 
nascent retroviral minus-strand cDNA to uracils. Subsequently, the uracils 
function as a template for the incorporation of plus-strand adenines resulting in 
guanine to adenine hypermutations in the viral genome that critically affect 
viability and infectivity of the virus (Harris et al., 2003; Zhang et al., 2003; 
Bishop et al., 2004; Liddament et al., 2004; Zheng et al., 2004).  
Recent studies propose that, in addition to deamination, deamination-
independent mechanisms of huA3G to inhibit viral replication exist (Shindo et 
al., 2003; Newman et al., 2005; Bishop et al., 2006; Guo et al., 2006; Opi et al., 
2006; Guo et al., 2007; Holmes et al., 2007; Iwatani et al., 2007; Li et al., 2007; 
Yang et al., 2007). These affect multiple reverse transcriptase-mediated DNA 
elongation reactions during reverse transcription and collectively impair the 
accumulation of reverse transcription products (Mangeat et al., 2003; Guo et al., 
2006; Guo et al., 2007; Iwatani et al., 2007; Li et al., 2007; Luo et al., 2007; 
Mbisa et al., 2007). 
 
1.5.5.3 APOBEC3-Vif interactions 
 
The primary role of HIV-1 Vif is to prevent huA3G incorporation into virions by 
targeting A3G for proteasome-mediated degradation (Conticello et al., 2003; 
Marin et al., 2003; Sheehy et al., 2003; Stopak et al., 2003; Liu et al., 2004; 
Mehle et al., 2004a; Mehle et al., 2004b). Vif bridges an interaction between 
huA3G and a ubiquitin E3 ligase complex consisting of elongins B and C, cullin 5 
and ring-box-1 (Yu et al., 2003; Mehle et al., 2004a; Yu et al., 2004b; Bergeron 
et al., 2010). The binding of HIV-1 Vif to huA3G is dependent on the presence of 
an Asp-Pro-Asp motif at amino acid sequence positions 128 to 130 in A3G (Bogerd 
et al., 2004; Mangeat et al., 2004; Schrofelbauer et al., 2004; Xu et al., 2004). A 
positively charged Asp-Arg-Met-Arg motif (residues 14-17) and a hydrophobic 
motif between residues 40-44 in HIV-1 Vif appear to be important for the 
interaction with huA3G (Mangeat et al., 2004; Xu et al., 2004; Navarro et al., 
2005; Mehle et al., 2007). A highly conserved, hydrophobic, zinc-coordinating 
His-X5-Cys-X17-18-Cys-X3-5-His (HCCH) motif and a conserved Ser-Leu-Gln-Tyr/Phe-
Leu-Ala (SLQ) motif at positions 144-149 of HIV-1 Vif are essential for interaction 
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of Vif with the ubiquitin ligase complex (Yu et al., 2003; Liu et al., 2004; Mehle 
et al., 2004b; Mehle et al., 2006; Xiao et al., 2006). Recently, the cellular 
transcription factor CBFβ has been shown to be associated with the E3 ubiquitin 
ligase complex (Hultquist et al., 2012; Jager et al., 2012; Zhang et al., 2012). 
CBFβ is required for HIV-1 and SIV Vif folding and stability, which is crucial for 
A3G degradation (Hultquist et al., 2012; Jager et al., 2012).  
The interaction between A3 proteins and Vifs is species-specific and partly 
determines the host range of a virus (Hatziioannou et al., 2006). HIV-1 and 
SIVagm Vif can inhibit the A3G proteins of their respective host species, but not 
that of other species (Simon et al., 1995; Simon et al., 1998; Mariani et al., 
2003). SIVmac Vif acts more broadly and can neutralise not only rhesus macaque 
A3G (rhA3G) but also African green monkey A3G (agmA3G) and huA3G (Mariani et 
al., 2003). HuA3G can block replication of Vif-deficient HIV-1, HIV-2 (Ribeiro et 
al., 2005), EIAV (Mangeat et al., 2003), MLV (Harris et al., 2003; Bishop et al., 
2004; Kobayashi et al., 2004) and foamy virus (Delebecque et al., 2006). 
 
1.5.5.4 APOBEC3 proteins in the Felidae 
 
Several APOBEC3 genes have recently been identified and characterised in the 
genome of domestic cats (Munk et al., 2008). The A3 gene locus encodes three 
highly similar A3C (A3Z2) genes and an A3H (A3Z3) gene. Additionally, a fifth 
transcript, which is generated by read-through alternative splicing, encodes the 
protein A3CH (A3Z2-Z3) (Munk et al., 2008; Zielonka et al., 2010). Domestic cat 
A3 proteins are overcome by FIV Vif and the FeFV Bet protein (Lochelt et al., 
2005; Munk et al., 2008; Stern et al., 2010; Zielonka et al., 2010). Similar to HIV-
1 Vif, FIV Vif recruits an E3 ubiquitin ligase complex consisting of elongin B, 
elongin C and cullin 5 to induce proteasomal degradation of A3 proteins (Wang 
et al., 2011). However, in contrast to HIV-1 Vif, FIV Vif does not possess the 
zinc-coordinating HCCH motif or the SLQ motif to interact with the E3 ubiquitin 
ligase complex (Wang et al., 2011), and it has yet to be determined which amino 
acid residues mediate the binding of FIV Vif to cullin 5. In addition to FIV Vif, 
domestic cat A3 proteins are also overcome by SIVmac Vif, but not by HIV-1 Vif 
(Stern et al., 2010). 
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The feline A3 proteins display different degrees of activity against feline 
retroviruses. Feline A3C proteins inhibit the replication of Bet-deficient FeFV 
(Lochelt et al., 2005) but do not restrict Vif-deficient FIV or FeLV. In contrast, 
feline A3H and A3CH proteins are active against Vif-deficient FIV as well as FeLV 
but not against Bet-deficient FeFV (Lochelt et al., 2005; Munk et al., 2008).  
The antiviral activities of A3 proteins from non-domestic cat resemble 
those of domestic cats (Zielonka et al., 2010). Lion, puma, tiger (Panthera 
tigris) and lynx (Lynx lynx) A3H and A3CH isoforms block replication of Vif-
deficient FIV, whereas non-domestic cat A3C proteins are sensitive to FIV lacking 
the Vif protein. FIV Vif induces degradation of all wild cat A3C, A3H and A3CH 
proteins.   
 
1.5.6 Tetherin 
 
In addition to the early post-entry blocks, restriction factors such as tetherin 
contribute to a late block to retroviral replication in that they prevent the 
release of mature enveloped viral particles from the membranes of infected 
cells. Tetherin (also called HM1.24/BST-2/CD317) was originally identified as a 
bone marrow stromal cell surface antigen selectively expressed on terminally 
differentiated normal and neoplastic human B cells and corresponding cell lines 
(Goto et al., 1994; Ishikawa et al., 1995). The antiviral activity of tetherin was 
not discovered until 2008, when it was noted that its cell-type specific 
expression matched closely the dependency of HIV-1 on the accessory protein 
Vpu for virus release from certain human cell lines (Strebel et al., 1989; 
Terwilliger et al., 1989; Klimkait et al., 1990; Varthakavi et al., 2003; Neil et 
al., 2008; Van Damme et al., 2008). Tetherin is constitutively expressed in 
human cell lines such HeLa cells (Gottlinger et al., 1993), several cancer cell 
lines (Ohtomo et al., 1999), B cells, T cells, monocytes, macrophages and 
plasmacytoid dendritic cells (Blasius et al., 2006; Miyagi et al., 2009), and its 
expression is induced or enhanced by type I and type II interferons in cell lines 
such as HOS, 293T, HT1080 cells (Neil et al., 2006; Neil et al., 2007; Neil et al., 
2008; Van Damme et al., 2008; Miyagi et al., 2009). IFN treatment renders cell 
lines Vpu-dependent that do not normally require Vpu for efficient virus release 
(Neil et al., 2007).  
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1.5.6.1 Domain structure of tetherins and intracellular 
localisation and trafficking 
 
Several studies have shown that tetherins are novel type II transmembrane 
proteins with a molecular weight of 30-36 kDa (Ishikawa et al., 1995; Ohtomo et 
al., 1999; Kupzig et al., 2003). They harbour an N-terminal cytoplasmic tail, 
followed by a transmembrane domain, an extracellular parallel, dimeric, alpha-
helical coiled-coil domain and a C-terminal GPI anchor (Fig. 1-9) (Ishikawa et al., 
1995; Ohtomo et al., 1999; Kupzig et al., 2003; Rollason et al., 2007; Hinz et al., 
2010).  
 
 
 
 
 
 
 
 
 
Figure 1-9 Schematic representation of the tetherin domain topology. 
Tetherins harbour an N-terminal cytoplasmic domain (red), a transmembrane 
domain (blue), an extracellular alpha-helical coiled-coil domain (cyan) and a C-
terminal GPI anchor (yellow). The positions of two putative N-linked glycosylation 
sites (arrows) in the extracellular domain are highlighted. The GPI-modification 
causes tetherin to partition into lipid rafts in the plasma membrane. 
 
Two potential N-linked glycosylation sites and three conserved cysteine residues 
are present in the extracellular domain (Ishikawa et al., 1995; Ohtomo et al., 
1999; Kupzig et al., 2003). Heterogeneous glycosylation of tetherin has been 
shown to be essential for efficient secretion and folding (Andrew et al., 2009; 
Goffinet et al., 2009; Kaletsky et al., 2009; McNatt et al., 2009; Miyagi et al., 
2009; Perez-Caballero et al., 2009). The cysteines take part in intra- and 
intermolecular disulfide bond formation and enable the homodimerisation of 
tetherin (Ohtomo et al., 1999; Kupzig et al., 2003; Perez-Caballero et al., 2009). 
The GPI-modification causes tetherin to partition into and cross-link cholesterol- 
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and sphingolipid-rich microdomains in the plasma membrane (Simons and 
Ikonen, 1997; Simons and Toomre, 2000; Kupzig et al., 2003). Tetherin cycles 
between these lipid rafts on the cell surface and an intracellular pool where it 
localises predominantly to the Golgi apparatus, the trans-Golgi network (TGN) 
and recycling endosomes (Kupzig et al., 2003). Internalisation from the plasma 
membrane is mediated by clathrin-dependent endocytosis (Rollason et al., 2007) 
(Masuyama et al., 2009). 
 
1.5.6.2 Mechanism of the antiviral activity of tetherin 
 
Tetherin causes the retention of fully formed mature virions on the surface of 
cells infected with Vpu-deficient HIV-1 (Neil et al., 2008; Van Damme et al., 
2008). At the expense of particle release, virions accumulate at the cell surface 
and a fraction of them are endocytosed via a clathrin-dependent mechanism and 
degraded (Neil et al., 2006; Neil et al., 2007). Current models predict that 
tetherin is present at sites of particle assembly in the cell membrane and is 
incorporated into virions (Perez-Caballero et al., 2009; Fitzpatrick et al., 2010). 
Presumably, one end of tetherin embeds in the lipid bilayer of the cell and the 
other in that of the virion, so that cell-surface tetherin homodimerises with 
virion-associated tetherin via disulfide bonds or via coiled-coil regions in the 
extracellular domain (Fitzpatrick et al., 2010). Thus, virions remain bound to the 
cell surface and are cross-linked to each other by tetherin. In addition to 
lentiviruses, tetherin blocks virion release from members of the alpharetrovirus, 
betaretrovirus, deltaretrovirus, spumaretrovirus, arenavirus (Lassa) and filovirus 
(Ebola, Marburg) families (Jouvenet et al., 2009; Kaletsky et al., 2009; Sakuma 
et al., 2009). 
 
1.5.6.3 Viral tetherin antagonists 
 
HIV-1 Vpu is an integral class I membrane phosphoprotein (Cohen et al., 1988) 
that promotes virion release from HIV-1 infected human cells that express 
tetherin (Klimkait et al., 1990; Neil et al., 2006; Neil et al., 2008; Van Damme et 
al., 2008). It has been shown to colocalise with tetherin (Neil et al., 2008; Van 
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Damme et al., 2008) and to reduce its cell-surface expression by targeting it for 
degradation (Van Damme et al., 2008; Douglas et al., 2009; Goffinet et al., 
2009; Mitchell et al., 2009; Miyagi et al., 2009). A well-studied role of Vpu is to 
mediate the proteasomal degradation of the HIV-1 receptor CD4 in the ER 
through the recruitment of the β-transducin repeat-containing protein (βTrCP) 
subunit of the Skp1-cullin1-F-box (SCF) ubiquitin ligase complex (Willey et al., 
1992a; Bour et al., 1995; Margottin et al., 1998). βTrCP is also involved in the 
antagonism of tetherin because disruption of the interaction between βTrCP and 
the βTrCP binding motif in the cytoplasmic domain of Vpu reduces the capacity 
of Vpu to promote virus release (Douglas et al., 2009; Mangeat et al., 2009; 
Mitchell et al., 2009). Vpu serves as an adapter between βTrCP and tetherin. 
Tetherin and Vpu bind to each other through their transmembrane domains 
(Iwabu et al., 2009; Rong et al., 2009). It seems that Vpu sequesters tetherin 
within the endolysosomal system either within the TGN after it has been 
synthesised or within recycling endosomes after natural endocytosis of tetherin 
from the cell surface has occurred (Dube et al., 2009; Mitchell et al., 2009). This 
intracellular sequestration is followed by partial lysosomal degradation of both 
tetherin and Vpu.   
Vpu is only encoded by a unique lineage of primate lentiviruses that 
include HIV-1 and the SIVs of chimpanzees (Pan troglodytes) (Cohen et al., 
1988), Mona monkeys (Cercopithecus mona), mustached monkeys (C. cephus) 
and greater spot-nosed monkeys (C. nictitans); SIVcpz, SIVmon, SIVmus and 
SIVgsn, respectively (Courgnaud et al., 2003). SIVmon, SIVmus and SIVgsn Vpu 
counteract tetherins of their respective host species as well as macaque 
tetherins, but, with the exception of SIVgsn, not human tetherin (huTHN) 
(Sauter et al., 2009; Yang et al., 2010). Accordingly, non-human, non-
chimpanzee tetherins are usually insensitive to antagonism by HIV-1 Vpu 
(Goffinet et al., 2009; Gupta et al., 2009a; Jia et al., 2009; McNatt et al., 2009; 
Sauter et al., 2009; Zhang et al., 2009a). SIVcpz is the immediate precursor of 
HIV-1 and its Vpu shares a common ancestry with SIVmon/mus/gsn Vpu (Sauter 
et al., 2009). However, SIVcpz Vpu is non-functional against both chimpanzee 
tetherin (cpzTHN) and huTHN. Instead, in SIVcpz the accessory protein Nef has 
adopted a Vpu-like function. It is likely that, after cross-species transmission 
from chimpanzees to humans, HIV-1 Vpu has adapted to counteract huTHN, 
because huTHN is resistant to Nef due to a deletion in its cytoplasmic tail 
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(Sauter et al., 2009; Zhang et al., 2009a). Species-specific tetherin antagonism 
by Nef is also conserved in SIVs of sooty mangabeys, rhesus macaques and 
African green monkeys, SIVsmm, SIVmac and SIVagm, respectively. Like Vpu, Nef 
also induces cell-surface downregulation of monkey tetherins (Jia et al., 2009). 
Additionally to Vpu and Nef, the HIV-2 and SIVagm.Tan (SIVagm of the Tantalus 
monkey, Chlorocebus tantalus) envelope glycoproteins possess anti-tetherin 
activities (Abada et al., 2005; Gupta et al., 2009b; Le Tortorec and Neil, 2009).  
 
1.6 Scope of the thesis 
 
FIV infection of domestic cats leads to the development of a fatal 
immunodeficiency syndrome similar to AIDS in humans; however, FIV infection of 
non-domestic cats is usually benign. It is likely that the relatively short period of 
time for which FIV has been circling in the domestic cat population was 
insufficient for host-virus co-adaptation to occur, leading to immunodeficiency. 
Non-domestic felids, on the other hand, have co-existed with lentiviruses for 
millions of years. Hence, non-domestic cat FIV strains could either be less 
virulent or less pathogenic, or spreading in species with genetic adaptations that 
confer efficient immunological defense to viral infection. 
In fact, although FIV is able to replicate in both domestic and non-domestic cats, 
in vitro studies have indicated that FIV infection of non-domestic cat T 
lymphocytes is significantly less efficient than that of domestic cat T cells. Thus, 
this thesis tests the hypothesis that non-domestic cat restriction factors are 
either more potent antagonists of lentiviral replication than domestic cat 
restriction factors or that their activity is less sensitive to viral counteraction. 
In this thesis, the activities of domestic and non-domestic cat restriction 
factors against lentiviruses are compared. Specific attention is further paid to 
the characterisation of viral accessory proteins and their ability to overcome the 
feline restriction factors. Finally, the potential of feline restriction factors for 
use in anti-retroviral therapies is explored.   
 
 Chapter 3 describes the generation of a synthetic feline-specific TRIM5α-
cyclophilin A fusion protein (feTRIMCyp). The study finds that feTRIMCyp 
is highly efficient at blocking lentiviral infection, an activity that can be 
78 
 
reversed by cyclosporine A and its derivatives. FeTRIMCyp and FIV 
infection of the cat offers a unique opportunity to evaluate TRIMCyp-
based approaches to genetic therapy for FIV and HIV infections and the 
treatment of AIDS. 
 
 In Chapter 4 domestic and non-domestic cat APOBEC3 proteins are 
characterised and their activities against FIV and other lentiviruses are 
compared. No significant differences in the antiviral potencies of these 
restriction factors against FIV lacking the viral APOBEC3 antagonist Vif are 
detected. Further analysis focuses on APOBEC3 expression levels in 
different feline cell lines, primary cells and tissues. Finally, insights in the 
evolution of lion APOBEC3 proteins in the presence or absence of FIV 
infection are provided. Surprisingly, no indication for viral selection 
pressure on the evolution of lion APOBEC3 proteins is found. 
Consequently, the activities of FIV Vif proteins against feline APOBEC3 
proteins are determined. Here, cat APOBEC3CH is significantly more 
sensitive to FIV containing Vif compared to non-domestic cat APOBEC3CH 
proteins. 
 
 In Chapter 5 felid homologues of tetherin are characterised and their 
effects on the replication of FIV are investigated. Domestic cat tetherin 
displays potent inhibition of FIV and HIV-1 particle release and no tetherin 
antagonist is found in the FIV genome. However, when stably expressed in 
feline cell lines, tetherin cannot abrogate the replication of FIV. In fact, 
tetherin expression is found to promote cell-to-cell spread of cell culture-
adapted, CD134-independent FIV strains. The study further focuses on the 
characterisation of non-domestic cat tetherins and their activity against 
feline retroviruses. No significant differences in the potencies of domestic 
and non-domestic cat paralogues are found.  
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 Materials and Methods 2
2.1 Molecular cloning 
 
2.1.1 Nucleic acid extraction 
 
Total RNA or genomic DNA were isolated from human, feline and canine cell 
lines, primary cells or cat tissue samples by homogenising 1x106 cells using 
QIAshredder Spin Columns and RNAeasy Mini Spin Columns (Qiagen, Crawley, UK) 
or the QIAamp DNA Mini and Blood Mini kit (Qiagen), respectively. Nucleic acids 
were eluted in RNase-free water (Life Technologies, Paisley, UK), quantified by 
spectroscopy at 260 nm and stored at -80°C until further use. 
 
2.1.2 cDNA synthesis 
 
First strand cDNA synthesis was performed using 1 μg total RNA and oligo(dT) 
primers and the Transcriptor High Fidelity cDNA Synthesis kit (Roche Applied 
Science, Roche Diagnostics Ltd., Burgess Hill, UK) according to manufacturer’s 
instructions. CDNA was stored at -20°C until further use.  
 
2.1.3 PCR methods 
 
 
Transcripts of interest were amplified by polymerase chain reaction (PCR) from 2 
μl cDNA using Phusion High-Fidelity DNA polymerase (Finnzymes, Hitchin, UK). 
Cycling parameters were set as per manufacturer’s instructions. The standard 
reaction mix composition used was 5x HF buffer 4 μl, dNTPs 200 μM each, gene-
specific primers 0.5 μM each, DMSO 3% v/v, Phusion High-Fidelity DNA 
polymerase 0.02 U/μl.  
PCR amplification from plasmid DNA was performed using 25-200 ng 
template DNA. PCR amplification from genomic DNA or bacterial colony 
suspensions (see below) was carried out using 100 ng genomic DNA or 2 μl of 
bacterial colony suspension as template and GoTaq Flexi DNA polymerase 
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(Promega, Southampton, UK). Cycling parameters were adjusted as per 
manufacturer’s instructions. The standard reaction mix composition used was 5x 
Green GoTaq Flexi Buffer 10 μl, dNTPs 200 μM each, gene-specific primers 0.2 
μM each, MgCl2 Solution 1.5 mM, GoTaq DNA polymerase 1.25 U/μl. Annealing 
temperature optimisation using temperature gradients was performed when 
necessary.  
Lyophilised primers were ordered from Eurofins MWG Operon (Ebersberg, 
Germany), resuspended in sterile distilled water to a stock concentration of 100 
pmol/μl and to a working stock concentration of 10 pmol/μl. Lyophilised real-
time PCR primers were resuspended in sterile distilled water to a stock 
concentration of 100 pmol/μl and to a working stock concentration of 20 
pmol/μl. Lyophilised real-time PCR probes were diluted in qPCR Probe dilution 
buffer (Eurofins MWG Operon) to a stock concentration of 100 pmol/μl and to a 
working stock concentration of 5 pmol/μl. Primers and probes were stored at -
20°C. A list of primers and probes used and a list of buffers and solutions are 
displayed in the Appendix. 
 
2.1.4 Cloning techniques 
 
PCR products were analysed and purified using agarose gel electrophoresis. TBE 
buffer containing 1% agarose was dissolved in a microwave and allowed to cool 
to 50°C. Ethidium bromide was added and the gel was cast into an 
electrophoresis chamber. It was immersed in TBE buffer prior to use. The DNA 
was loaded in 1x DNA loading buffer and fragments were separated at 80 V for 
40 minutes. 0.5 μg of 1 kb DNA ladder (New England Biolabs, Hitchin, UK) was 
loaded for product size estimation. DNA products were observed on a UV 
transilluminator and excised from the gel using a sterile scalpel. Gel extraction 
was performed using the QIAquick Gel Extraction kit (Qiagen) and PCR products 
were eluted in 35 μl distilled water. 
For molecular cloning, purified PCR products and vectors were digested 
with restriction endonucleases (New England Biolabs; Life Technologies, Paisley, 
UK) at a concentration of 1 U/μl for 2 hours at 37°C with the buffers 
recommended by the manufacturers. Digested DNA was purified using the 
QIAquick PCR Purification kit (Qiagen) and eluted in 35 μl distilled water. 
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Digested vector DNA was purified by agarose gel electrophoresis prior to further 
purification using the QIAquick Gel Extraction kit (Qiagen). Digested vector DNA 
was eluted in 35 μl distilled water. Digested PCR product was ligated into 
digested vector DNA using T4 DNA polymerase (New England Biolabs) at 1 U/μl 
overnight at 14°C. 30% of the ligation mix was transformed into 35 μl chemically 
competent Escherichia coli (New England Biolabs; Life Technologies) using the 
respective heat shock protocols supplied by the manufacturers. Transformed 
bacteria were plated onto Luberia Bertani (LB) broth agar plates containing 50 
μg/ml ampicillin or kanamycin (Sigma-Aldrich, Dorset, UK) and grown overnight 
at 30°C (applies to FIV envelope glycoproteins) or 37°C.  
Colonies were screened for the presence of the insert-vector combination 
of interest by colony PCR or by restriction digestion. For colony PCR, colonies 
were picked and resuspended in 20 μl distilled water. 2 μl of the bacterial colony 
suspensions and GoTaq Flexi DNA polymerase (Promega) were used per PCR 
reaction as described above. Gene-specific or vector-specific primers were 
designed to detect the presence or absence of the desired insert in the bacterial 
clones. Alternatively, colonies were grown overnight in 5 ml LB broth at 30°C or 
37°C in an orbital shaker set to 200 rpm. Plasmid DNA was extracted from the 
cultures using the QIAprep Spin Miniprep kit (Qiagen) and eluted in 35 μl distilled 
water. Plasmid DNA was subjected to restriction digestion and agarose gel 
electrophoresis as previous. Glycerol stocks of clones of interest were made by 
diluting cultures to a final glycerol concentration of 25% followed by storage at -
80°C.  
Large-scale plasmid DNA preparations were performed by inoculating 200 
ml LB broth containing appropriate antibiotics with bacterial clones. Cultures 
were grown overnight at 30°C or 37°C and plasmid DNA was isolated using the 
PureLink HiPure Filter Plasmid Maxiprep kit (Life Technologies). Maxiprep DNA 
was resuspended in sterile TE buffer and stored at 4°C. 
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2.1.5 DNA mutations 
 
Site-directed mutagenesis PCRs were carried out to insert nucleotide or amino 
acid codon changes into plasmid DNA. The QuikChange Site-Directed Mutagenesis 
kit (Agilent Technologies, Wokingham, UK) was used for plasmids of up to 8 kb in 
length and the QuikChange XL Site-Directed Mutagenesis Kit (Agilent 
Technologies) for plasmids over 8 kb in length according to the manufacturer’s 
instructions. The standard reaction mix composition used was 10x reaction 
buffer 5 μl, dNTP mix 1 μl, gene-specific primers 125 ng each, plasmid DNA 
template 25 ng, PfuTurbo DNA polymerase 2.5 U/μl. Deviating from the 
instructions, mutated and DpnI-digested DNA contained in 50 μl reaction mix was 
added to 50 μl of distilled water. The DNA was then precipitated with 200 μl 
ethanol (100%) containing sodium acetate at a concentration of 15 mM for 30 
minutes at – 80°C. The DNA was pelleted at 14,000 rpm (Eppendorf FA-45-18-11 
rotor) for 20 minutes and the DNA pellet was resuspended in 10 μl distilled 
water. The DNA was then transformed into chemically competent Escherichia 
coli strain DH5α as described above. Colonies were picked from the LB agar 
plates, plasmid DNA was prepared (QIAprep Spin Miniprep kit) and analysed by 
DNA sequencing.  
 
2.1.6 DNA sequencing 
 
Chain termination sequencing reactions were set up in house using BigDye v1.1 
(Applied Biosystems, Life Technologies, Paisley, UK) and thermally cycled 
according to manufacturer’s instructions. Template-specific primers were used 
at a final concentration of 0.16 μM. PCR reactions were ethanol-precipitated and 
the DNA pellets were resuspended in 20 μl HiDi (Applied Biosystems). Sequencing 
reactions were run on an ABI 3700 automated capillary array sequencer (Applied 
Biosystems) and sequence traces were analysed using the DNADynamo software 
(Blue Tractor Software Limited, Llanfairfechan, UK).  
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2.2 Cells and viruses 
 
2.2.1  Culture of cell lines and primary cells 
 
Adherent cells were maintained in Dulbecco’s modification of Eagle’s medium 
(DMEM) containing 10% fetal bovine serum (FBS), 2 mM glutamine and antibiotics 
(100 U/ml penicillin, 100 μg/ml streptomycin) at 37°C and 5% CO2. Suspension 
cells were grown in RPMI 1640, supplemented with 10% FCS, 2 mM glutamine, 
antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin), 10% HEPES, 1 mM 
sodium pyruvate and 0.05 mM 2-mercaptoethanol at 37°C and 5% CO2. Cells were 
grown in disposable plastic tissue culture flasks (Corning, Ewloe, UK) and 
passaged when confluent. When confluent, medium was removed from the cells 
and the cell monolayer was washed with PBS. Cells were dissociated from the 
flask by incubation with 0.05% trypsin (Life Technologies) in PBS for 5 minutes at 
room temperature. Trypsin activity was stopped by resuspension of the cells in 
complete DMEM. Cells were pelleted at 1,000 rpm (Eppendorf A-4-62 rotor) for 5 
minutes and the cell pellet was resuspended in complete DMEM. New cultures 
were seeded at the desired density.  
The feline T-cell line Mya-1 and primary T lymphocytes were maintained 
in complete RPMI containing conditioned medium from a murine cell line (L2.3) 
transfected with a human IL-2 expression construct (equivalent to 100 U/ml of 
recombinant human IL-2). Primary T lymphocytes were expanded from PBMCs by 
stimulation with concanavalin A (2 μg/ml; Sigma-Aldrich). Cells were passaged at 
the required density by centrifugation at 800 rpm (Eppendorf A-4-62 rotor) for 5 
minutes and resuspension in complete RPMI.  
Cells used throughout the study are HEK-293T cells (human embryonic 
kidney cells) (Graham et al., 1977), the feline cell lines 3201 (thymic 
lymphosarcoma cells) (Snyder et al., 1978), AH927 (fibroblasts) (Rasheed and 
Gardner, 1980), Crandell feline kidney (CrFK; clone ID10; kidney epithelioid 
cells) (Crandell et al., 1973), FEA (foetal embryo fibroblast-like cells) (Jarrett et 
al., 1973) and Mya-1 (IL-2 dependent T cell line) (Miyazawa et al., 1989). 
Additionally, CLL cells (canine chronic lymphocytic leukaemia cells) (Willett et 
al., 2006), primary feline macrophages and primary lion T lymphocytes were 
used.  
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2.2.2 Infection of cells with replication-competent viruses 
 
Infection of cells with replication-competent FIVs was performed by incubating 
target cells with viral inocula. Supernatant containing clonal FIV was produced 
by transfection of 293T cells with full-length molecular clones of different FIV 
strains using SuperFect transfection reagent (see below). Three days post-
transfection, supernatant from 293T cells was harvested, cleared by 
centrifugation at 2,000 rpm (Eppendorf A-4-62 rotor) for 10 minutes and 
incubated with Mya-1 cells. FIV replication was confirmed using a lentivirus 
reverse transcriptase activity assay (see below). Supernatant from infected Mya-
1 culture was then harvested and cleared. Virus stocks were stored at -80°C.  
Prior to infection, adherent cells were seeded at a density of 2x105 cells 
per well in 6-well plates and left to adhere overnight. Cells were incubated with 
100 μl viral inoculum for 2 hours at 37°C, washed with PBS and cultured in 
complete DMEM. Typically 2x106 suspension cells per well of a 6-well plate were 
transferred to Falcon tubes (BD Biosciences, Oxford, UK) and pelleted. They 
were resuspended in 0.9 ml complete RPMI and incubated with 100 μl viral 
inoculum for 2 hours at 37°C, washed with PBS and cultured in 6-well plates in 
complete RPMI. To monitor virus growth, 100 μl aliquots of cell-free supernatant 
were collected on a daily basis and stored at -80°C for quantification by reverse 
transcriptase activity assays.  
 
2.2.3 Stable transduction of cells 
 
For stable expression, transgenes were inserted into the mammalian expression 
vector pDON-AI-2neo (Takara Bio Europe S.A.S./Clontech, Saint-Germain-en-
Laye, France). Retroviral vector transduction was performed to integrate the 
vector construct into CrFK, FEA or CLL cells. MLV pseudotypes containing the 
vector construct to be transduced were produced by seeding 1x106 293T cells in 
100-mm cell culture dishes overnight and transfecting them with pCIG3N (MLV-N 
Gag-Pol) (Bock et al., 2000), pMDG (VSV-G) (Yee et al., 1994) and the transgene-
pDON-AI-2neo construct. 72 hours post-transfection, MLV pseudotypes were 
harvested, cleared by centrifugation at 2,000 rpm (Eppendorf A-4-62 rotor) for 
10 minutes and used to infect target cells. For transduction, target cells were 
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seeded in T-25 flasks 16 hours prior to transduction at a low density. Target cells 
were incubated with the pseudotypes for 2 to 4 hours. Cells were then washed in 
PBS and resuspended in complete cell culture media. 48 hours post-transduction, 
stably-transduced cells were selected in geneticin (G418; 800 μg/ml) (Life 
Technologies). After selection the geneticin concentration was reduced to 400 
μg/ml. Certain stable cell lines used in this study, especially those expressing 
CD134, were created using the vector pDsRed2 (Takara Bio Europe/Clontech) 
instead of p-DON-AI-2 Neo. These cell lines were selected using puromycin (1 
μg/ml) (Life Technologies).  
 
2.2.4 Transient transfection of cells 
 
293T cells were seeded in 12-well plates at a density of 1x105 cells per well or in 
100-mm culture dishes at a density of 1x106 cells per dish and allowed to adhere 
overnight. Cells were then transfected using SuperFect (Qiagen) according to the 
manufacturer’s recommendations. The medium of transfected cells was removed 
4 hours post-transfection. The cell monolayer was washed with PBS and cells 
were grown in complete DMEM for 48 to 72 hours at 37°C.  
 
2.2.5 Pseudotype production and pseudotype assay 
 
In this study pseudotype assays were performed to investigate the effect of 
feline restriction factors on lentiviral egress from producer cells or on early post-
entry processes in target cells in the absence of viral spread. Pseudotypes were 
produced by three-vector transfection of 293T cells. Equal amounts of a vector 
encoding a lentiviral Gag-Pol protein, a marker protein and an Env protein were 
transfected. The gag-pol-expression construct is known as the packaging vector. 
In producer cells, gag and pol are transcribed and their mRNAs are translated. 
Env is produced from the env-expressing vector. Gag, Pol and Env assemble into 
VLPs. The marker gene-expressing plasmid contains the RNA packaging signal Ψ. 
In producer cells, the marker gene is transcribed and marker gene transcripts 
are translated. Marker gene vector mRNA is also packaged into VLPs. In target 
cells, the marker gene is reverse transcribed into DNA by RT contained in viral 
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particles. The marker gene then integrates in the host genome with the help of 
VLP-contained lentiviral integrase and is stably expressed. In contrast, viral 
particles do not contain Gag-Pol or Env-encoding RNAs so that in target cells only 
Gag-Pol and Env proteins are present. Thus, in pseudotype assays only single-
cycle lentiviral replication occurs. In pseudotyped viral particles the lentiviral 
Env protein is replaced by a foreign envelope glycoprotein. In this study the 
vesicular stomatitis virus G glycoprotein (VSV-G) was used as a surrogate Env. 
VSV-G enables high-titre VLP production and exhibits a broad cell tropism as it 
binds to phospholipids in plasma membranes (Burns et al., 1993; Yee et al., 
1994). VSV-G pseudotyped viral particles enter target cells by clathrin-mediated 
endocytosis instead of receptor-mediated uptake (Matlin et al., 1982).  
HIV-1 pseudotypes were prepared using the HIV-1-derived packaging 
plasmids p8.91 (expressing Gag-Pol, Tat and Rev) or p8.2 (expressing Gag-Pol, 
Tat, Rev, Vpr, Vpu, Vif and Nef) (Zufferey et al., 1997), SIN CSGW (GFP-encoding 
HIV-1 genome) (Naldini et al., 1996), and pMDG (VSV-G) (Naldini et al., 1996). 
SIV pseudotypes were produced using the SIVmac-derived vectors SIV4+ 
(expressing Gag-Pol, Tat, Rev) or SIV3+ (expressing Gag-Pol, Tat, Rev, Vif, Vpx 
and Vpr) (Negre et al., 2000), SIV-GFP (GFP) (Negre et al., 2000) and pMDG (VSV-
G). FIV pseudotypes were prepared using the FIV-based vectors FP93 (Gag-Pol) 
(Poeschla et al., 1998; Saenz and Poeschla, 2004), pGinSin (GFP) (Poeschla et 
al., 1998) and pMDG (VSV-G). 
In this study pseudotypes were often produced in the presence of 
restriction factor expression plasmids. In this case, 1x105 293T cells per well in 
12-well plates or 1x106 293T cells in 100-mm culture dishes were left to adhere 
overnight at 37°C. Transfections in 12-well plates were performed using 600 ng 
of each of the respective three lentiviral vectors described above and 100 ng 
(tetherin) or 200 ng (APOBEC3 proteins) restriction factor expression plasmid. 
The eukaryotic expression vector VR1012 (Vical Inc., San Diego, U.S.A.) was 
chosen in these experiments because it enables CMV promoter-driven, high-level 
expression of restriction factors in 293T cells. Transfections in 100-mm culture 
dishes were carried out using five times the amount of plasmid DNA used for 12-
well plates. Unless otherwise stated, APOBEC3 activity assays were performed in 
12-well plates with or without 500 ng FIV Vif expression construct. Tetherin 
activity assays were performed in 100-mm culture dishes using 750 ng tetherin 
expression plasmid in the presence or absence of 250 ng FIV OrfA expression 
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plasmid 1S-5RL (Pistello et al., 2003), 3 µg FIV Env expression plasmids or a 
replication-defective molecular clone of FIV (CMVG8MΔpol4). 
 48 hours post-transfection, fresh 293T cells (target cells) were seeded in 
12-well plates at a density of 2.5x104 cells per well and left to adhere overnight 
at 37°C. 72 hours post-transfection, the medium was removed from target cells 
and 1 ml pseudotype-containing supernatant from transfected 293T cells was 
used to transduce target cells. Remaining supernatant was stored at -80°C until 
further use. Transfected 293T cells were washed with PBS, harvested, pelleted 
and stored at -20°C for immunoblotting. 72 hours post-transduction, the medium 
was removed from target cells and the cells were resuspended in 1 ml PBS-BSA-
azide in 5-ml round-bottom Falcon tubes (BD Biosciences). The cells were then 
analysed for marker gene expression by flow cytometry using a BD Accuri C6 
cytometer (BD Biosciences).  
 
2.3 Quantitative techniques and immunoblotting 
 
2.3.1 Quantification of reverse transcriptase activity 
 
Reverse transcriptase activity in supernatants of virus-producing cells was 
assayed using a Lenti-RT (for FIV) or C-type RT (for FeLV and RD114) non-isotopic 
RT assay kit (Cavidi Technology, Uppsala, Sweden). The procedure consists of a 
DNA synthesis and a DNA quantification step. A reaction mixture is added to a 
96-well plate that is coated with a RNA template. The reaction mixture contains 
a primer and nucleotides (BrdUTP) both of which are used by RT in the sample to 
synthesise a DNA strand. After incubation at 33°C the plates are washed using 
the provided wash buffer and tracer reagent is added which contains alkaline 
phosphatase (AP)-conjugated anti-BrdU antibodies. These bind to the double-
stranded DNA/RNA molecule. Plates are again washed and the product is 
quantified by addition of the chromogenic AP substrate para-
Nitrophenylphosphate (pNPP). PNPP is converted into yellow para-Nitrophenol 
(pNP). AP activity is proportional to the RT activity present in the sample. 10 μl 
of sample were used for RT assay and absorbance of pNP at 405 nm was 
determined using a spectrophotometer.  
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2.3.2 Real-time PCR 
 
Real-time PCR was carried out on 1 μl cDNA template. Cycling parameters were 
1 cycle of 50°C for 2 minutes; 1 cycle of 95°C for 10 minutes; 40 cycles of 95°C 
for 15 seconds and 60°C for 1 minute. The standard reaction mix composition 
used was 2x Universal TaqMan Mastermix (Applied Biosystems) 25 μl, gene-
specific primers 0.9 μM each, dual-labelled (5’ FAM, 3’ TAMRA) probe 225 nM. 
Serially diluted (109–100 copies/μl) plasmid DNA was used as standard for real-
time PCR. 18S ribosomal RNA (rRNA) was used as housekeeping gene. Reactions 
were set up in MicroAmp Optical 96-well plates (Applied Biosystems) and results 
were analysed on an Applied Biosystems 7500 real-time PCR system. ΔCT values 
(where “CT” represents “threshold cycle”) were calculated by subtracting the 
mean CT for 18S rRNA from the CT for the transcript of interest. 
 
2.3.3 SDS-PAGE and immunoblotting 
 
Cells were pelleted and lysed in CHAPS lysis buffer supplemented with protease 
inhibitor cocktail (Complete protease inhibitor; Roche). Protein concentration of 
lysates was determined in 96-well plates using Coomassie Blue Bradford Assay 
Reagent (Thermo Scientific, Fisher Scientific, Loughborough, UK). Absorbance of 
samples was measured at 650 nm in a spectrophotometer. Virions in cleared cell 
culture supernatants were pelleted by ultracentrifugation at 28,000 rpm for 2 
hours at 4°C in a Beckman L8-70M ultracentrifuge (SW-41 rotor; Beckman 
Coulter Limited, High Wycombe, UK). Cell lysates and corresponding pelleted 
virions were combined with protein loading dye and separated using sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 12% Bis-Tris 
SDS-PAGE gels (Life Technologies) in NuPAGE MES SDS Running buffer (Life 
Technologies). Separated proteins were then transferred onto nitrocellulose 
membranes using the iBlot system (Life Technologies) and blocked with 5% dried 
milk powder in PBS containing 0.1% (vol/vol) Tween-20 for 1 hour at room 
temperature. Membranes were incubated with the appropriate primary antibody 
diluted to 1 μg/ml in PBS-0.1% Tween-20-5% dried milk powder for 1 hour at 
room temperature. Membranes were washed with PBS-0.1% Tween-20 three 
times for 5 minutes. Primary antibodies were detected with biotinylated anti-
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mouse/rabbit/goat IgG secondary antibodies (Vector Laboratories, 
Peterborough, UK) at a dilution of 1:1,000 in PBS–0.1% Tween-20 for 1 hour at 
room temperature and subsequent chromogenic development using a Vectastain 
ABC system (Vector Laboratories) and 5-bromo-4-chloro-3-indolyl phosphate–
nitroblue tetrazolium (BCIP/NBT; Vector Laboratories) as a substrate.  
 
2.4 In silico techniques 
 
2.4.1 Use of databases 
 
Nucleotide and protein sequences were retrieved from Genbank 
(http://www.ncbi.nlm.nih.gov/genbank) and aligned using ClustalW2 
(http://www.ebi.ac.uk/tools/msa/clustalw2/) (Larkin et al., 2007; Goujon et 
al., 2010). Nucleotide and protein sequence similarity searches were carried out 
using Blast (http://blast.ncbi.nlm.nih.gov/blast.cgi) (Altschul et al., 1990). The 
annotation of the 1.9x domestic cat (Felis catus) genome (GARField, 
http://lgd.abcc.ncifcrf.gov/cgi-bin/gbrowse/cat/) was used to identify genes of 
interest.  
 
2.4.2 Nucleotide and protein sequence alignments 
 
Nucleotide and protein sequence alignments and analyses of sequences obtained 
by in-house sequencing were performed using DNADynamo (Blue Tractor 
Software Limited). 
  
2.4.3 Graphs and statistics 
 
Graphs were prepared and statistical analyses (unpaired, two-tailed student’s t- 
test) were carried out using GraphPad Prism 5 software (GraphPad Software, La 
Jolla, U.S.A.). Where shown, error bars represent standard errors. 
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 Generation of a synthetic feline TRIM5α-cyclophilin A fusion 3
protein with potent antilentiviral properties 
3.1 Summary 
 
Primate TRIM5α provides an early, post-entry block to lentiviral replication. It 
contains a C-terminal B30.2 (PRY/SPRY) domain, which mediates binding to 
lentiviral capsids, and an N-terminal RING domain, which poly-ubiquitinates 
capsid proteins and targets them for proteasomal degradation. This results in a 
premature uncoating of the virus and the inhibition of reverse transcription. 
Feline (domestic cat) TRIM5α (feTRIM5α), however, bears a truncation in its 
B30.2 (PRY/SPRY) domain, which ablates its binding to lentiviral capsids and its 
antiviral function (McEwan et al., 2009). Interestingly, this truncation was found 
to be conserved among members of the Feliformia (McEwan et al., 2009) and, 
hence, cannot account for the block to FIV infection that we observed in lion T 
lymphocytes (see Fig. 1-4). However, the feTRIM5α RBCC (RING-B-box2-coiled-
coiled) domain is abundantly expressed in feline cells (McEwan et al., 2009) and 
little is known about its biological role. 
FIV is potently restricted by TRIM5α proteins from rhesus macaques and 
African green monkeys (Saenz et al., 2005) and by TRIM5α-cyclophilin A fusion 
proteins (TRIMCyps) of New World owl monkeys (Diaz-Griffero et al., 2006b) and 
of certain Old World macaques (Brennan et al., 2008; Newman et al., 2008; 
Virgen et al., 2008; Wilson et al., 2008). Moreover, it was shown that high-titre 
FIV replication in feline cells is dependent upon the interaction between 
cyclophilin A (CypA) and the FIV capsid (McEwan, 2009). The molecular basis for 
this dependency remains poorly understood but it has been hypothesised that 
CypA may regulate the timing of uncoating by stabilising capsid-capsid 
interactions. Although FIV is restricted by primate TRIMCyps and its capsid is 
able to interact with both primate TRIM5α and primate and feline CypA, no 
evidence of a feline TRIMCyp was found in domestic or non-domestic felids 
(McEwan, 2009).  
In this study a synthetic feline TRIM5α-cyclophilin A fusion protein 
(feTRIMCyp) was therefore generated by fusing feline CypA (feCypA) to the 
feTRIM5α RBCC and its antilentiviral activity was tested. As expected, feTRIMCyp 
was highly efficient at preventing infection with both HIV-1 and FIV-based 
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pseudotypes, and feTRIMCyp-expressing cells resisted productive infection with 
either FIV-Fca or FIV-Pco. The restriction of FIV infection by feTRIMCyp was 
reversed by the cyclosporine A (CsA) derivatives NIM811 and Debio-025 indicating 
that the feCypA domain mediates binding to FIV capsid and enables FIV 
restriction by the feTRIM5α RBCC domain present in feTRIMCyp.  
This feline-specific TRIMCyp represents an effective antiviral defence agent 
with very low potential for toxicity and could be used in the treatment of FIV-
positive cats. FeTRIMCyp and FIV infections of the domestic cat further offer a 
unique opportunity to evaluate TRIMCyp-based approaches to genetic therapy 
for HIV infection and the treatment of AIDS in humans (Neagu et al., 2009). 
 
3.2 Materials and Methods 
 
3.2.1 Generation of feTRIMCyp 
 
As the feTRIM5α RBCC is encoded by exons 2 to 6 of feTRIM5, the start codon of 
feCypA was fused to the last codon of exon 6 to generate feTRIMCyp. The feline 
TRIM5α RBCC was reamplified from feT5-CXCR (McEwan, 2009) using primers 
feT5a-1 (5’-GCGGATCCATGGCTTCTGAACTCCTGAAAT-3’) (BamHI restriction site 
underlined) and feT5a-2 (5’-CACGATGGGGTTGACCATTTTTTTAAAGGCTTGTATTAT 
-3’). FeCypA was amplified from cDNA derived from Mya-1 cells using primers 
directed to the predicted feCypA (GenBank AANG01610851), fCypA R69 5’ Nde 
(5’-AACATATGGTCAACCCCATCGTG-3’) (NdeI restriction site underlined) and 
feCypA 3’ Mlu (5’-AAACGCGTTTAGATTTGTCCACAGTCA-3’) (MluI restriction site 
underlined). The amplicon was cloned into the prokaryotic expression vector 
pOPTH using NdeI and MluI restriction sites and subsequently reamplified using 
primers feCypA-1 (5’-ATAATACAAGCCTTTAAAAAAATGGTCAACCCCATCGTG-3’) 
and feCypA-2 (5’-GCGTCGACTTAGATTTGTCCACAGTCAGC-3’) (SalI restriction site 
underlined). The feTRIM5α RBCC and feCypA amplification products were 
annealed and used as templates to generate a feline TRIMCyp gene fusion by 
reamplification with feT5a-1 and feCypA-2. 
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3.2.2 Stable expression of feTRIMCyp 
 
FeTRIMCyp DNA was cloned into BamHI and SalI sites of the retroviral vector 
pDON-AI-2neo (Takara Bio Europe S.A.S.), and the nucleic acid sequence of the 
feTRIMCyp fusion was confirmed by DNA sequencing (GenBank accession number 
HM246715). CrFK cells were transduced with MLV(VSV-G) pseudotypes bearing 
pDON-AI-2neo or the feTRIMCyp-pDON-AI-2neo construct to create stable cell 
lines. 
 
3.2.3 Molecular cloning of feline CD134 
 
Feline CD134 (feCD134) was amplified from cDNA derived from Mya-1 cells using 
primers directed to the predicted feCD134 transcript (GenBank AB128982), 
feCD134-Fwd (5’-TTGGATCCAGGATGAGGGTGGTTGTGGGGGCT-3’) (BamHI 
restriction site underlined) and feCD134-Rev (5’-AAGAATTCTCAGATCTTGGCCAGG 
GTGGAGT-3’) (EcoRI restriction site underlined). The amplicon was cloned into 
the eukaryotic expression vector pDsRed2 (Takara Bio Europe/Clontech) using 
BamHI and EcoRI restriction sites. 
 
3.2.4 Inhibitors of the CypA-capsid interaction 
 
The CypA antagonists cyclosporine A (CsA; Sigma-Aldrich) and its derivatives 
NIM811 (Novartis, Basel, Switzerland) and Debio-025 (Debiopharm S.A., 
Lausanne, Switzerland) were diluted to 5 mM working stock in ethanol or DMSO 
and stored at -20°C until further use. In order to inhibit the interaction between 
the CypA domain of feTRIMCyp and lentiviral capsids, control or feTRIMCyp-
expressing CrFK cells were pre-treated with CypA antagonists for 1 hour at 37°C. 
In lentiviral pseudotype cell entry assays and in FIV replication assays these 
drugs were used at final concentrations of 2 µM or 2.5 µM. In some experiments 
CypA antagonists were titrated to final concentrations of 0 µM, 0.25 µM, 0.5 µM, 
1 µM and 2 µM.  
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3.3 Results 
 
3.3.1 Generation of a synthetic feline TRIM5α-cyclophilin A 
fusion protein (feTRIMCyp) 
 
To assess whether a synthetic TRIMCyp of feline origin would display the potent 
lentiviral restriction activity observed in primate TRIMCyps, feline TRIM5α and 
feline CypA were fused experimentally (Fig. 3-1). FeTRIM5α lacks a full-length 
B30.2 (PRY/SPRY) domain due to a premature stop codon in the exon 
homologous to human TRIM5 exon 8 (McEwan, 2009). As the feTRIM5α RBCC 
domain is encoded by exons 2 to 6, the start codon of feCypA was fused to the 
last codon of exon 6 of feTRIM5. Thus, the synthetic feline TRIMCyp was 
designed to mimic the naturally occurring TRIMCyp of rhesus macaques 
(rhTRIMCyp). The feTRIMCyp transgene was then cloned into the retroviral 
vector pDON-AI-2neo, transduced into CrFK cells and stably selected. 
94 
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Figure 3-1 Scheme for the generation of a synthetic feline TRIM5-cyclophilin A gene fusion (feTRIMCyp). Because feTRIM5 bears 
a premature stop codon in the gene region homologous to human TRIM5 exon 8, the start codon of feline CypA was fused to the last 
codon of exon 6 of feTRIM5. The nucleotide and amino acid sequence of the fusion site is shown. Non-coding exons of feTRIM5 are 
marked by a dotted line and coding exons by a solid line. The colour coding indicates which of the coding exons encode for the feTRIM5α 
RING, B-box 2 and coiled-coil domains and the feCypA domain.  
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3.3.2 Specific restriction of lentiviral replication by feTRIMCyp 
 
In primate TRIMCyp proteins the CypA domain is responsible for binding of the 
protein to retroviral capsids known to interact with cyclophilins, such as HIV-1 
and FIV CA. The TRIM5α RING domain of TRIMCyp then ubiquitinates capsid 
proteins and targets them for rapid proteasomal degradation. This leads to a 
premature uncoating of the virus, a block to reverse transcription and the 
inhibition of viral DNA integration into the host genome. To test whether 
feTRIMCyp could exert a similar early post-entry, reverse transcription block to 
lentiviral replication, FIV(VSV-G), HIV-1(VSV-G) and SIVmac(VSV-G) pseudotypes 
containing a green fluorescent protein (GFP) marker gene were titrated onto 
control or feTRIMCyp-expressing CrFK cells (Fig. 3-2). In this assay the activity of 
feTRIMCyp is inversely proportional to the number of GFP-positive cells.  
In CrFK cells expressing feTRIMCyp, infection with FIV(VSV-G) (Fig. 3-2A) 
and HIV-1(VSV-G) (Fig. 3-2B) pseudotypes was blocked completely, while 
SIVmac(VSV-G) pseudotypes infected feTRIMCyp-expressing CrFK cells with 
similar efficiency to that of control cells (Fig. 3-2C). These data indicate that 
feTRIMCyp possesses potent antilentiviral activity and that this activity is 
specific to lentiviruses whose capsids are able to interact with CypA. Because 
pseudotypes undergo a single cycle of viral entry and gene expression and thus 
distinguish entry from productive infection, it can be concluded that viral 
replication was targeted at an early stage of the viral life cycle. 
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Figure 3-2 Specific inhibition of lentiviral infection at an early post-entry step 
by feTRIMCyp. CrFK cells stably transduced with vector only (CON, circles) or a 
vector bearing feline TRIMCyp (feTRIMCyp, squares) were infected with two-fold 
serial dilutions of (A) FIV(VSV-G), (B) HIV-1(VSV-G) or (C) SIVmac(VSV-G) 
pseudotypes containing GFP as a marker gene. Infection was assessed 72 hours 
post-infection by flow cytometry. Points represent the mean of duplicate infections 
assayed in duplicate (n=2). 
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3.3.3 Reversal of the antilentiviral activity of feTRIMCyp by CypA 
antagonists 
 
The mechanism of the inhibitory effect of feTRIMCyp was further confirmed by 
the addition of specific antagonists of the CypA-capsid interaction. Control or 
feTRIMCyp-expressing CrFK cells were pre-treated with 2 µM CsA or its non-
immunosuppressive derivatives NIM811 or Debio-025 and infected with FIV(VSV-
G) and HIV-1(VSV-G) pseudotypes as before (Fig. 3-3). While CsA reversed the 
inhibition of HIV-1(VSV-G) pseudotype infection of target cells by feTRIMCyp 
modestly (Fig. 3-3D), it was unable to reverse the inhibition of FIV(VSV-G) 
pseudotype infection (Fig. 3-3A). NIM811 was slightly more effective and 
reversed the inhibition of FIV(VSV-G) modestly (Fig. 3-3B) and of HIV-1(VSV-G) 
completely (Fig. 3-3E). Finally, Debio-025 was able to block the inhibitory 
activity of feTRIMCyp against both FIV(VSV-G) (Fig. 3-3C) and HIV-1(VSV-G) (Fig. 
3-3F) pseudotype infection. These data indicate that the restriction of FIV by 
feTRIMCyp is less sensitive to antagonism by CsA and NIM811 than that of HIV-1. 
Debio-025 is the most potent of the tested CypA antagonists at the 
concentration used. 
Titrating the CypA antagonists confirmed the differential sensitivities of 
FIV(VSV-G) and HIV-1(VSV-G) pseudotypes to reversal of the feTRIMCyp 
restriction (Fig. 3-4). Restriction of HIV-1(VSV-G) was readily reversed by NIM811 
and Debio-025 (Fig. 3-4B,C), while Debio-025 alone reversed the restriction of 
FIV(VSV-G) to near control levels of infection (Fig. 3-4C). CsA displayed a low 
potency at all concentrations used (Fig. 3-4A). These findings suggest that the 
antilentiviral activity of feTRIMCyp against FIV is extremely potent, and that the 
FIV CA-feTRIMCyp interaction is less sensitive to disruption by CypA antagonists 
than the HIV-1 CA-feTRIMCyp interaction. 
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Figure 3-3 Reversal of feTRIMCyp-mediated lentiviral restriction by CypA 
antagonists. CrFK cells stably transduced with vector only (circles) or a vector 
bearing feTRIMCyp (squares) were infected with a two-fold serial dilution of 
FIV(VSV-G) (A-C) or HIV-1(VSV-G) (D-F) pseudotypes containing GFP as a 
marker gene. Infections were performed in the presence of 2 μM of the CypA 
antagonists CsA (A,D), NIM811 (B,E), or Debio-025 (C,F) (open symbols) or in the 
presence of their respective solvents DMSO (CsA and NIM811) or ethanol (Debio-
025) (filled symbols). Infection was assessed 72 hours post-infection by flow 
cytometry. Points represent the mean of duplicate infections assayed in duplicate 
(n=2). 
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Figure 3-4 Sensitivity of FIV and HIV-1 to reversal of feTRIMCyp restriction 
by CypA analogues. CrFK cells stably expressing feTRIMCyp were incubated 
with CsA (A), NIM811 (B) and Debio-025 (C) at final concentrations of 0, 0.25, 0.5, 
1.0, or 2.0 µM prior to infection with FIV(VSV-G) (circles) or HIV-1(VSV-G) 
(squares) pseudotypes containing GFP as a marker gene. Infection was assessed 
72 hours post-infection by flow cytometry. Points represent the mean of duplicate 
infections assayed in duplicate (n=2). 
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3.3.4 Inhibition of productive lentiviral infection by feTRIMCyp 
and its reversal by CypA antagonists 
 
Next, the ability of feTRIMCyp to inhibit productive infection with replication-
competent feline lentiviruses was investigated. CrFK cells support the 
replication of cell culture-adapted, CD134-independent feline lentiviruses such 
as the FIV-Fca strain Petaluma isolate F14 or FIV-Pco isolate CoLV. CrFK cells 
stably transduced with vector only or a vector bearing feTRIMCyp were infected 
with F14 and CoLV (Fig. 3-5). Expression of feTRIMCyp rendered CrFK cells 
refractory to the replication of both viruses, while they replicated efficiently in 
control cells.  
Figure 3-5 Inhibition of productive replication of cell culture-adapted, CD134-
independent FIV strains by feTRIMCyp. CrFK cells stably transduced with 
vector only (circles) or a vector bearing feTRIMCyp (squares) were infected with 
FIV-Fca Petaluma strain F14 (A) or FIV-Pco strain CoLV (B). Cell culture 
supernatants were collected on days 0, 2, 4, 7 and 10 post-infection and assayed 
for RT activity by non-isotopic Lenti-RT assay. Points represent the mean of 
duplicate infections assayed in duplicate (n=2).  
 
The infection assays were then repeated in the presence of 2.5 µM NIM811 and 
Debio-025 or their solvents (DMSO or ethanol, respectively) to determine 
whether CypA antagonists could reverse the inhibitory effect of feTRIMCyp on 
productive viral replication (Fig. 3-6). Both NIM811 and Debio-025 blocked 
replication with FIV-Fca and FIV-Pco in control cells (Fig. 3-6A-D), indicating an 
important role for CypA in the replication of these viruses in CrFK cells and, 
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consistent with previous studies, suggesting a role for CypA in the replication of 
FIV (Lin and Emerman, 2006). In contrast, both Debio-025 (Fig. 3-6B,D) and 
NIM811 (Fig. 3-6A,C) countered the inhibition of viral growth by feTRIMCyp to a 
small extent. Moreover, whereas FIV-Fca replication in control cells was 
accompanied by the formation of prominent syncytia (Fig. 3-6E), no syncytia 
were observed in feTRIMCyp-expressing cells infected with FIV-Fca (Fig. 3-6G). 
Treatment of control cells with 2.5 µM Debio-025 prior to infection with FIV-Fca 
prevented viral growth and syncytium formation (Fig. 3-6F). However, pre-
treatment of feTRIMCyp-expressing cells with Debio-025 restored viral growth to 
a level at which small syncytia could be visualised (Fig. 3-6H, arrows) and RT 
activity could be detected (Fig. 3-6B). 
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Figure 3-6 Reversal of feTRIMCyp-mediated restriction of productive FIV 
infection by CypA antagonists. CrFK cells stably transduced with vector only 
(circles) or a vector bearing feTRIMCyp (squares) were infected with FIV-Fca 
Petaluma strain F14 (A,B) or FIV-Pco strain CoLV (C,D). Infections were 
performed in the presence of 2.5 μM of the CypA antagonists NIM811 (A,C), or 
Debio-025 (B,D) (open symbols) or in the presence of their respective solvents 
DMSO (NIM811) or ethanol (Debio-025) (filled symbols). Cell culture supernatants 
were collected on days 0, 2, 4, 7 and 10 post-infection and assayed for RT activity 
by non-isotopic Lenti-RT assay. Points represent the mean of duplicate infections 
assayed in duplicate (n=2). (E-H) Syncytium formation in CrFK cells infected with 
FIV-Fca. Cells expressing vector only (E,F) or feTRIMCyp (G,H) were infected with 
FIV-Fca in the presence of 2.5 µM Debio-025 (F,H) or its solvent ethanol (E,G). 
They were fixed and stained 10 days post-infection with 1.0% methylene blue-
0.2% basic fuchsin in methanol. The arrows indicate small syncytia, magnified in 
the inset (H). 
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It needs to be considered that, where endogenous CypA and ectopically 
expressed feTRIMCyp are coexpressed, the CypA antagonists prevent binding of 
both proteins to FIV CA. While disruption of the interaction between endogenous 
CypA and FIV CA would impact negatively on viral replication, blocking of 
binding of feTRIMCyp to FIV CA would rescue viral growth. It appears that, at a 
CypA antagonist concentration of 2.5 µM, the activity of feTRIMCyp is inhibited 
while binding of endogenous CypA to FIV CA continues to occur at low levels so 
that in total viral replication is favoured. To gain a better understanding of the 
dynamics between inhibition and restoration of viral infection in the presence of 
endogenous and exogenous CypA and CypA antagonists, the viral replication 
assay was repeated in the presence of a reduced antagonist concentration of 2 
µM (Fig. 3-7). 
While growth of FIV-Pco in control cells was suppressed efficiently by both 
NIM811 (Fig. 3-7E) and Debio-025 (Fig. 3-7F), growth of FIV-Fca was reduced 
modestly (Fig. 3-7B,C). In feTRIMCyp-expressing cells FIV-Fca replication was 
partially restored by 2 µM NIM811 and completely by Debio-025 (Fig. 3-7B,C), 
with viral replication accompanied by prominent syncytium formation. Notably, 
the CypA antagonists did not restore FIV-Pco growth in the presence of 
feTRIMCyp. 
It can be concluded that the effect of CypA antagonists on the interaction 
between endogenous and exogenous CypA with FIV CA was concentration-
dependent. Lower CypA antagonist concentrations were needed to overcome the 
inhibitory activity of feTRIMCyp than were necessary to fully block binding of 
endogenous CypA to FIV CA. Again, Debio-025 was more potent than NIM811. 
Differences between FIV strains were observed which seem to have a different 
degree of dependence on endogenous CypA. 2 µM Debio-025 restored FIV-Fca F14 
growth in feTRIMCyp-expressing cells which indicates that the number of 
endogenous CypA molecules binding to FIV CA in these cells was sufficiently high 
to support F14 growth. In contrast, endogenous CypA was insufficient to promote 
FIV-Pco CoLV replication. Thus, FIV strains may have adapted to the CypA levels 
in their natural target cells so that these levels are optimal for their growth.  
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Figure 3-7 Restoration of viral replication in feTRIMCyp-expressing CrFK 
cells by 2.0 µM NIM811 and Debio-025. CrFK cells stably transduced with vector 
only (circles) or a vector bearing feTRIMCyp (squares) were infected with FIV-Fca 
Petaluma strain F14 (A-C) or FIV-Pco strain CoLV (D-F). Infections were 
performed in the presence of 2 μM of the CypA antagonists NIM811 (B,E), or 
Debio-025 (C,F) (open symbols) or in their absence (A) (filled symbols). Cell 
culture supernatants were collected on days 0, 2, 4, 6, 8 and 10 post-infection and 
assayed for RT activity by non-isotopic Lenti-RT assay. Points represent the mean 
of duplicate infections assayed in duplicate (n=2). 
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In addition to cell culture-adapted, CD134-independent feline lentiviruses the 
activity of feTRIMCyp against the primary, CD134-dependent FIV-Fca strains 
Glasgow 8 (GL8) and PPR was assessed. CrFK cells stably expressing vector only 
or feTRIMCyp were transduced with the retroviral vector pDsRed2 or a feline 
CD134-pDsRed2 construct and stably selected. All four cell lines were infected 
with GL8 and PPR (Fig. 3-8). Replication of GL8 (Fig. 3-8A) and PPR (Fig. 3-8B) 
occurred only in the presence of feline CD134 and was completely blocked by 
the feline TRIMCyp fusion protein.  
Figure 3-8 Inhibition of productive replication of primary, CD134-dependent 
FIV strains by feTRIMCyp. CrFK cells stably transduced with vector only (circles) 
or a vector bearing feTRIMCyp (squares) were retransduced with the retroviral 
vector pDsRed2 (filled symbols) or a feline CD134-pDsRed2 construct (open 
symbols) and infected with FIV-Fca strain GL8 (A) or FIV-Fca strain PPR (B). Cell 
culture supernatants were collected on days 0, 1, 3-7 and 10 post-infection and 
assayed for RT activity by non-isotopic Lenti-RT assay. Points represent the mean 
of duplicate infections assayed in duplicate (n=2).  
 
3.4 Discussion 
 
In this study a synthetic feline TRIM5α-cyclophilin A fusion protein (feTRIMCyp) 
was created based on the naturally occurring TRIMCyp of Old World rhesus 
monkeys (M. mulatta). FeTRIMCyp exhibited a robust antilentiviral activity 
confirming that the feTRIM5α RBCC retains full ability to restrict FIV and HIV-1 
and simply lacks a capsid-targeting B30.2 (PRY/SPRY) domain. The inability of 
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feTRIM5α to bind lentiviral capsids is compensated for by the feCypA domain of 
feTRIMCyp. FeTRIMCyp potently blocked infection with FIV(VSV-G) and HIV-1 
(VSV-G) pseudotypes at an early post-entry, pre-reverse transcription step (Fig. 
3-2). In contrast, SIVmac pseudotype replication was unaffected by feTRIMCyp 
because of the inability of SIVmac CA to interact with cyclophilins (Franke et al., 
1994; Braaten et al., 1996b; Lin and Emerman, 2006) (Fig. 3-2). Furthermore, 
feTRIMCyp completely ablated in vitro growth of all tested cell-culture adapted, 
CD134-independent (Fig. 3-5) and primary, CD134-dependent strains of FIV (Fig. 
3-8). 
The specificity of the feTRIMCyp-capsid interaction is dependent on its 
feCypA domain; thus, this interaction, like the interaction between endogenous 
feCypA and lentiviral capsid, was sensitive to disruption by CsA and its 
derivatives NIM811 and Debio-025. In control cells, CypA antagonists blocked the 
replication of FIV(VSV-G) and HIV-1(VSV-G) pseudotypes (Fig. 3-3) and of 
replication-competent FIV-Fca and FIV-Pco viral strains (Fig. 3-6 and 3-7). 
Interestingly, the CypA antagonists displayed different degrees of potency to 
inhibit lentiviral replication with CsA having the lowest and Debio-025 having the 
highest activity at the antagonist concentrations used. These findings indicate 
that the CypA antagonists bind CypA with different affinities. In fact, the Ki 
values (a measure of the binding affinity of an inhibitor) of CsA, NIM811 and 
Debio-025 for human CypA inhibition have been measured to be 9.8, 2.1 and 
0.35 nM, respectively (Ptak et al., 2008). Binding affinities of the CypA 
antagonists to feCypA have not been determined. In feTRIMCyp-expressing cells, 
the antilentiviral activity of feTRIMCyp was modestly reversed by Debio-025 and 
partially by NIM811, but not by CsA (Fig. 3-4, 3-6 and 3-7). As mentioned before, 
in cells stably expressing feTRIMCyp, endogenous and exogenous feCypA are co-
expressed and influence viral replication in opposite manners. Whereas the 
presence of endogenous feCypA is essential for viral replication (McEwan, 2009), 
feTRIMCyp acts as a viral restriction factor. CypA antagonists negatively affect 
the activities of both forms of feCypA. Hence, the overall effect of CypA 
antagonists on viral replication is determined by the affinity of feCypA for the 
respective lentiviral capsid and on the dependence of the virus on endogenous 
feCypA. Indeed, it was observed that HIV-1 replication was more susceptible to 
CsA and its derivatives than FIV replication (Fig. 3-3 and 3-4). Because the 
binding affinities of FIV and HIV-1 CA for feline and human CypA lie within the 
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same range (McEwan, 2009) it is unlikely that FIV CA binding to feCypA and 
feTRIMCyp is stronger than that of HIV-1 CA. Thus, it can be concluded that HIV-
1 replication is dependent on higher endogenous feCypA levels than FIV 
replication. Moreover, 2 μM NIM811 and Debio-025 inhibited FIV-Pco CoLV growth 
in control cells completely and FIV-Fca F14 growth only modestly (Fig. 3-7). In 
feTRIMCyp-expressing cells infected with FIV-Fca F14, Debio-025 was able to 
overcome feTRIMCyp and to restore infection to control cell levels while the 
drug showed no activity against feTRIMCyp in FIV-Pco CoLV-infected cells. Again, 
because the FIV CA proline-rich feCypA binding loop is conserved across different 
FIV strains (McEwan, 2009) the more likely explanation for these results is that 
FIV-Pco strain CoLV requires higher endogenous feCypA levels for its replication 
than FIV-Fca F14.   
Although this study has confirmed the requirement of feCypA for efficient 
FIV replication, the mechanism by which feCypA promotes FIV growth is still 
unknown. The FIV feCypA binding site within FIV CAN differs from the HIV-1 CypA 
binding site in that the proline-rich loop is considerably shorter which results in 
a reduced region of contact with CypA (McEwan, 2009). Furthermore, the HIV-1 
CAN Gly89-Pro90 bond exists as cis-trans isomers. Cis-trans isomerisation is 
mediated by human CypA and it has been proposed that this enzymatic reaction 
in combination with structural changes in HIV-1 CA contributes to capsid stability 
which prevents premature uncoating of viral particles (Braaten et al., 1996a; 
Braaten et al., 1996b; Bosco et al., 2002; Howard et al., 2003; Bosco and Kern, 
2004; Luban, 2007; Li et al., 2009; Ylinen et al., 2009). In FIV CAN, however, the 
glycine in position 89 is replaced by an arginine (Arg89) and the Arg89-Pro90 
bond is not cis-trans isomerised by feCypA (Leo James, personal 
communication). The glycine to arginine change is structurally important as 
Arg89 comes in close proximity with feCypA residues Phe60 and Phe113. Cation-
π interactions between these residues may contribute to the affinity of the 
interaction between FIV CAN and feCypA (McEwan, 2009). In the absence of 
feCypA enzymatic activity simple binding to FIV CAN may be sufficient for 
promoting FIV infectivity (Luban, 2007). 
Additionally, the data presented here indicate that the feTRIM5α RBCC 
domain possesses the ability to target lentiviral capsids for proteasome-
mediated degradation. Although feTRIM5α lacks a capsid-binding B30.2 
(PRY/SPRY) domain and therefore an antiviral activity, it is abundantly 
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expressed in feline cells. Recent studies have provided evidence that human 
TRIM5α is involved in innate immune signalling (Pertel et al., 2011; Tareen and 
Emerman, 2011). TRIM5α bound to the lentiviral capsid lattice has been shown 
to interact with the heteromeric, ubiquitin-conjugating enzyme UBC13–UEV1A 
(UBE2N-UBE2V1) and to synthesise unattached K63-linked ubiquitin chains that 
activate the TAK1 protein kinase complex and stimulate AP-1 (activator protein-
1) and NF-κB signalling (Pertel et al., 2011). Thus, TRIM5α is both an 
antiretroviral restriction factor and a pattern recognition receptor for the viral 
capsid lattice. Because of the inability of feTRIM5α to bind lentiviral capsids, it 
is important to note that human TRIM5α also signals in the absence of capsid but 
that binding to capsid greatly enhances signalling and expression of 
inflammatory chemokines and cytokines (Pertel et al., 2011). Capsid-
independent signalling is mediated by the TRIM5α RING domain rather than the 
B30.2 (PRY-SPRY) domain and activates AP-1 and NF-κB (Pertel et al., 2011; 
Tareen and Emerman, 2011). Thus, a critical role in immune signalling may 
explain why the expression of the TRIM5α RBCC domain remains high in felids. 
Given the high potency of feTRIMCyp to block lentiviral replication, 
feTRIMCyp would be an excellent candidate for use in gene therapy in FIV-
infected cats. Treatment of the lentivirus-infected host using feTRIMCyp may be 
achieved by transduction of bone marrow-derived haematopoietic progenitor 
stem cells and repopulation of the host immune system following bone marrow 
ablation. However, transduction of peripheral blood-derived CD4+ T cells and ex 
vivo expansion of the transduced cells prior to repopulation of the host immune 
system may be sufficient to provide a pool of FIV-resistant T lymphocytes to 
overcome the immunodeficiency associated with feline AIDS. Accordingly, in 
addition to the successful in vitro studies described here in vivo analyses should 
be performed to examine the effects of feTRIMCyp expression on the function 
and development of feline haematopoietic stem cells and T lymphocytes and to 
exclude any detrimental effects that may manifest following ectopic expression 
of feTRIMCyp in primary cells.  
An insight into the likely therapeutic utility of TRIMCyp fusions in humans 
has been provided by Neagu et al. (2009) in their study on the effect of stable 
expression of a synthetic human TRIMCyp on human T cell function. Human CD4+ 
T lymphocytes stably transduced with human TRIMCyp (hT5Cyp) proliferated at 
the same rate, produced similar levels of IL-2 and expressed comparable levels 
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of cell surface CD4, CXCR4 and MHC class I as cells transduced with an empty 
vector (Neagu et al., 2009). Human CD4+ T cells stably expressing hT5Cyp were 
then transplanted into Rag2-/-/γc-/- mice, a mouse strain that lacks B, T and NK 
cells and which does not reject xenografts (Mazurier et al., 1999). Following 
challenge of the engrafted mice with HIV-1 they resisted infection, as evidenced 
by reduced plasma viral load and maintenance of CD4+ T lymphocyte numbers in 
peripheral blood and in lymphoid tissues (Neagu et al., 2009). Rag2-/-/γc-/- mice 
were also transplanted with hT5Cyp-transduced CD34+ haematopoietic 
progenitor cells. The mean viraemia following HIV-1 challenge was less than 30% 
of that observed in mice reconstituted with a non-functional TRIMCyp construct 
(HT5CypHis126Gln) (Neagu et al., 2009). Thus, initial studies with a synthetic 
human TRIMCyp offer great hope for the use of TRIMCyp as an approach to gene 
therapy for lentiviral infections. TRIMCyp-based lentiviral gene therapies have 
significant advantages over other approaches. By targeting viral entry the virus is 
denied the opportunity to replicate and thus, escape mutants cannot be 
generated. Moreover, as TRIMCyp does not target the function of an 
endogenously expressed molecule, it is unlikely to have side effects that are 
detrimental to the host. In addition, the generation of synthetic TRIMCyp fusion 
proteins using endogenous TRIM5α and CypA circumvents the potential pitfall of 
the host mounting an immune response against xenoantigens.  
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 Investigation into the role of APOBEC3 cytidine deaminases in 4
the Felidae 
4.1  Summary  
 
APOBEC3 (A3) proteins are cellular cytidine deaminases that catalyse cytidine-
to-uracil changes in nascent viral minus-strand cDNA during reverse 
transcription. Viral uracil-containing cDNAs that escape degradation by host DNA 
repair enzymes give rise to viral cDNAs containing guanine-to-adenine 
hypermutations (Harris et al., 2003; Lecossier et al., 2003; Mangeat et al., 2003; 
Mariani et al., 2003; Zhang et al., 2003; Bishop et al., 2004; Liddament et al., 
2004). A low number of proviruses will survive; however, the hypermutations 
lead to an increased number of alternate splicing and premature termination 
events of the viral transcripts. Non-functional proteins are produced and the 
virions are defective and non-infective (Zheng and Peterlin, 2005). Deamination-
independent mechanisms of A3 proteins to block viral replication have also been 
reported. It has been shown that both wild-type forms and catalytically inactive 
mutants of human APOBEC3G and APOBEC3F interfere with individual steps of 
reverse transcription, such as minus- and plus-strand DNA synthesis, and cDNA 
transfer and elongation, which consequently leads to a reduction of viral cDNA 
transcript levels being produced (Newman et al., 2005; Holmes et al., 2007; 
Iwatani et al., 2007). Human, simian and feline A3s are overcome and targeted 
for proteasomal degradation by lentiviral Vif proteins in a species-specific 
manner (Conticello et al., 2003; Marin et al., 2003; Sheehy et al., 2003; Stopak 
et al., 2003; Yu et al., 2003; Mehle et al., 2004b; Munk et al., 2008; Stern et al., 
2010; Zielonka et al., 2010). Feline A3C proteins are counteracted by the FeFV 
Bet protein (Lochelt et al., 2005; Munk et al., 2008).  
A3 proteins belong to a large family of cytidine deaminases that have 
arisen to protect vertebrate genomes from mobile endogenous retroelements, 
the ancestors of modern exogenous retroviruses (Mangeat and Trono, 2005; 
Goila-Gaur and Strebel, 2008). During their evolution A3 genes have undergone a 
series of gene duplications and positive selection (Sawyer et al., 2004; Zhang 
and Webb, 2004; Conticello, 2008). A3s are unique in their ability to restrict 
retroviruses and their presence is limited to placental mammals (Conticello, 
2008). All species possess two ancestral A3 genes from which different 
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repertoires of A3 genes have evolved through gene duplications and fusions, 
ranging from only one double deaminase domain A3 gene in rodents, pigs and 
cattle to seven single and double catalytic domain A3 genes in primates 
(Conticello et al., 2005; Munk et al., 2008). The domestic cat genome possesses 
four single deaminase domain A3 genes that give rise to a fifth, double catalytic 
domain A3 protein (A3CH) by read-through alternative splicing using exons from 
both A3C and A3H genes (Munk et al., 2008). 
In the absence of a functional TRIM5α in felids and no evidence for a 
naturally occurring feline TRIMCyp, differences in the antiretroviral activities of 
A3 proteins may be responsible for the inability of FIV to grow efficiently in lion 
T lymphocytes (see Fig. 1-4) and to establish immunodeficiency in lions. Studies 
on the phylogeny of feline lentiviruses and felids have indicated that lions have 
been harbouring lentiviruses for a considerably longer time than domestic cats 
(Johnson et al., 2006; Antunes et al., 2008; Poss et al., 2008). Thus, we 
hypothesise that lion A3 proteins are more potent against FIV than cat A3s, or, 
alternatively, that the anti-A3 activity of FIV-Ple Vif has decreased over time 
resulting in host-virus adaptation and a lower pathogenicity of FIV infections in 
lions.  
In this study lion A3 cDNAs were amplified, cloned and characterised. The 
organisation of the lion A3C gene locus was determined and found to resemble 
that of domestic cats. Furthermore, the activities of lion A3 proteins against FIV 
lacking Vif (FIVΔvif) and FIV harbouring Vifs of different feline lentiviruses were 
compared to those of domestic cats and pumas in single-cycle replication assays. 
While all felid A3C isoforms showed only modest activity against FIVΔvif and FIV 
wild-type, all felid A3H and A3CH isoforms restricted FIVΔvif completely. 
Differences were observed between the activities of cat and lion A3CH (FcaA3CH 
and PleA3CH, respectively) against FIV containing FIV-Fca Vif and FIV-Pco Vif, 
with PleA3CH being more potent than FcaA3CH. It should be noted that the 
expression of particular FIV Vifs in 293T cells, which were used in A3 activity 
assays, was inefficient so that the activity of FIV-Ple E Vif and FIV-Oma Vif 
against feline A3s could not be studied.  
Furthermore, expression levels of domestic cat and lion A3 genes in 
several cat cell lines and cat tissues as well as primary lion PBMCs were 
quantified. Domestic cat and lion A3C and A3H genes were expressed modestly 
and their expression was upregulated by interferons only in certain cell lines. 
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Interestingly, A3C gene expression was higher than that of A3H in cat cell lines 
and tissues, whereas the opposite trend was found in lion PBMCs. FcaA3CH and 
PleA3CH expression levels were low in all samples tested.  
Surprisingly, an investigation into the long-term evolution of lion A3 
proteins in the presence or absence of FIV infection revealed no evidence for 
selection pressure by FIV on A3 proteins. 
The data presented here confirm the important role of A3 proteins in the 
protection of mammalian genomes against DNA mutators and support the 
hypothesis of A3-FIV Vif coadaptation in lions that may prevent 
immunodeficiency from occurring. 
 
4.2 Materials and Methods 
 
4.2.1 Amplification and molecular cloning of feline APOBEC3 
cDNAs 
 
Cat (Felis catus, Fca), lion (Panthera leo, Ple) and puma (Puma concolor, Pco) 
A3s were amplified from cDNA derived from Mya-1 cells, Angolan lion PBMCs or 
puma PBMCs using primers directed to their predicted sequences. FcaA3Ca and 
FcaA3H (GenBank AY971954, EU011792) (Munk et al., 2008) were amplified using 
the primer pairs FeA3Ca F (5’-ACTGGTCGACACCATGGAGCCCTGGCGCCCCAGCCCA 
AGAAACCCAATGG-3’) and FeA3Ca R (5’-ACAGCGGCCGCTCACCTAAGGATTTCTTGA 
AGCTCTGCAGCC-3’), and FeA3H F (5’-ACTGGTCGACACCATGAATCCACTACAGGAA 
GTCATATTC-3’) and FeA3H R (5’-ACAGCGGCCGCTCATTCAAGTTTCAAATTTCTGAA 
GTCATTC-3’), respectively. The FcaA3H cDNA sequence obtained differed in two 
positions from the GenBank entry (G193T and G231C), resulting in two changes 
at the amino acid level (Ala65Ser and Met77Ile). These changes may represent 
nucleotide polymorphisms in the different cell lines used for amplification (CrFK 
compared to Mya-1 cells). FcaA3CH (GenBank EF173021) (Munk et al., 2008) was 
amplified using primers FeA3Ca F and FeA3H R. PleA3C1 and PleA3H (GenBank 
EU007543, EU007549) were obtained using primers LiA3C1 F (5’-
ACTGGTCGACACCATGGAGCCCTGGCGCCCCAGCCCAAGAAACCCAATGC-3’) and 
LiA3C1 R (5’-ACAGCGGCCGCTCACCTAAGGATTTCTTGAAGCTCTGCAGCC-3’), and 
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LiA3H F (5’-ACTGGTCGACACCATGAATCCACTACAAGAAGACATATTC-3’) and LiA3H 
R (5’-ACAGCGGCCGCTCATTCAAGTTTCAAATTTCTGAAATCATTC-3’), respectively. 
PleA3CH (GenBank GU097662) (Zielonka et al., 2010) was amplified using 
primers LiA3C2 F (5’-ACTGGTCGACACCATGGAGCCCTGGCGCCCCAGCCCAAGAAACC 
CAATGG-3’) and LiA3H R. PcoA3C and PcoA3H (GenBank EU007545, EU007552) 
were amplified using primers LiA3C2 F and LiA3C1 R, and primers LiA3H F and 
LiA3H R, respectively. PcoA3CH (GenBank GU097659) (Zielonka et al., 2010) was 
amplified using primers LiA3C2 F and LiA3H R. All forward primers contained SalI 
restriction sites and all reverse primers NotI restriction sites (restriction sites 
underlined). The amplicons were cloned into the eukaryotic expression vector 
VR1012 (Vical Inc.) using SalI and NotI sites.  
 
4.2.2 Characterisation of the lion A3C gene locus 
 
The domestic cat genome contains an A3 gene locus (GenBank EU109281) on 
chromosome B4 in which three A3C genes (A3Cc, A3Ca and A3Cb), which have 
arisen by two gene duplication events and thus share high nucleotide similarity, 
are aligned in a head-to-tail orientation (Munk et al., 2008). The A3C genes 
consist of four exons (E1-E4) and three introns (I1-I3). A3Cc and A3Ca and A3Cb, 
respectively, are separated from each other by a stretch of genomic sequence. 
Downstream of A3Cb lies A3H. In order to determine the number and order of 
PleA3C genes in the lion genome primers were designed based on the published 
sequences of PleA3C1 and PleA3C2 (GenBank EU007544) and fragments between 
exons were amplified using GoTaq Flexi DNA polymerase (Promega). Domestic 
cat A3Cc can be distinguished from A3Ca and A3Cb by shorter I1 and I2. Primers 
used to amplify the fragment between PleA3C E1 and E2 were LiA3C-Ex1-Fwd 
(5’-ATGGAGCCCTGGCGCCCCA-3’) and LiA3C-Ex2-Rev (5’-CCGAAAAACTCCCCAGTC 
GCTGTCATT-3’) (primers were designed to bind to both PleA3C1 and PleA3C2). 
Primers used to amplify the fragment between E2 and E3 were LiA3C-Ex2-Fwd-1 
(5’-CCTTCCATTTCCAGTTTCCA-3’) and LiA3C-Ex3-Rev-1 (5’-GTCACGGAACCAAAAG 
AGGA-3’) (primer pair designed to bind specifically to PleA3C1) and LiA3C-Ex2-
Fwd-2 (5’-TGGGCGGAAACTCTGTTATC-3’) and LiA3C-Ex3-Rev-2 (5’-ACGGATACTG 
GTTACGGAAC-3’) (primer pair designed to bind specifically to PleA3C2). 
Alternative reverse primers used to bind to E3 were LiA3C-Ex3-Rev-3 (5’-
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TATTCATCACGGCATGGATAC-3’) (specific to PleA3C1) and LiA3C-Ex3-Rev-4 (5’-
TCCTCATCACGGTACGGATAC-3’) (specific to PleA3C2). Fragments between E3 of 
one PleA3C gene and E1 of the following PleA3C gene were amplified using 
primer pairs LiA3C-Ex3-Fwd-1 (5’-GTATCCATGCCGTGATGAATA-3’) and LiA3C-
Ex1-Rev-1 (5’-TGGGGCGCCAGGGCTCCAT-3’) (specific to PleA3C1) or LiA3C-Ex3-
Fwd-2 (5’-GTATCCGTACCGTGATGAGGA-3’) and LiA3C-Ex1-Rev-1 (specific to 
PleA3C2). Amplified gene fragments were cloned into the vector pCR2.1-TOPO 
(Life Technologies) and sequenced. In this study a previously uncharacterised 
PleA3C was discovered which differs from PleA3C1 in one nucleotide position in 
E3 (A499G) and in four nucleotides in E4 (G515A, A539G, A561G, G575A). This 
new PleA3C was named PleA3C3, amplified with primers LiA3C1 F and LiA3C3-
Rev (5’-ACAGCGGCCGCTTACCTAAGGATTTCCTG-3’) (NotI restriction site 
underlined) and cloned into VR1012 (Vical Inc.) using SalI and NotI restriction 
sites. 
 
4.2.3 Amplification and molecular cloning of FIV Vifs 
 
All FIV Vifs used in this study were tagged with a C-terminal haemagglutinin (HA) 
tag. FIV-Fca Vif was amplified from the GL8Mya molecular clone (Hosie et al., 
2002) of FIV-Fca isolate GL8 using primers GL8 Vif F (5’-ACTGGTCGACACCATGAG 
TGACGAAGATTGGCAGG-3’) and GL8 Vif Rev HA (5’-ACAGCGGCCGCTCAAGCGTAA 
TCTGGAACATCGTATGGGTATAGTTTTCCCGACCATAACAG-3’). FIV-Ple E Vif was 
amplified from cDNA derived from Mya-1 cells infected with a primary isolate of 
FIV-Ple E obtained from serum of a wild, 8 year old male lion (Sangre) from the 
Moremi reserve in the Okavango Delta, Botswana (McEwan, 2009). Primers were 
designed based on the available FIV-Ple E 1027 sequence (GenBank EU117992) 
(Pecon-Slattery et al., 2008a): LLV-E Vif F (5’-ACTGGTCGACACCATGAGTGGTGAA 
GATATAAGTCAGG-3’) and LLV-E Vif Rev HA (5’-ACAGCGGCCGCTCAAGCGTAATCT 
GGAACATCGTATGGGTAGCCACCTTTCCCTATTAAATATAG-3’). FIV-Pco Vif was 
amplified from cDNA derived from Mya-1 cells infected with FIV-Pco strain PLV-
14 (GenBank U03982) using primers PLV Vif F (5’-ACTGGTCGACACCATGGCTTCAA 
TCAGACAGACAGAACAG-3’) and PLV Vif Rev HA (5’-ACAGCGGCCGCCTCAAGCGTAA 
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TCTGGAACATCGTATGGGTAGAATGATAATGTTAAATCCATCCA-3’). FIV-Oma Vif 
was amplified from FIV-Oma molecular clone pOma3 (GenBank AY713445) using 
primers FIV-Oma Vif F (5’-ACTGGTCGACACCATGAGTGGTGAAGAGGATTGGCAGGT 
AAG-3’) and Oma3 Vif Rev HA (5’-ACAGCGGCCGCTCAAGCGTAATCTGGAACATCGT 
ATGGGTAACTCTTCATCCGATATAACACTTCATAGGGTACA-3’). All forward primers 
contained SalI restriction sites and all reverse primers NotI restriction sites 
(restriction sites underlined). The HA tag coding sequence in the reverse primers 
is marked in bold. The amplicons were cloned into the eukaryotic expression 
vector VR1012 (Vical Inc.) using SalI and NotI sites.  
FIV-Fca GL8 Vif was also cloned into the FIV-Fca Gag-Pol-expressing 
construct FP93 (Saenz and Poeschla, 2004) in order to express vif in cis to other 
viral genes and to achieve higher vif expression levels in 293T cells. FP93 is 
based on the FIV-Fca strain Petaluma (molecular clone 34TF10) (GenBank 
M25381) (Talbott et al., 1989) and bears deletions in vif, orf2 and env, among 
others. To delete large parts of vif, a unique SalI restriction site near the 5’ end 
of vif has been introduced into FP93 (nucleotide positions 5390-5395) (Saenz and 
Poeschla, 2004). FP93 also possesses a unique BclI restriction site between 
nucleotides 6782 and 6787. Untagged FIV-Fca GL8 Vif was amplified with primers 
GL8Mya Vif-Fwd (5’-ACTGGTCGACATTGGCAGGTAAGTAGAAGACT-3’) (SalI 
restriction site underlined) and GL8Mya Vif-Rev (5’-ACATGATCAGTGGGATTTGTA 
ATGGGTCTGTAC-3’) (BclI restriction site underlined). FP93 was propagated in 
Escherichia coli SCS110 cells (dam methylation-negative; Stratagene, LaJolla, 
U.S.A.). GL8 Vif was then cloned into FP93 using SalI and BclI restriction sites. 
The construct was sequenced using primers GL8MyaVifSeq-Fwd (5’-
GTGTCTTAGGAACTCACCTCCA-3’), GL8MyaVifSeq-F_1 (5’-TGAGACTATAACAGGAC 
CATTAG-3’) and GL8MyaVifSeq-Rev (5’-ATCTCTAGTATGAAAGCTCCAT-3’). Site-
directed mutagenesis was performed to delete one nucleotide near the 5’ end of 
vif to shift the vif sequence after the SalI restriction site into frame with the vif 
start codon. Mutagenesis primers used were GL8MVifMut-Fwd (5’-
CCTGAAGGGGATGAGTGATCGACATTGGCAGGTAAGTAG-3’) and GL8MVifMut-Rev 
(5’-CTACTTACCTGCCAATGTCGATCACTCATCCCCTTCAGG-3’). The new construct 
(GL8Mya Vif-FP93) expresses FIV-Fca GL8 Vif in the background of FIV-Fca 
Petaluma 34TF10 gag and pol. Vif bears two amino acid changes compared to 
the original GL8Mya Vif (Glu4Arg, Asp5His). 
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4.2.4 Quantification of feline APOBEC3 mRNAs by quantitative 
real-time reverse transcription PCR 
 
Quantitative real-time reverse transcription PCR (RT-qPCR) was employed to 
determine the expression levels of domestic cat and lion A3 genes in the feline 
cells lines FEA, CrFK, AH927 and 3201, in Mya-1 cells, in primary lion PBMCs and 
in different cat tissues. Lion full blood samples for isolation of PBMCs were 
obtained from Bojnice Zoo, Slovakia. Cat tissues included bone marrow, lymph 
nodes, ovarian tissue, spleen, thymus and tonsils, which were isolated from 
three FIV-negative cats that had been enrolled in a previous study (Kraase et al., 
2010). Before RNA isolation, feline cell lines and lion PBMCs were either left 
untreated or were stimulated with 103 IU/ml recombinant feline IFN-α (R&D 
Systems Europe Ltd, Abingdon, UK) or 103 IU/ml recombinant feline IFN-ω 
(Virbac Limited, Bury St Edmonds, UK), respectively, for 24 hours. All RNAs were 
treated with DNAse I (Life Technologies) prior to cDNA synthesis. 1 µg or 450 ng 
of domestic cat cell line and lion PBMC or domestic cat tissue RNA, respectively, 
was used for cDNA synthesis.  
All three FcaA3C isoforms were detected using primers qPCR-FcA3C-Fwd 
(5’-GGACAGGATAGATCCTAACACC-3') and qPCR-FcA3C-Rev (5'-CCACTTGGAAGCAG 
AGATAAC-3') and probe qPCR-FeA3C-Pro (5'FAM-TTCCACTTTCCAAACCTGCTCTATG 
CTTCT-3'TAMRA). FcaA3H was amplified with primers qPCR-FeA3H-Fwd (5'-
CAAGATCAAGGCACTGACGC-3') and qPCR-FeLiA3H-Rev (5'-ACAAACGCAACCAGTTC 
C-3') and probe qPCR-FeLiA3H-Pr (5'FAM-CGAAATCATCTGCTATATCACATGGAGCCC 
CT-3'TAMRA). FcaA3CH and PleA3CH were detected using primers qPCR-FcA3CH-
Fwd (5’-TCCTGGCTGCAAAGCTTCAAG-3’) and qPCR-FcA3CH-Rev (5’-
TCTGGGCAAGAGGAAGGAAACC-3’) and probe qPCR-FeLiA3CH-P (5'FAM-
CAGGAGGTGACAGAGCCTGGGATAAACACCAGA-3'TAMRA). All three PleA3C 
isoforms were detected using primers qPCR-LiA3C-Fwd (5'-GATCCTAAGACCTTCCA 
TTTCC-3') and qPCR-LiA3C-Rev (5'-ACCTTGTTCCGAAAAACTCC-3') and probe 
qPCR-LiA3C-Pro (5'FAM-GTTTCCAAACCTGCGCTACGCTTCT-3'TAMRA). PleA3H was 
amplified with primers qPCR-LiA3H-Fwd (5'-CAAGATCAAGTCACTGACGC-3') and 
qPCR-FeLiA3H-Rev and probe qPCR-FeLiA3H-Pr. Domestic cat 18S rRNA was used 
as housekeeping gene and was amplified with primers rDNA 343F cat (5'-
CCATTCGAACGTCTGCCCTA-3') and rDNA 409 R (5'-TCACCCGTGGTCACCATG-3') 
and probe rDNA 370Pcat (5'FAM-CGATGGTAGTCGCCGTGCCTA-3'TAMRA). 
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Because specific A3C and A3H primer and probe sets could not be 
designed, A3CH copy numbers were subtracted from A3C and A3H copy numbers. 
With the help of the standard curve equations copy numbers were then 
converted back into CT values (where “CT” represents threshold cycle) and 
expression levels between A3 genes in different samples were compared using 
the ΔCT method. ΔCT values were calculated by subtracting the mean CT for the 
abundant 18S rRNA from the CT for A3 mRNAs.  
 
4.2.5 Genetic APOBEC3 diversity in African and Asian lion 
populations 
 
A total of eight lion whole blood samples were obtained from Angola (kindly 
provided by Pieter Kat and Rodrigo Serra of the Investigacao Veterinaria 
Independente, Lisbon, Portugal), from the Moremi reserve in the Okavango Delta 
(Botswana), from the Serengeti National Park (Tanzania; kindly provided by 
Sarah Cleaveland, University of Glasgow, UK), from Lahore Zoo and Lahore Safari 
Park (Pakistan) and from Bristol Zoo (UK). Genomic DNA was prepared using the 
PAXgene Blood DNA kit (Qiagen) or the QIAamp DNA Mini and Blood Mini kit 
(Qiagen).  
To determine the geographical origin of the lions from which the samples 
had been taken, the genetic variation of their 12S-16S mitochondrial DNA 
(mtDNA) genes was investigated. Fragments of the 12S-16S mtDNA genes were 
amplified using GoTaq Flexi DNA polymerase (Promega) and primer pair 12S-UP-F 
(5’-AAAAAGCTTCAAACTGGGATTAGATACCCCACTAT-3’) and PAN-16S-Cy-R (5’-
CAGAACTCAGATCACGTAG-3’) or L12S-Cy-F (5’-CTTAAGTGACTAGCCCCTA-3’) and 
PAN-16S-Cy-R (Antunes et al., 2008). Cycling parameters were 1 cycle of 94 °C 
for 3 minutes; 1 touch-down cycle of 94 °C for 30 seconds, 52 °C for 1 minute 
decreased by 1 °C in the next cycle for 10 cycles, 72 °C for 2 minutes; then 35 
cycles of 94 °C for 30 seconds, 52 °C for 1 minute, 72 °C for 2 minutes; then 1 
cycle of 72 °C for 5 minutes. The fragments were cloned into pCR2.1-TOPO (Life 
Technologies) and five clones of each fragment per animal were sequenced. The 
sequences were aligned to twelve lion 12S-16S mtDNA gene sequences (GenBank 
FJ151641-FJ151652) corresponding to different haplotypes specific for the 
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geographic location of African and Asian lion population habitats (Antunes et al., 
2008).  
PleA3C genes were amplified, cloned and sequenced as described in section 
4.2.3. Sequences were compared to the sequences of PleA3C1 (GenBank 
EU007543), PleA3C2 (EU007544) and PleA3C3 (this study). PleA3H genes were 
amplified using primers LiA3H F and LiA3H R (see section 4.2.1), cloned into 
pCR2.1-TOPO and sequenced. Sequences were compared to that of PleA3H 
(GenBank EU007549).  
 
4.3 Results 
  
4.3.1 Amplification of feline APOBEC3 cDNAs 
 
In addition to the well-characterised domestic cat APOBEC3 transcripts (Munk et 
al., 2008), puma and lion A3C and A3H transcripts were amplified from cDNA 
derived from puma and Angolan lion PBMC RNA, respectively, using primers 
directed against their predicted sequences (GenBank EU007545 and EU007552, or 
EU007543 and EU007549, respectively) (Fig. 4-1). Amplification of PleA3C2 cDNA 
(GenBank EU007544) was attempted, but proved unsuccessful due to the high 
nucleotide similarity to PleA3C1. Puma and lion A3CH transcripts (PcoA3CH and 
PleA3CH) were amplified using primers LiA3C2 F and LiA3H R. Their sequences 
were determined and were found to resemble the recently published sequences 
(GenBank GU097659 and GU097662, respectively) (Zielonka et al., 2010). 
Domestic cat, lion and puma A3C amplicons were cloned into the eukaryotic 
expression vector VR1012 (Vical Inc.).  
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A3C     A3H     A3CH  A3C1     A3H     A3CH 
Puma concolor (Pco) Panthera leo (Ple) 
Marker 
 
 
 
 
 
 
 
 
 
Figure 4-1 Amplification of puma and lion A3 transcripts. Puma and lion A3 
transcripts were amplified from puma or lion PBMC-derived cDNA using primers 
directed against their predicted sequences. PcoA3C, PcoA3H, PleA3C1 and 
PleA3H transcripts encode for single deaminase domain A3s, whereas PcoA3CH 
and PleA3CH give rise to double deaminase domain A3s.  
 
4.3.2 Genomic organisation of the lion A3 gene locus  
 
The domestic cat A3 gene locus (GenBank EU109281) on chromosome B4 spans 32 
kb and contains three A3C (A3Cc, A3Ca and A3Cb) and one A3H gene, which are 
aligned in a head-to-tail orientation (Munk et al., 2008) (Fig. 4-2A). A3Cc is the 
most ancient of the A3C genes and duplicated to give rise to an A3Ca/b 
precursor gene that further duplicated to create A3Ca and A3Cb (Munk et al., 
2008). Due to the common origin of the three domestic cat A3C genes, they 
share the same exon-intron structure and their nucleotide sequences are highly 
similar (Munk et al., 2008). The A3C genes each consist of four exons (E1-E4) and 
three introns (I1-I3) (Fig. 4-2B). A3Cc possesses 97.8% and 97.1% nucleotide 
identity with A3Ca and A3Cb cDNAs, respectively, whereas there is 98.8% 
identity between A3Ca and A3Cb cDNAs. This results in 96.3 to 96.5% amino acid 
sequence identity between the various A3C proteins (Munk et al., 2008). 
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Figure 4-2 Schematic representation of the domestic cat A3 gene orientation 
and their exon/intron organisation. (A) The domestic cat A3 gene locus is 
situated on chromosome B4 and spans 32 kb. It contains the three A3C genes 
A3Cc, A3Ca and A3Cb as well as an A3H gene. A fifth A3 protein, FcaA3CH, is 
expressed by read-through alternative splicing using exons of FcaA3Ca, FcaA3Cb 
and FcaA3H. (B) Each FcaA3C gene consists of four exons (E1-E4) and three 
introns (I1-I3) of indicated lengths (nt). 
 
In order to determine the number and order of PleA3C genes in the lion genome 
primers were designed that bound specifically within the exon regions of either 
PleA3C1 or PleA3C2 (GenBank EU007543 and EU007544, respectively). PleA3C1 
and PleA3C2 showed 97% nucleotide and 94% amino acid identity. Fragments 
between exons E1 and E2, E2 and E3, E3 and E1 of the following PleA3C gene 
were amplified from lion genomic DNA, cloned and sequenced (Fig. 4-3).  
Domestic cat A3Cc can be distinguished from A3Ca and A3Cb by shorter I1 
and I2 (Fig. 4-2B). Thus, if the lion genome contained an A3C gene that 
resembled the oldest domestic cat A3C gene (A3Cc), the shorter intron 
sequences between E1 and E2 and between E2 and E3 could be used to identify 
its presence. Also, possible amplification of longer fragments between E1 and 
E2, and E2 and E3 would indicate the existence of at least one other A3C gene in 
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the lion genome analogous to FcaA3Ca/b. Finally, successful product 
amplification between E3 of both the lion A3C genes that resembled FcaA3Cc 
and FcaA3Ca/b and E1 of any PleA3C gene would confirm the presence of a third 
PleA3C gene and would provide an insight into the order in which the lion A3C 
genes are arranged in the lion A3C gene locus.  
Firstly, the genomic DNA (gDNA) fragment between E1 and E2 of both 
PleA3C1 and PleA3C2 was amplified using primers LiA3C-Ex1-Fwd and LiA3C-Ex2-
Rev. Only one fragment of about 1.3 kb in length was obtained (Fig. 4-3A), 
similar to the short intron I1 of FcaA3Cc. A fragment of 3.2 kb in length 
resembling the longer intron I1 of FcaA3Ca or FcaA3Cb could not be amplified 
despite repeated attempts at further optimisation of the PCR.  
Next, the gDNA fragment between E2 and E3 of either PleA3C1 (primers 
LiA3C-Ex2-Fwd-1 and LiA3C-Ex3-Rev-1) or PleA3C2 (primers LiA3C-Ex2-Fwd-2 and 
LiA3C-Ex3-Rev-2) was amplified. Both PCR reactions yielded two fragments of 
approximately 1.6 kb and 2.5 kb in length (Fig. 4-3B), indicating that the primer 
combinations used could not discriminate between PleA3C1 and PleA3C2, but 
that there are two species of I2, similar to FcaA3Cc and FcaA3Ca/b I2. The PCR 
was repeated using primer sets LiA3C-Ex2-Fwd-1/LiA3C-Ex3-Rev-3 and LiA3C-
Ex2-Fwd-2/LiA3C-Ex3-Rev-4 that were specific for PleA3C1 and PleA3C2, 
respectively (Fig. 4-3C). The first primer pair enabled amplification of a 2.5 kb 
fragment, which confirms that PleA3C1 is homologous to FcaA3Ca/b. Use of the 
second primer pair led to amplification of a 1.6 kb fragment, which indicates 
that PleA3C2 is homologous to FcaA3Cc. Furthermore, the gDNA fragment 
between E3 of one PleA3C gene and E1 of the one downstream was amplified 
using forward primers LiA3C-Ex3-Fwd-1 (specific for PleA3C1) or LiA3C-Ex3-Fwd-
2 (specific for PleA3C2) and reverse primer LiA3C-Ex1-Rev-1. In both cases, PCR 
products of 3.5 kb were obtained (Fig. 4-3D), showing that both genes lay 
upstream of a distinct PleA3C gene. However, upon sequencing of the PleA3C1 
E3-E1 fragment multiple nucleotides were identified in the E4 region that 
differed from the E4 sequence of PleA3C1. Thus, not PleA3C1 but a similar 
PleA3C gene is situated upstream of another PleA3C gene. The newly identified 
PleA3C was termed PleA3C3 and the corresponding cDNA was amplified using 
specific primers LiA3C1 F and LiA3C3-Rev (Fig. 4-3E), cloned into VR1012 (Vical 
Inc.) and sequenced. PleA3C3 differs from PleA3C1 at two nucleotide positions in 
E3 (C412G, A499G) and in four nucleotides in E4 (G515A, A539G, A561G, G575A), 
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which result in the amino acid changes Arg138Gly, Arg167Gly, Arg172Lys and 
Asp180Gly. 
 
 
Figure 4-3 Identification of lion A3C genes by intron lengths and 
determination of A3C gene order within the lion A3 gene locus. PleA3C 
genomic DNA fragments between E1 and E2 (A), E2 and E3 (B,C) and E3 and the 
E1 of the following PleA3C gene (D) were amplified with specific primers based on 
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the published PleA3C1 or PleA3C2 cDNA sequence as indicated. (E) The 
PleA3C3 transcript was amplified from Angolan lion PBMC-derived cDNA.  
 
This study provides evidence for the presence of three PleA3C genes in the lion 
genome. Because both PleA3C2 and PleA3C3 lay upstream of a PleA3C and 
because PleA3C3 was similar to PleA3C1 in its intron lengths and exon 
sequences, the most likely order of the three genes in the lion genome is 5’-
PleA3C2-PleA3C3-PleA3C1-3’ (Fig. 4-4). It can be assumed that these genes have 
arisen in a comparable fashion to the domestic cat A3C genes, namely from an 
ancestral A3C gene undergoing two sequential gene duplication events.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4 Schematic representation of the lion A3C gene locus as 
determined by PCR amplification of genomic DNA fragments and binding 
sites of primers used in the study. According to data obtained by PCR 
amplification of genomic intron and exon sequences within the lion A3 gene locus, 
the lion genome contains three A3C genes that are aligned in a head-to-tail 
fashion in the order 5’-PleA3C2-PleA3C3-PleA3C1-3’. PleA3C1 and PleA3C2 
cDNA sequences have been previously described (GenBank EU007543 and 
EU007544, respectively). PleA3C3 has been identified in this study. The binding 
sites of primers used in this study are indicated. Primer pair (PP) 1 consisted of 
primers LiA3C-Ex1-Fwd and LiA3C-Ex2-Rev and was used to amplify a 1.3 kb 
genomic DNA (gDNA) fragment between PleA3C3 exons 1 and 2 (E1-E2) (Fig. 4-
3A). PP2 (LiA3C-Ex2-Fwd-1/LiA3C-Ex3-Rev-3) mediated amplification of a 2.5 kb 
gDNA fragment between exons 2 and 3 (E2-E3) of PleA3C3 and PleA3C1 (Fig. 4-
3C). PP3 (LiA3C-Ex2-Fwd-2/LiA3C-Ex3-Rev-4) bound specifically to PleA3C2 
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exons 2 and 3 (E2-E3) and PCR amplification yielded a 1.6 kb gDNA fragment 
(Fig. 4-3C). To amplify the gDNA fragment between exon 3 of PleA3C2 and exon 
1 of PleA3C3 (E3-E1) or exon 3 of PleA3C3 and exon 1 of PleA3C1 (E3-E1), PP5 
(LiA3C-Ex3-Fwd-2/LiA3C-Ex1-Rev-1) or PP4 (LiA3C-Ex3-Fwd-1/LiA3C-Ex1-Rev-
1) were used. Both PCR fragments obtained were 3.5 kb in length (Fig. 4-3D). 
 
4.3.3 Antilentiviral activity of feline APOBEC3 proteins 
 
In order to identify possible differences in the anti-lentiviral activities of 
domestic cat and non-domestic cat A3 proteins that may offer an explanation for 
the resistance of lion T lymphocytes to FIV infection, lentiviral single-cycle 
replication assays in the presence of A3 proteins were performed. Wild-type or 
vif-deleted, GFP-labelled HIV-1, SIVmac and FIV-Fca pseudotypes were produced 
in cells co-expressing either empty VR1012 vector or domestic cat A3 proteins 
(FcaA3Ca, FcaA3H, FcaA3CH), lion A3 proteins (PleA3C1, PleA3C3, PleA3H, 
PleA3CH) or puma A3 proteins (PcoA3C, PcoA3H, PcoA3CH). Pseudotypes were 
then used to infect target cells. Activity of A3s was assessed by flow cytometry 
and assumed to be inversely proportional to the percentage of transduced, GFP-
expressing cells. 
Firstly, the activities of domestic cat and lion A3 proteins against HIV-
1Δvif, HIV-1 wild-type, SIVmacΔvif and SIVmac wild-type were investigated (Fig. 
4-5). Whereas FcaA3Ca and PleA3C1 showed no activity against HIV-1Δvif and 
very little activity against HIV-1, FcaA3H, FcaA3CH, PleA3H and PleA3CH were 
able to strongly inhibit replication of HIV-1Δvif and HIV-1 (Fig. 4-5A,B). A similar 
trend was observed for SIVΔvif and SIV, against which FcaA3Ca and PleA3C1 were 
slightly more potent than against HIV-1Δvif and HIV-1 (Fig. 4-5C,D). These data 
indicate that domestic cat and lion A3 proteins are functional restriction factors, 
which block the replication of primate lentiviruses and are not counteracted by 
the HIV-1 or SIVmac Vif proteins. 
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Figure 4-5 Domestic cat and lion A3 proteins block primate lentivirus 
pseudotype infection. VSV-G-pseudotyped, GFP-expressing HIV-1 (A,B) and 
SIVmac (C,D) wild-type and vif-deleted particles were produced in 293T cells co-
transfected with empty vector only (CON), domestic cat (FcaA3) (A,C) or lion 
(PleA3) (B,D) A3 expression constructs. Pseudotype-containing cell supernatant 
was then used to transduce 293T target cells and activity of A3 proteins was 
assessed by measuring GFP-expression in target cells by flow cytometry. Single-
cycle replication assays were performed in triplicate (n=3; results shown as mean 
± S.E.). Statistically significant differences relative to the empty vector only control 
are indicated by asterisks (*, P<0.05, Dunnet’s t-test), non-significant differences 
by ‘ns’.  
 
Next, the activity of domestic cat, lion and puma A3 proteins against FIVΔvif and 
FIVΔvif provided with either vector only (CON), FIV-Fca GL8Mya Vif-HA, FIV-Ple E 
Vif-HA, FIV-Pco Vif-HA or FIV-Oma Vif-HA in trans was studied (Fig. 4-6B,D,F). 
Firstly, the expression levels of the FIV Vif proteins in 293T cells were assessed 
(Fig. 4-6A). For that, 2x106 cells in 100-mm cell culture dishes were transfected 
with 5 µg of each FIV Vif-HA expression construct and cell lysates were blotted 
with an anti-HA antibody. Immunoblotting confirmed that only FIV-Pco Vif was 
expressed in 293T cells at detectable levels, whereas all other FIV Vifs were not 
expressed at detectable levels and could not be used in A3 activity assays. Thus, 
FIV-Fca GL8Mya Vif was then also expressed in cis to FIV-Fca Petaluma gag and 
pol (GL8Mya Vif-FP93). Expression of GL8Mya Vif in the FP93 backbone could not 
be assessed by immunoblotting due to the lack of appropriate antibodies. 
However, because expression of lentiviral Vif protein is Rev-dependent (Garrett 
et al., 1991; Schwartz et al., 1991), it can be assumed that expression of FIV vif 
in cis to other FIV genes, as opposed to vif expression in trans, improved Vif 
protein expression to a level where an anti-A3 effect, if present, could be 
observed.  
FIV p24 Gag expression in producer cells was investigated to rule out a 
negative impact of A3 or Vif expression on particle production (Fig. 4-6C,E,G). 
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Figure 4-6 Activities of domestic cat, lion and puma A3 proteins against FIV-
Fca pseudotype infection in the presence and absence of FIV Vifs. VSV-G-
pseudotyped, GFP-bearing FIV-FcaΔvif particles were produced in 293T cells co-
transfected with empty vector only (CON), domestic cat (FcaA3) (B), lion (PleA3) 
(D) or puma (PcoA3) (F) A3 protein expression vectors in the presence or absence 
of different FIV Vif-HA expression constructs. Pseudotype-containing cell 
supernatant was then used to transduce 293T target cells and activity of A3 
proteins was assessed by measuring GFP-expression in target cells by flow 
cytometry. Single-cycle replication assays were performed in triplicate (n=3; 
results shown as mean ± S.E.). Statistically significant differences relative to the 
empty vector only control are indicated by asterisks (*, P<0.05, Dunnet’s t-test), 
non-significant differences by ‘ns’. (A) Expression of FIV Vifs in 2x106 293T cells 
transfected with 5 µg of either of the FIV-Vif expression constructs was assessed 
by immunoblotting using a rabbit anti-HA antibody (Sigma-Aldrich). (C,E,G) FIV-
Fca Gag (p24) expression in transfected 293T producer cells was assessed by 
immunoblotting using mouse anti-FIV p24 antibody (vpg50) to exclude a negative 
effect of A3 expression on Gag production.  
 
As observed for primate lentivirus pseudotypes, feline A3C isoforms could limit 
FIVΔvif pseudotype infectivity of target cells only modestly, if at all (Fig. 4-
6B,D,F). Co-expression of different FIV Vifs did not result in an increase of 
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pseudotype infectivity. In contrast, feline A3H and A3CH proteins were able to 
block FIVΔvif replication significantly (Fig. 4-6B,D,F). FcaA3H and FcaA3CH 
reduced FIVΔvif infectivity 47- and 119-fold, PleA3H and PleA3CH 27- and 28-
fold, and PcoA3H and PcoA3CH 13.2- and 42-fold, respectively. Interestingly, 
FIV-Pco Vif and GL8Mya Vif expressed in cis with FIV-Fca Petaluma gag and pol 
(GL8Mya Vif-FP93) were able to antagonise feline A3H and A3CH proteins to 
different degrees. FcaA3CH was more sensitive to counteraction by FIV-Pco and 
FIV-Fca Vif than FcaA3H (Fig. 4-6B). FIV(VSV-G) pseudotype infectivity in the 
presence of PleA3H was rescued slightly when either of the two Vifs was co-
expressed. However, Vif expression had no negative effect on the activity of 
PleA3CH and even augmented restriction (Fig. 4-6D). Finally, PcoA3H and 
PcoA3CH were equally sensitive to the Vif proteins (Fig. 4-6F). 
The data presented here indicate that domestic cat, lion and puma A3H 
and A3CH proteins potently restricted not only primate but also feline lentivirus 
replication in single-cycle replication assays. However, in contrast to primate 
lentivirus Vif proteins, which do not show any activity against feline A3s, FIV Vifs 
were able to overcome feline A3 proteins in an A3-specific, non-species specific 
manner. Due to the lack of expression of some FIV Vifs in 293T cells and the low 
expression of others it was difficult to evaluate their maximum potency against 
feline A3 proteins. Because the activity of FIV-Pco Vif and FIV-Fca GL8 Vif in 
FP93 rescued viral infectivity to a significant degree, future work should include 
the insertion of FIV-Ple Vif and FIV-Oma Vif into the FP93 backbone for use of 
these constructs in A3 activity assays.  
 
4.3.4 Quantification of feline APOBEC3 expression 
 
This study has shown that feline A3 proteins function as anti-lentiviral restriction 
factors in vitro. However, information about their expression in vivo, which may 
give an insight into their role in limiting viral infection, is sparse. Thus, RT-qPCR 
was performed to generate feline A3 expression profiles in domestic cat cell 
lines and tissues and in lion PBMCs. Moreover, the effect of type I interferon on 
A3 expression was determined.  
Cat and lion A3C and A3H were modestly expressed in all samples tested 
(Fig. 4-7A-C). Cat and lion A3CH, however, were expressed only at low levels in 
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most samples and were not expressed in three domestic cat tissue samples (Fig. 
4-7B). Interestingly, in cat cell lines and tissues FcaA3C expression was higher 
than FcaA3H expression whereas the opposite trend was observed in lion PBMCs. 
Interferon treatment upregulated A3 expression in 3201, CrFK and Mya-1 cells, 
but had no effect on A3 expression in AH927 or FEA cells (Fig. 4-7A). 
The data indicate that A3 genes have a broad expression profile in 
domestic cat cells and tissues. Importantly, expression levels of A3H and A3CH, 
whose gene products have been shown to possess the highest anti-lentiviral 
activity (Fig. 4-5 and 4-6), were lower than that of the three A3C isoforms 
together. However, a small number of A3H and A3CH proteins per cell may 
suffice to elicit a potent antiviral response.  
Moreover, expression levels of lion A3 genes were comparable between 
PBMCs of African and Asian lion origin, indicating that A3 expression did not 
increase in the process of long-term host-FIV co-evolution that took place in 
African, but not in Asian lion populations.  
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Figure 4-7 Quantification of domestic cat and lion mRNA by real-time reverse 
transcription PCR and effect of interferon treatment. A3 expression in the 
domestic cat cell lines 3201, AH927, CrFK (ID10) and FEA as well as in IL-2-
dependent CD4+ T cells (Mya-1) (A), in tissues of three FIV-negative cats (B; cats 
labelled C1-C3) and in African and Asian lion PBMCs (C) was quantified by RT-
qPCR. Domestic cat cell lines were cultured overnight with or without IFN-α at 103 
IU/ml prior to RNA extraction, cDNA preparation, and A3 cDNA quantification. Lion 
PBMCs were cultured overnight with or without IFN-ω at 103 IU/ml prior to RNA 
extraction, cDNA preparation, and A3 cDNA quantification. Real-time PCR was 
performed using 1 µl cDNA (1/20) or standard plasmid DNA once in triplicates 
(n=1). CT values (where “CT” represents threshold cycle) for A3C, A3H and A3CH 
transcripts were determined and converted into copy numbers with the help of the 
standard curve equation. Because A3C and A3H primer and probe sets non-
specific and could also detect A3CH transcripts, A3CH copy numbers were 
subtracted from A3C and A3H copy numbers. Copy numbers were then converted 
back into CT values. Results are expressed as ΔCT values, which were calculated 
by subtracting the mean CT for the abundant 18S rRNA from the CT for A3 
mRNAs.  
 
4.3.5 Analysis of APOBEC3 diversity in African and Asian lion 
populations 
 
Currently, a total of eleven distinct lion populations exist across Africa and in 
the Gir forest in India (see Fig. 1-5). Of these lion populations, only the three 
populations in the Gir forest in India, in southern Botswana and in Namibia are 
FIV-negative (Brown et al., 1994; O'Brien et al., 2006), whereas in other lion 
populations in Africa the FIV seroprevalence can be as high as 90% (see Table 1-
1). In order to investigate whether long-term FIV prevalence in African lions and 
host-virus co-evolution has led to an adaptive evolution of A3 proteins that may 
have altered their anti-lentiviral activity, the genetic diversity of African lion 
A3s was compared to that of Asian lion A3s.  
Antunes et al. (2008) found that maternal inherited (mitochondrial DNA, 
mtDNA) sequence variation in lions is generally low. Only twelve 12S-16S mtDNA 
haplotypes (H1-H12) were identified, which cluster into four distinct mtDNA 
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lineages (I-IV). Interestingly, their pairwise genetic distances among the eleven 
lion populations showed a significant relationship with geographic distances 
between lion populations (Antunes et al., 2008). MtDNA lineage I is present in 
East Africa and includes haplotype 4 (H4) which can be found exclusively in 
Kenya (KEN) (Fig. 1-5). MtDNA lineage II comprises haplotypes H1 to H3 which 
are present in the southern African lion populations in northern Botswana (BOT-
II), Kruger National Park in South Africa and Mozambique (KRU) and Namibia 
(NAM), respectively. MtDNA lineage III includes haplotypes present in northern 
and central African (H5 and H6) and in Asian lion populations (H7 and H8). H5 
and H6 can be found in Morocco (ATL), Angola (ANG) and Zimbabwe (ZBW), and 
H7 and H8 can be found solely in the Gir forest in India (GIR) (Fig. 1-5). Finally, 
mtDNA lineage IV is predominant in southern and East Africa and comprises 
haplotypes H9 to H12. H9 is limited to BOT-II and H10 to KRU. H11 is the most 
prevalent mtDNA haplotype and exists in lion populations in southern Botswana 
(BOT-I), KRU, in the Ngorongoro Crater in Tanzania (NGC), in the Serengeti 
National Park in Tanzania (SER-I, SER-II, SER-III) and in Uganda (UGA) (Fig. 1-5). 
H12 can be found in SER-I. Hence, mtDNA haplotypes can be used to identify 
geographic origins of individual lions.  
In this study mtDNA haplotypes of eight lion samples were determined in 
order to link possible A3 gene sequence variations with geographic origin of 
lions. It was of particular importance to distinguish African from Asian lion 
samples, as cross-breeding regularly takes place in captive settings, which leads 
to the generation of genetic hybrids. Table 4-1 summarises mtDNA haplotypes 
and geographic origins of the samples used. One sample was of Angolan origin 
(ANG; H5; “ANG1”). Three samples possessed mtDNA haplotype H1 and hence 
originated from Northern Botswana (BOT-II; “Chianti”, “Clairette”, “Krystal”). 
Two samples mapped to haplotypes H2 and thus, originated from lions from the 
Kruger National Park (KRU; “KRUA1”, “KruA4”). One sample came from the 
Serengeti National Park (SER; H11; “SER 156.04”). Finally, one sample was of 
Asian origin (GIR; H7; “BRISTOL 9971”). Thus, lion samples from different African 
and Asian lion populations were used to investigate the diversity of lion A3 
genes.  
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Table 4-1 Analysis of geographic origins of lion whole blood samples by 
mtDNA haplotyping. Genomic DNA from eight lion whole blood samples obtained 
from different sources was isolated. In order to determine the geographic origin of 
the lions, a 1882-nt fragment of 12S-16S mtDNA was amplified from the gDNA, 
cloned and sequenced. This fragment contains variable sites, which allows 
classification of sequences into twelve lion mtDNA haplotypes (H1-H12) and four 
mtDNA lineages (I-IV) (Antunes et al., 2008). Haplotype and lineage affiliation 
correlates with geographic origin of samples (see Fig. 1-5). Samples used in this 
study originated from Angola (ANG), northern Botswana (BOT-II), Kruger National 
Park (KRU), the Serengeti National Park (SER) and the Gir forest (GIR). 
 
 
 
A3C gene fragments from individual lion gDNAs were amplified, cloned and 
sequenced as described in Section 1.3.2. Additionally, the full-length PleA3H 
gene was amplified, cloned and sequenced. Sequences were aligned to the 
known PleA3C1 (GenBank EU007545), PleA3C2 (GenBank EU007544), PleA3C3 
(this study) and PleA3H (GenBank EU007552) cDNA sequences. The reference 
Sample name Source 
MtDNA 
haplotype 
MtDNA 
lineage 
Geographic 
origin 
ANG1 Angola H5 III ANG 
Chianti 
Moremi reserve, 
Okavango Delta, 
Botswana 
H1 II BOT-II Clairette 
Krystal 
KRUA1 
Lahore Zoo, 
Pakistan 
H2 II KRU 
KRUA4 
Lahore Safari Park, 
Pakistan 
SER 156.04 
Serengeti National 
Park, Gol Kopjes, 
Shinyanga, 
Tanzania 
H11 IV SER 
BRISTOL 9971 Bristol Zoo, UK H7 III GIR 
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sequences had originally been obtained from an Angolan lion (H5) (Munk et al., 
2008). Unexpectedly, none of the tested lion samples contained any nucleotide 
changes in the PleA3C or PleA3H coding region compared to the reference 
sequences. Thus, it can be concluded that FIV, and in particular the FIV Vif 
protein, did not exert a selection pressure on A3 proteins during extended 
periods of host-virus co-evolution.  
 
4.4 Discussion 
 
The data presented here suggest that the number and nature of A3 transcripts is 
conserved between domestic and non-domestic cat genomes and that A3 genes 
are broadly expressed in various feline cell types and tissues. Feline A3H and 
A3CH proteins were shown to be potent anti-FIV restriction factors in the 
absence of the FIV Vif protein. In contrast, feline A3C proteins displayed only a 
low antiviral activity. Although FIV Vif is an A3 antagonist, no evidence was 
found to support the hypothesis that Vif has shaped the functions of A3 proteins 
during long-term host-virus co-adaptation. 
The activities of feline A3 proteins and their susceptibility to FIV Vifs have 
also been investigated in other recent studies (Munk et al., 2008; Stern et al., 
2010; Zielonka and Munk, 2011). In agreement with our findings, feline A3C 
isoforms did not reduce the infectivity of FIVΔvif or FIV. However, because the 
A3 activity assay used in this study relies heavily on mutation of the reporter 
protein GFP by deamination of GFP minus-strand cDNA during reverse 
transcription, deamination events outwith the cDNA sequence that encodes for 
the fluorophore active site or deamination-independent A3 activities may have 
been missed. 
Production of FIVΔvif(VSV-G) pseudotypes in the presence of FcaA3H or 
FcaA3CH led to an inhibition of viral replication by five- or ten-fold, 
respectively, and was accompanied by an increased G-to-A mutation rate of viral 
genomes (Munk et al., 2008). Likewise, A3H and A3CH proteins of non-domestic 
felids decreased FIV infectivity in the absence of Vif (Zielonka and Munk, 2011). 
In contrast, in this study and in the study by Stern et al. (2010) significantly 
higher fold reductions in FIV infectivity by feline A3H and A3CH proteins were 
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observed that could be explained by differences in A3 expression from the 
various expression constructs used (data not shown).  
Notably, FIV-Fca Vif not only suppressed the activities of domestic cat A3s 
and induced their depletion from producer cells, but also counteracted lion and 
puma A3 proteins (Zielonka and Munk, 2011). In comparison, our results indicate 
that there are indeed differences in the sensitivity of feline A3 proteins to FIV 
Vifs (Fig. 4-6B,D,F). Whereas the antiviral activity of FcaA3CH was partially 
overcome by FIV Vifs, Vif proteins were less potent against FcaA3H. Similarly, Vif 
modestly counteracted PleA3H, PcoA3H and PcoA3CH. Paradoxically, FIV Vifs 
enhanced the PleA3CH-mediated reduction of FIVΔvif infectivity. The inability of 
FIV Vifs to suppress PleA3CH may be caused by impaired Vif-PleA3CH binding, 
which has been shown to be essential for Vif-mediated A3 degradation (Stern et 
al., 2010). Future research should thus focus on the identification of amino acid 
residues that are essential for the FIV Vif-feline A3 interaction. Importantly, the 
resistance of PleA3CH to FIV Vif may contribute to the inability of FIV to 
replicate in lion T lymphocytes. Other feline A3 proteins do not seem to play a 
major role in limiting FIV replication and interspecies transmission.   
No differences in activity against feline A3 proteins were observed 
between FIV-Pco Vif (in VR1012) and GL8Mya Vif (in FP93), which suggests that 
FIV Vif is not specific for A3 proteins of a particular felid species. In contrast, 
HIV-1 Vif degrades human A3G but not non-human primate A3Gs (Marin et al., 
2003). However, FIV-Fca Vif is non-functional against human A3G (Munk et al., 
2008; Zielonka et al., 2010). The expression of FIV-Ple E Vif and FIV-Oma Vif was 
attempted but proved unsuccessful (Fig. 4-6G). Codon usage optimisation of 
these FIV Vifs could be performed to improve their expression in 293T cells.  
The data presented here show that feline A3H and A3CH proteins possess 
a broad anti-lentiviral activity that extends to HIV-1 and SIVmac (Fig. 4-5). In 
agreement with the work of Stern et al. (2010), HIV-1 Vif was non-functional 
against feline A3 proteins and even augmented domestic cat A3C-mediated 
restriction (Fig. 4-5A). Surprisingly, Stern et al. (2010) reported that SIVmac Vif 
counteracts FcaA3CH while increasing the restriction of SIV by FcaA3Ca and 
FcaA3H. In contrast, in this study no evidence for activity of SIV Vif against 
FcaA3CH was found (Fig. 4-5C). However, our data confirm the augmentation of 
feline A3H activity by SIV Vif. No differences between the potencies of domestic 
and non-domestic cat A3s against primate lentiviruses were detected. 
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Because A3 and Vif proteins are highly overexpressed in the in vitro 
single-cycle replication assays commonly used to determine their activities, the 
results obtained may not reflect the situation in natural lentiviral target cells. 
To gain a better insight into the role of feline A3 proteins in FIV restriction it 
was important therefore to link in vitro A3 restriction potentials with A3 
expression levels in relevant feline cell lines and tissues.  
A recent study has investigated the human A3 mRNA expression profile in 
human lymphocytes (T cell lines and leukocytes) and tissues (Refsland et al., 
2010). The data showed that multiple A3 genes were expressed constitutively in 
most cell types and tissues and that the expression of some of them could be 
enhanced by T-cell activation and interferon treatment. As would be expected, 
genes encoding human A3G and A3F, the cytidine deaminases known to inhibit 
HIV-1 replication (Sheehy et al., 2002; Liddament et al., 2004; Zheng et al., 
2004), were highly expressed in non-permissive cell lines such as CEM and H9, 
but not in permissive cell lines like CEM-SS or SupT1 (Refsland et al., 2010). High 
A3G expression levels were also found in un-stimulated primary PBMCs. In 
comparison, A3F expression levels were approximately 10-fold lower in these 
cells (Koning et al., 2009; Refsland et al., 2010). IL-2 and mitogen 
(phytohaemagglutinin, PHA) stimulation of the CD4+ T lymphocyte fraction led to 
upregulation of A3G, but not A3F expression (Refsland et al., 2010). Treatment 
of PBMCs or CD4+ T cells with leukocyte interferon resulted in an upregulation of 
A3G expression in PBMCs, but not in CD4+ T lymphocytes. Other recent reports 
have shown that A3 expression is only IFN-responsive in CD14+ phagocytic cells 
such as monocytes and macrophages (Peng et al., 2006; Koning et al., 2009).  
Lastly, A3G and A3F expression was very low in tissues such as brain, 
heart, kidney, skeletal muscles or small intestine and low in bone marrow, liver, 
thymus and tonsils. Tissues with high A3G and A3F expression were lung, lymph 
node, ovary and spleen (Koning et al., 2009; Refsland et al., 2010). With the 
exception of ovarian tissue, high A3G and A3F expression levels correlated with 
high expression levels of the lymphocyte marker CD3 suggesting that the 
lymphocyte content of a particular tissue was a major determinant of the 
A3G/A3F expression level (Koning et al., 2009). 
In the current study, differences between the FcaA3C, FcaA3H and 
FcaA3CH expression levels in feline cell lines were observed. Feline thymic 
lymphosarcoma cells (3201) and kidney epitheliod cells (CrFK) showed higher 
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basal expression levels of all domestic cat A3 genes than fibroblasts (AH927), 
foetal embryo fibroblast-like cells (FEA) and feline T lymphocytes (Mya-1) (Fig. 
4-7A). A3 gene expression was inducible by IFN-α treatment in 3201, CrFK and 
Mya-1 cells. In all cell lines expression of FcaA3C was higher than that of FcaA3H 
and significantly higher than that of FcaA3CH. Expression of PleA3C, PleA3H and 
PleA3CH was comparable between un-stimulated and un-stimulated, IFN-ω-
treated African and Asian lion PBMCs (Fig. 4-7C). However, PleA3H expression 
was higher than PleA3C and significantly higher than PleA3CH expression. 
One possible explanation why FcaA3C expression in domestic cat cells was 
higher than that of FcaA3H, while PleA3H was expressed at higher levels in lion 
PBMCs than PleA3C may be that domestic cat FcaA3C expression has responded 
to the presence of other retroviruses that have a significantly higher prevalence 
in domestic cats than in lions, such as feline foamy virus (FeFV) (Lutz et al., 
1994). Indeed, FcaA3Ca has been shown to possess potent antiviral activity 
against FeFVΔbet (Lochelt et al., 2005). 
A3 expression levels in eleven different tissues from three FIV-negative 
cats were quantified. In accordance with A3 expression data in human tissues 
(Refsland et al., 2010), bone marrow and tonsils had lower A3 mRNA contents 
than different species of lymph nodes, spleen and thymus. A3 expression in 
ovarian tissue closely resembled those in bone marrow and tonsils and was, 
therefore, lower than expected. Apart from ovaries all tissues used in this study 
were lymphoid tissues and thus rich in lymphocytes, which should have high A3 
gene expression levels. It can be assumed that, similar to the study by Koning et 
al. (2009), there are differences in the lymphocyte content of these tissues that 
may explain the observed variation in A3 gene expression. 
A3 proteins are single-stranded DNA-editing enzymes that protect hosts 
from viral infection. Lentiviral Vif proteins, in return, target A3 proteins for 
ubiquitination and proteasome-mediated degradation. The Vif-A3 interaction is 
mostly species-specific as Vif of a particular lentivirus will only counteract A3 
proteins of the lentivirus’ host species, but not that of other hosts. Thus, to 
constantly escape from or enhance interactions, respectively, both A3 and vif 
genes are expected to engage in adaptive co-evolution (Zhang and Webb, 2004), 
a concept known as the red queen hypothesis (Van Valen, 1973). 
Indeed, multiple A3 and lentiviral vif genes have been shown to be under 
positive (diversifying) selection (Yang et al., 2003; Sawyer et al., 2004; Zhang 
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and Webb, 2004; Munk et al., 2008; Compton et al., 2012). In felids, A3C genes 
were found to be under positive selection, whereas A3H genes evolve under 
negative (purifying) selection (Munk et al., 2008). It was proposed that feline 
A3C genes may be under high selective pressure from FeFV, given that FcaA3C 
proteins possess potent anti-FeFV activity (Lochelt et al., 2005; Munk et al., 
2008). In contrast, feline A3H genes do not evolve adaptively, although feline 
A3H proteins can counteract FeLV and FIV (Munk et al., 2008).  
Here, we tested the hypothesis that the long-term presence of FIV in 
African lion populations has driven adaptive evolution of African lion A3 genes 
and has shaped the activities of lion A3 proteins through the continuous activity 
of Vif. For that, fragments of A3C and A3H genes were amplified from different 
African lion gDNAs and their sequences were compared to that of Asiatic lion 
A3C and A3H genes. Currently, only one Asian lion population exists, namely in 
the Gir forest in India, which is FIV-negative (Lutz et al., 1992; Spencer et al., 
1992; Brown et al., 1994) and can thus serve as a control for A3 evolution in the 
absence of FIV Vif. Unexpectedly, no differences in the sequences of African and 
Asiatic lion A3C and A3H gene exons were identified, indicating that FIV Vif has 
not been a driving force in feline A3 gene evolution.  
One reason for the apparent lack of Vif selection pressure on African lion 
A3 genes may be that FIV-positive African and FIV-negative Asian lion 
populations have not been separated from each other for sufficient amounts of 
time in order for adaptive evolution to take place. The most recent ancestor of 
modern lion populations dates back to only 325,000 years ago. Starting from 
Eastern and Southern Africa, lions migrated into Central and North Africa and 
finally into Eurasia about 100,000 years ago (Antunes et al., 2008). 
Unfortunately, it is not clear when lions first became infected with FIV. 
Interestingly, other groups have investigated the impact of HIV-1 Vif on 
human A3G evolution and found that, although A3G has been subject to strong 
diversifying selection throughout primate evolution, the selection pressure 
driving this evolution predates the emergence of modern lentiviruses about 1 
MYA (Sawyer et al., 2004; Zhang and Webb, 2004). This indicates the presence of 
more ancient genetic conflicts involving A3G (Sawyer et al., 2004). Such 
conflicts may have taken place not only in lymphocytes but also in the germline 
and may have involved LTR-bearing human endogenous retroviruses (HERVs) or 
retrovirus-like eukaryotic mobile elements (Sawyer et al., 2004). Furthermore, 
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in agreement with our findings, Zhang and Webb (2004) found no difference in 
selective pressure on A3G between hosts and non-hosts of HIV-1 or SIV (Zhang 
and Webb, 2004), demonstrating again that lentiviral Vif proteins are not likely 
to have a major impact on A3 selection.  
Conversely, A3 proteins may well be the driving force for the positive 
selection of lentiviral Vifs, especially given the high mutation rate of lentiviruses 
that would allow for rapid adaptation (Sawyer et al., 2004; Zielonka et al., 2010; 
Compton et al., 2012). 
It is plausible that positive evolution of feline A3C genes is also not 
influenced by FIV Vif, especially given its low anti-FIV activity, and that it may 
predate the presence of FIV. Similar to human A3G, feline A3H may be under 
negative selection because A3H may protect against endogenous retroelements 
(Munk et al., 2008). Alternatively, the current A3H amino acid sequence and 
activity may be optimal to target highly conserved viral structures of FeLV or 
FIV. Although A3H alone has only intermediate activity against lentiviruses, its 
combination with exons of A3C genes has created a potent lentiviral restriction 
factor (A3CH). Lastly, apart from innate immune defence, A3H may also be 
required for other, currently unknown processes. 
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 The role of BST-2/tetherin in feline retrovirus infection 5
5.1 Summary 
 
The findings presented in Chapter 4 indicate that, with the exception of 
PleA3CH, which potently restricted FIV even in the presence of FIV Vif, feline A3 
proteins do not contribute significantly to the prevention of FIV replication and 
its interspecies transmission. 
In addition to TRIM5α and A3 proteins a third restriction factor against 
HIV-1 has been characterised. BST-2/tetherin/CD317 exerts a late block to 
retroviral replication in that it prevents the release of mature enveloped viral 
particles from membranes of viral producer cells, an activity that is 
counteracted by Vpu of HIV-1 and certain SIVs, HIV-2 and SIV Envs, and SIV Nef 
proteins (Neil et al., 2007; Neil et al., 2008; Van Damme et al., 2008; Gupta et 
al., 2009b; Jia et al., 2009; Le Tortorec and Neil, 2009; Perez-Caballero et al., 
2009; Sauter et al., 2009; Zhang et al., 2009b; Goffinet et al., 2010; Yang et al., 
2010). Tetherin is a specific cell surface marker of type I IFN-producing 
plasmacytoid dendritic cells (pDCs); however, its expression can be upregulated 
in many different cell types by stimulation with type I IFN and IFN-γ (Blasius et 
al., 2006). The antiviral activity of tetherin has been studied almost exclusively 
in single-cycle replication assays using lentiviral pseudotypes but information on 
its potency to block viral spread is sparse.  
In this study a gene encoding the feline homologue of tetherin was 
identified in the domestic cat genome. Alignment of the coding sequence of this 
feline tetherin with cDNAs of other bona fide tetherins revealed significant 
homology between them on both nucleotide and amino acid levels. Interestingly 
though, the feline tetherin cDNA was predicted to lack the otherwise conserved 
initiation codon. Hence, the full-length protein was likely to possess a shorter N-
terminus than other tetherins. However, because the tetherin 5’ region was still 
encoded in the domestic cat genome and would contain a double tyrosine motif 
shown to be important for tetherin endocytosis from the cell surface (Rollason et 
al., 2007; Iwabu et al., 2009; Masuyama et al., 2009) we initially decided to 
amplify the feline tetherin cDNA with a forward primer that contained an 
initiation codon followed by the tetherin 5’ sequence naturally present in the 
domestic cat genome and feline tetherin cDNA. The protein encoded by this 561 
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nt long feline tetherin cDNA is referred to as ”FcaTHN” in this thesis. Later 
during the course of this study the 504 nt long feline tetherin cDNA, whose 
translation is initiated at a downstream ATG, was amplified and characterised. 
To our current knowledge, this cDNA encodes for the wild-type feline tetherin, 
which is referred to as “FcaTHN-WT”. The term “feline tetherin” is used when 
reference is made to both FcaTHN and FcaTHN-WT.  
Feline tetherin was found to be expressed in many feline cell lines, and 
expression was IFN-inducible. Like human tetherin, FcaTHN displayed potent 
inhibition of FIV and HIV-1 particle release; however, this activity resisted 
antagonism by either HIV-1 Vpu or the FIV Env and OrfA proteins. Interestingly, 
stable expression of FcaTHN in feline cell lines did not abrogate the replication 
of FIV. Indeed, syncytium formation was significantly enhanced in FcaTHN-
expressing cells and in type I interferon-treated CrFK cells infected with cell 
culture-adapted, CD134-independent strains of FIV. Thus, while tetherin may 
prevent the release of nascent viral particles, its expression seems to facilitate 
viral transmission by inducing a shift from a cell-free to a cell-to-cell 
transmission mode.  
In the second part of the study, the activity of FcaTHN against other feline 
retroviruses was determined. Most notably, the replication of RD114, an 
endogenous feline retrovirus, was severely affected by FcaTHN. Furthermore, 
tetherins of non-domestic felids were characterised and their potential to limit 
retroviral replication was tested. Lion and puma tetherins (PleTHN and PcoTHN, 
respectively) were amplified using the same strategy as described for FcaTHN 
and resembled FcaTHN in their inability to block viral spread.  
Finally, the activity of FcaTHN-WT to limit FIV particle release in the 
presence or absence of different FIV Envs and to prevent FIV spread was 
assessed. FcaTHN-WT was slightly more potent in blocking FIV particle release 
than FcaTHN, but again, this activity was not overcome by FIV Envs. Importantly, 
like FcaTHN, FcaTHN-WT was not able to control FIV spreading infection.  
In summary, these data suggest that while felid tetherins prevent particle 
release, they do not play a significant role in the suppression of retroviral 
replication in vivo. 
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5.2 Materials and Methods 
 
5.2.1 Amplification, molecular cloning and stable expression of 
feline and human tetherin cDNAs 
 
The genomic sequence of the prospective domestic cat homologue of tetherin 
was identified by blasting the sequences of human (HsaTHN; GenBank 
NM_004335) and dog (Canis lupus familiaris) tetherins (CluTHN; GenBank 
XM_847295, XM_860510) against the 2X domestic cat genome using megaBLAST 
(Zhang et al., 2000). A candidate domestic cat tetherin gene was identified on 
Felis catus c430601298.contig1 (GenBank ACBE01053987). This gene showed a 
high degree of nucleotide and amino acid homology to other known tetherin, but 
was lacking an otherwise conserved initiation codon at the 5’ end of its first 
coding exon. To determine the initiation site of the coding sequence of feline 
tetherin, 5’RACE PCR was performed using the 5’/3’ RACE kit (Roche Applied 
Science) and gene-specific primers FcTHN-SP1 (5’-GAAGCCAACAGGGTTACCAA-3’) 
and FcTHN-SP2 (5’-GACACCGTGACACTCCTCCT-3’) according to manufacturer’s 
instructions. A feline tetherin cDNA fragment (referred to as FcTHN-WT; 504 nt; 
DDBJ [Data Base of Japan] AB564550), that would encode for a tetherin with a 
shortened N-terminus compared to other tetherins, was identified as full-length 
transcript and amplified using primers FcTHN-delCT-Fwd (5’-ACTGGTCGACACCAT 
GGTGCCAGGTCGGAGTCTT-3’) (SalI restriction site underlined) and FcTHN-Rev-1.  
A longer cDNA containing an engineered  5’ initiation codon and the naturally 
present feline tetherin 5’ cDNA sequence (FcaTHN; 561 nt; GenBank 
HM461970/NM_001243085) was amplified from Mya-1-derived cDNA with primers 
FcTHN-Fwd-2 (5’-ATCGGTCGACACCATGGCACCTGCTTTTTTACCAC-3’) (SalI 
restriction site underlined) and FcTHN-Rev-1 (5’-ACAGCGGCCGCTCAGGCCAGCAG 
AGCAACGAA-3’) (NotI restriction site underlined). The sequence of FcaTHN has 
been deposited in GenBank under accession number HM461970. The same primer 
set as for FcaTHN was used to amplify lion tetherin (PleTHN) from Angolan lion 
PBMC cDNA and puma tetherin (PcoTHN) from puma PBMC-derived cDNA. 
HsaTHN was amplified from 293T cell-derived cDNA using primers HuTHN-Fwd-1 
(5’-ACTGGTCGACACCATGGCATCTACTTCGTAT-3’) (SalI restriction site 
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underlined) and HuTHN-Rev-1 (5’-ACAGCGGCCGCTCACTGCAGCAGAGCGCTG-3’) 
(NotI restriction site underlined). 
All tetherin cDNAs were cloned into VR1012 (Vical Inc.) using SalI and NotI 
restriction sites to generate constructs FcaTHN-VR1012, PleTHN-VR1012, 
PcoTHN-VR1012, HsaTHN-VR1012 and FcaTHN-WT-VR1012.  
Furthermore, site-directed mutagenesis was performed to delete a 
putative endocytosis motif at the N-terminus of FcaTHN. At first the mutation 
Tyr8Ala was created using FcaTHN-VR1012 as template and mutagenesis primers 
FcTHN-Y8A-Fwd (5’-GCACCTGCTTTTTACCACGCGTGGCCTGTGCCCAGGAC -3’) and 
FcTHN-Y8A-Rev (5’-GTCCTGGGCACAGGCCACGCGTGGTAAAAAGCAGGTGC-3’). 
Another mutation (Tyr6Ala) was then introduced into FcaTHN-Y8A-VR1012 using 
mutagenesis primers FcTHN-Y6/8A-Fwd (5’-GCACCTGCTTTTGCGCACGCGTGGCCT 
GTGCCCAGGAC-3’) and FcTHN-Y6/8A-Rev (5’-GTCCTGGGCACAGGCCACGCGTGCG 
CAAAAGCAGGTGC-3’) to generate construct FcaTHN-Y6/8A-VR1012. 
For stable expression in CrFK, FEA and canine CLL cells, all tetherins were 
cloned into pDON-AI-2neo (Takara Bio Europe S.A.S./Clontech) using NotI and 
BamHI restriction sites. For confocal microscopy experiments, FcaTHN was 
labeled with an internal haemagglutinin (HA) tag by amplification of two 
fragments by the use of primer pair FcTHN-Fwd-3 (5’-ATCGGCGGCCGCATGGCAC 
CTGCTTTTTACCAC-3’) (NotI restriction site underlined) and FcTHN-HA-Rev-1 (5’-
GACGTAGTCTGGGACGTCGTATGGGTATTCCTTTTTCTTGCTCGAG-3’) and primer 
pair FcTHN-HA-Fwd-1 (5’-TACCCATACGACGTCCCAGACTACGTCGTCGCGTCTGCCA 
GCTCCTTGA-3’) and FcTHN-Rev-2 (5’-ACAGGATCCTCAGGCCAGCAGAGCAACGAAG-
3’) (BamHI restriction site underlined), with the construct FcaTHN-VR1012 used 
as template. The products were then purified, combined, and used as a 
template for a second round of amplification using primers FcTHN-Fwd-3 and 
FcTHN-Rev-2. The product (FcaTHN-HA) was then cloned into pDON-AI-2 Neo 
using NotI and BamHI restriction sites and transduced into CRFK cells. 
 
5.2.2 Quantification of domestic cat tetherin mRNA by real-time 
reverse transcription PCR 
 
Quantitative real-time reverse transcription PCR (RT-qPCR) was performed to 
determine the expression levels of the domestic cat tetherin gene (THN) in the 
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feline cells lines FEA, CrFK, AH927 and 3201, in Mya-1 cells and in primary feline 
macrophages. Before RNA isolation, feline cell lines and macrophages were 
either left untreated or were stimulated with 103 IU/ml feline IFN-α, feline IFN-γ 
(both from R&D Systems Europe Ltd, Abingdon, UK) or recombinant feline IFN-ω 
(Virbac Limited, Bury St Edmonds, UK), respectively, for 24 hours. All RNAs were 
treated with DNAse I (Life Technologies) prior to cDNA synthesis.  
Feline tetherin mRNA was detected using primers qPCR-FcTHN-Fwd (5’-
GAGAAGGCCCAGAGCCAGGAG-3') and qPCR-FcTHN-Rev (5'-GCAACGAAGGCCAGGA 
GCAG-3') and probe qPCR-FcTHN-Pro (5'FAM-TGCAGAACGCTTCGGTGGAGGTGGAA 
AGACTGAGAAA-3'TAMRA). Domestic cat 18S rRNA was used as housekeeping gene 
and was amplified with primers rDNA 343F cat (5'-CCATTCGAACGTCTGCCCTA-3') 
and rDNA 409 R (5'-TCACCCGTGGTCACCATG-3') and probe rDNA 370Pcat (5'FAM-
CGATGGTAGTCGCCGTGCCTA-3'TAMRA). Feline tetherin gene expression levels 
were analysed using the ΔCT method. ΔCT values were calculated by subtracting 
the mean CT for the abundant 18S rRNA from the CT for feline tetherin mRNA.  
 
5.2.3 Amplification, molecular cloning and detection of lentiviral 
tetherin antagonists 
 
In order to identify putative lentiviral tetherin antagonists, FIV OrfA (Orf2), 
various FIV envelope glycoproteins (Envs) and HIV-1 Vpu were amplified, cloned 
and expressed in conjunction with HIV-1(VSV-G) and FIV(VSV-G) pseudotypes in 
the presence or absence of feline tetherins in single-cycle replication assays as 
described under 2.2.5. 
HIV-1 NL-43 Vpu in pCDNA3.1 (Life Technologies) was a kind gift of Greg Towers, 
University College London, UK. FIV-Fca GL8 OrfA was amplified from GL8Mya 
molecular clone (Hosie et al., 2002) using primers GL8 orf2 Fwd (5’-
ACTGGTCGACACCATGGAAGAAATAATAGTATTATTC-3’) (SalI restriction site 
underlined) and GL8 orf2 Rev (5’-ACAGCGGCCGCCTAAGCAGTACGATGGATAATGTA 
-3’) (NotI restriction site underlined) and cloned into VR1012. In addition, codon-
optimised FIV OrfA was expressed from construct 1S-5RL (kindly provided by 
Mauro Pistello, Università di Pisa, Italy). FIV-Fca GL8 Env (GenBank X69496) was 
amplified from GL8Mya molecular clone using primers GL8 Env-Fwd (5’-ACTGGTC 
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GACACCATGAATGAAGAAGGGCCACTA-3’) (SalI restriction site underlined) and 
GL8 Env-Rev (5’- ACAGCGGCCGCTCATTCCTCCTCTTTTTCAGA-3’) (NotI restriction 
site underlined). C8.1 (CrFK-adapted GL8) Env was amplified using the same 
primer set. FIV-Fca strain Petaluma clone F14 and clone 34TF10 Envs (GenBank 
NC_001482) were amplified with primers PET Env-Fwd (5’-ACTGGTCGACACCATG 
GCAGAAGGATTTGCAGCCA) (SalI restriction site underlined) and GL8 Env-Rev. All 
FIV-Fca Env cDNAs were cloned into VR1012 using the SalI and NotI restriction 
sites. Furthermore, FIV-Fca Petaluma KKS Env (Env of in vivo readapted FIV-Fca 
Petaluma; [Bendinelli et al., 2001; Pistello et al., 2003]) was expressed from the 
mammalian expression vector pEE14 (Lonza Biologics, Slough, UK). The construct 
pEE14-Env (Pistello et al., 2010) was a kind gift of Mauro Pistello, Università di 
Pisa, Italy. FIV-Ple E Env was amplified from cDNA derived from Mya-1 cells 
infected with a primary isolate of FIV-Ple E obtained from serum of a wild, 8 
year old male lion (Sangre) from the Moremi reserve in the Okavango Delta, 
Botswana (McEwan, 2009). Primers were designed based on the available FIV-Ple 
E 1027 sequence (GenBank EU117992) (Pecon-Slattery et al., 2008a), LLV-E Env-
Fwd (5’-ACTGGTCGACACCATGGCAGAAGGAGGAAGAGTA -3’) (SalI restriction site 
underlined) and LLV-E Env-Rev (5’-ACAGCGGCCGCTTAGGTATTAGACTCATCATTCA 
C-3’) (NotI restriction site underlined). FIV-Ple B Env was amplified from cDNA 
derived from Mya-1 cells infected with a FIV-Ple B 458 using primers directed to 
the published FIV-Ple B sequence (GenBank EU117991), LLV-B Env-Fwd (5’-
ACTGGTCGACACCATGGCGGAAGGAGGAAGAGTA-3’) (SalI restriction site 
underlined) and LLV-B Env-Rev (5’-ACAGCGGCCGCTCAAAGATCCTCATCAGACTCCC 
T-3’) (NotI restriction site underlined). Both Env cDNAs were cloned into VR1012.  
FIV-Fca GL8 Env and OrfA were also expressed from CT5G8MΔpol4, a 
derivative of pCT5b (Poeschla et al., 1998) in which a PacI-NdeI fragment was 
exchanged with the equivalent fragment from the GL8 Mya molecular clone. The 
resulting clone, CT5-G8M, was then modified by deleting a fragment of pol by 
PacI/SanDI digestion followed by treatment with the Klenow fragment of DNA 
polymerase I prior to religation. CT5G8MΔpol4 thus produces all FIV-encoded 
proteins under the control of a cytomegalovirus (CMV) promoter but is not 
replication-competent. 
Immunoblotting was performed to confirm expression of FcaTHN-HA and 
FIV-Fca Envs. FcaTHN-HA was detected using a rabbit anti-HA antibody (Sigma-
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Aldrich). FIV-Fca Env expression was verified using mouse anti-FIV Env antibody 
(vpg71.2). 
 
5.2.4 Confocal microscopy 
 
CrFK cells stably expressing FcaTHN-HA were seeded onto 13 mm-diameter glass 
coverslips in 24-well plates and incubated overnight. Cells were then infected 
with FIV-Fca F14 for 72 hours. Cells were fixed with 4% paraformaldehyde in PBS 
(pH 7.4) for 15 minutes and neutralised with 0.1 M glycine in PBS for 5 minutes. 
Where appropriate, cells were then permeabilised with 0.2% triton-X100 in PBS 
for 20 minutes. Cells were blocked by incubation with 2% FCS in PBS for 20 
minutes before incubation with a mixture of primary antibodies comprising 
mouse anti-FIV Env (vpg71.2) and rabbit anti-HA (Sigma-Aldrich) antibodies in 1% 
FBS in PBS for 1 hour at room temperature. Cells were then washed three times 
with PBS, incubating for 5 minutes with each wash. Secondary antibodies were 
then added (Alexa-Fluor 594-conjugated F(ab')2 fragment of goat anti-rabbit IgG 
[Life Technologies/Molecular Probes] and fluorescein isothiocyanate [FITC]-
conjugated F(ab')2 fragment of goat anti-mouse IgG [Abd Serotec, Oxford, UK]) 
and incubated in 1% FBS in PBS for 45 minutes at room temperature. Cells were 
washed three times with PBS, incubating for 5 minutes with each wash, removed 
from the 24-well plate, mounted onto glass slides in mounting medium 
containing DAPI (4',6’-diamidino-2-phenylindole; Vectashield, Vector 
Laboratories). Slides were analysed on a Leica TCS SP2 confocal microscope. 
 
5.2.5 Electron microscopy 
 
Electron microscopy was performed with the help of David Bhella, University of 
Glasgow. Monolayer cultures of FIV-infected CrFK cells were fixed in situ for 2 
hours at room temperature with 4% paraformaldehyde–0.1 M sodium phosphate 
buffer (pH 7) and stored at 4°C in 0.2% paraformaldehyde. Prior to processing 
for electron microscopy, the cells were exposed to 2.5% glutaraldehyde 
overnight at 4°C. The cells were then scraped and pelleted by centrifugation 
followed by 1% osmium tetroxide fixation. Fixed cells were then resuspended 
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and pelleted through 1% SeaPlaque agarose (Lonza, Slough, UK). The cell pellets 
were dehydrated through a graded alcohol series and embedded in EPON 812 
resin. Sections approximately 120 nm in thickness were cut with an UC6 
ultramicrotome (Leica Microsystems, Germany) and stained with saturated 
uranyl acetate (in 50% ethanol) and Reynolds lead citrate (Reynolds, 1963). 
Sections were observed and photographed with JEOL 1200 EX and JEOL JEM-
2200FS transmission electron microscopes, and images were recorded on a Gatan 
Ultrascan camera. 
 
5.2.6 Feline foamy virus replication assays 
 
Feline foamy virus (FeFV) molecular clones were kind gifts of Martin Löchelt, 
German Cancer Research Center, Heidelberg, Germany. Wild-type FeFV was 
expressed from construct pCF-7 (Schwantes et al., 2002). FeFV devoid of bel2 
and bet (FeFVΔbel/bet) was expressed from construct pCF-7-BBtr (Alke et al., 
2001). Single-cycle replication assays were performed in 293T cells by co-
transfecting FcaTHN and FeFV expression constructs in molar ratios of 0:1, 0.1:1, 
0.25:1, 0.5:1, 1:1 and 2:1. Transfections were set up in 60-mm cell culture 
dishes using constant amounts of FeFV expression plasmids (5 µg DNA) and 
increasing amounts of FcaTHN-VR1012 (0 µg, 0.2 µg, 0.5 µg, 1 µg, 2 µg or 4 µg 
DNA). Where appropriate, the total amount of transfected DNA was adjusted to 
9 µg using VR1012. FeFV titres were determined 48 hours post-transfection by 
titration of cell supernatants onto FeFAB reporter cells in 24-well plates (Zemba 
et al., 2000). FeFAB cells are genetically modified CrFK cells, which stably carry 
the β-galactosidase gene (lacZ) under transcriptional control of the FeFV LTR 
promoter in their genomes. Upon transduction of these cells with bel1-
expressing FeFV vectors, Bel1 transactivates the FeFV LTR promoter which leads 
to expression of lacZ. LacZ expression in cell nuclei was visualised 72 hours post-
transduction by LacZ staining and light microscopy. Briefly, cell medium was 
removed, cells were washed with 1 mM MgCl2 in PBS and fixed with 1% 
formaldehyde/0.2% glutaraldehyde/1 mM MgCl2 in PBS for 5 minutes. Cells were 
then stained with 4 mM K4[Fe(CN)6] (II)/4 mM K3[Fe(CN)6] (III)/4 mg/ml X-Gal/1 
mM MgCl2 in PBS overnight at 37°C. Staining solution was removed and the 
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staining reaction was stopped with ddH2O. FeFV titres were expressed as focus 
forming units per ml of cell supernatant (FFU/ml). 
 
5.3 Results 
 
5.3.1 Identification of a feline homologue of BST-2/tetherin 
 
A genomic sequence with significant homology to canine (Canis lupus familiaris) 
(GenBank XM_860510) and human (GenBank NM_004335) BST-2/tetherin was 
identified by screening the 2X domestic cat genome. The predicted associated 
cDNA was 504 nt in length. However, the genomic sequence upstream of the 
putative start codon shared high similarity with 5’ termini of known tetherin 
cDNAs but was missing a thymidine in its start codon. Because of this high 
similarity and because only the longer cDNA (561 nt) would encode for a double 
tyrosine motif important for tetherin endocytosis from the cell surface (Rollason 
et al., 2007; Iwabu et al., 2009; Masuyama et al., 2009) we initially decided to 
amplify the longer cDNA of domestic cat tetherin (FcaTHN) and engineered the 
forward primer to contain a complete start codon.  
FcaTHN (GenBank HM461970) possesses 65% nucleotide and 38% amino 
acid sequence identity to human tetherin (HsaTHN), and 79% nucleotide and 57% 
amino acid sequence identity to canine tetherin (Fig. 5-1). Secondary structure 
prediction softwares NetSurfP (Petersen et al., 2009) and TMHMM Server 2.0 
(http://www.cbs.dtu.dk/services/TMHMM-2.0/) indicated that the 184 amino 
acid long protein contained an N-terminal cytoplasmic domain, followed by a 
transmembrane domain, an extracellular loop with three conserved cysteines 
(C59, C69, and C97) involved in tetherin dimerisation via disulfide bond 
formation, and a coiled-coil domain. The big-π predictor software (Eisenhaber et 
al., 2000) revealed a potential attachment site for a glycosylphosphatidylinositol 
(GPI) anchor at serine 161 followed by a C-terminal hydrophobic domain (Fig. 5-
1). Thus, FcaTHN adopts the same protein topology described for other tetherins 
(Ishikawa et al., 1995; Ohtomo et al., 1999; Kupzig et al., 2003). 
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Figure 5-1 Identification of a feline homologue of tetherin.  Predicted amino 
acid sequences of feline (FcaTHN), human, murine (rat) (GenBank NM_198134), 
equine (GenBank XM_001915091) and canine tetherins were aligned. Black bars 
denote N-terminal cytoplasmic domain (CP), transmembrane (TM) and 
extracellular, α-helical coiled-coil regions (coiled coil). An arrow marks a predicted 
site for glycosylphosphatidylinositol (GPI) anchor attachment. Amino acid residues 
are colour-coded as follows: light gray, hydrophobic FILMPV; dark gray, 
amphiphilic AGW; green, hydrophilic neutral CNQST; light blue, slightly basic H; 
blue, basic KR; pink, slightly acidic Y; red, acidic DE. 
 
In the mouse, tetherin is expressed constitutively in B cells and plasmacytoid 
dendritic cells, however, expression may be upregulated in many cell types 
following exposure to both type I (Ohtomo et al., 1999; Blasius et al., 2006; Neil 
et al., 2007; Kawai et al., 2008; Miyagi et al., 2009) and type II (Blasius et al., 
2006) interferons. Four feline cell lines, 3201, AH927, CrFK and FEA, and two 
primary cell cultures (IL-2-dependent CD4+ T cells [Mya-1] and monocyte-derived 
macrophages) were treated with type I (α and ω) and type II (γ) interferons and 
151 
 
tetherin mRNA expression levels were examined by RT-qPCR (Fig. 5-2A). The cell 
lines showed various levels of basal tetherin mRNA expression, with the lowest 
levels in FEA cells. 3201, AH927 and CRFK cells expressed broadly similar levels 
of tetherin. The highest level of basal expression was seen with the IL-2-
dependent CD4+ T Mya-1 cell line. Treatment of feline cells with the type I 
interferons IFN-α and IFN-ω increased tetherin expression for all of the cell 
types examined. A similar increase in tetherin expression was also noted with 
the AH927, CrFK and FEA cells treated with IFN-γ. A more modest induction of 
tetherin expression was observed with 3201 cells following treatment with IFN- α 
and IFN-ω, while IFN-γ did not have a significant effect on 3201 tetherin 
expression. Mya-1 cells and monocyte-derived macrophages responded to IFN-α 
and IFN-ω treatment by increasing expression of tetherin, whereas IFN-γ had a 
modest effect on CD4+ T cells and no effect on macrophages. Treatment of 
AH927, CrFK, FEA and Mya-1 cells with INF-ω for either 48 or 72 hours led to a 
significant upregulation of tetherin expression within 24 hours post-stimulation 
(Fig. 5-2B). Therefore, as with previous observations with human tetherin, feline 
tetherin expression may be induced by both type I and type II interferons and is 
expressed on the known in vivo cellular targets for FIV, activated T cells and 
macrophages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32
01
A
H
92
7
C
rF
K
 
FE
A
 
M
ya
-1
M
ac
5
10
15
20
25
IFN
A
CON
IFN
IFN
Cell type

C
T
 (
C
T
 t
e
th
e
ri
n
 -
C
T
 r
R
N
A
)
152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2 Quantification of feline tetherin mRNA by real-time reverse 
transcription PCR and effect of interferon treatment on tetherin expression. 
(A) IL-2-dependent CD4+ T cells (Mya-1), macrophages (Mac), and the feline cell 
lines 3201, AH927, CrFK and FEA were cultured overnight in the presence or 
absence of feline IFN-α, IFN-ω, and IFN-γ at 103 IU/ml prior to RNA extraction, 
cDNA preparation, and tetherin cDNA quantification by RT-qPCR. (B) AH927, 
CrFK, FEA and Mya-1 cells were stimulated with 103 IU/ml IFN-ω and feline 
tetherin gene expression was monitored over 48 (AH927 and FEA cells) or 72 
hours (CrFK and Mya-1 cells) by RT-qPCR. Results are expressed as mean ΔCT 
values ± S.E. as determined in three independent experiments (n=3), with three 
replicate experiments per analysis. 
 
5.3.2 Inhibition of lentiviral particle release by FcaTHN 
 
In order to assess the ability of FcaTHN to prevent lentiviral particle release 
from infected cells, single-cycle replication assays were performed using 
FIVΔvif(VSV-G), HIV-1(VSV-G) or HIV-1Δvpu(VSV-G) pseudotypes in the presence 
or absence of FcaTHN (Fig. 5-3). FcaTHN reduced the titre of the FIVΔvif(VSV-G) 
pseudotypes significantly (Fig. 5-3A), suggesting inhibition of particle release 
from the transfected cells. In agreement with this notion, viral p24 released into 
the culture supernatant was reduced by tetherin expression, whereas virus 
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production in the transfected cells was largely unaffected (Fig. 5-3D). Similar 
activity of FcaTHN against HIV-1 lacking a functional Vpu (HIV-1Δvpu) was 
detected (Fig. 5-3B). Furthermore, FcaTHN prevented the release of wild-type 
HIV-1 encoding an intact vpu open reading frame (Fig. 5-3C) indicating that, 
unlike human tetherin, the activity of FcaTHN was not overcome by HIV-1 Vpu.  
 
 
 
 
 
 
 
 
 
Figure 5-3 FcaTHN restricts FIV and HIV-1 particle release and is not 
overcome by the HIV-1 accessory protein Vpu. VSV-G-pseudotyped, GFP-
expressing FIVΔvif (A), HIV-1Δvpu (B) or HIV-1 (C) particles were produced in 
293T cells co-transfected with empty vector only (VR1012) or indicated amounts of 
FcaTHN expression vector. Pseudotype-containing cell supernatant was then 
used to transduce 293T target cells and activity of FcaTHN was assessed by 
measuring GFP-expression in target cells by flow cytometry. Single-cycle 
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replication assays were performed in triplicate (n=3; results shown as mean ± 
S.E.). (D) FIV and HIV-1 Gag (p24) expression in lysates and in pelleted virions 
from supernatants of transfected 293T producer cells were assessed by 
immunoblotting using mouse anti-FIV p24 (vpg50) and 183-H12-5C anti-HIV-1 CA 
(NIH AIDS Research and Reference Reagent Program) antibodies, respectively. 
 
5.3.3 Characterisation of putative tetherin antagonists in the FIV 
genome 
 
In the absence of an open reading frame with significant homology to HIV-1 vpu 
in the FIV genome, we asked whether the FIV env or orfA gene products were 
able to counteract the activity of domestic cat tetherin (FcaTHN), in analogy to 
the activities ascribed to HIV-2 Env and the SIV Nef and Env proteins (Neil et al., 
2007; Gupta et al., 2009b; Jia et al., 2009; Le Tortorec and Neil, 2009; Zhang et 
al., 2009a). Co-expression of a replication-defective molecular clone of FIV 
(CT5G8MΔpol4) in which expression of the entire FIV molecular clone is 
enhanced by a cytomegalovirus (CMV) promoter, thus increasing expression of all 
FIV proteins, had no effect on the ability of FcaTHN to counteract FIV release 
from transfected cells (Fig. 5-4A). Similarly, co-transfection of codon-optimised 
FIV OrfA expression vector 1S-5RL (Pistello et al., 2003), or of a GL8 orfA 
expressed from VR1012 (data not shown), had no effect on the activity of 
domestic cat tetherin against the release of FIVΔvif from transfected cells (Fig. 
5-4B). Thus, no evidence for a tetherin-counteracting activity was found in the 
FIV genome.  
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Figure 5-4 Absence of a feline tetherin countermeasure in the FIV genome. 
VSV-G-pseudotyped, GFP-expressing FIVΔvif particles were produced in 293T 
cells co-transfected with empty vector only (CON) or FcaTHN expression vector 
(FcaTHN) in the presence or absence of (A) a replication-defective molecular 
clone of FIV, CT5G8MΔpol4 (+ FIVΔpol) or (B) a codon-optimised FIV OrfA (+ 
OrfA). Pseudotype-containing cell supernatant was used to transduce 293T target 
cells and activity of FcaTHN was assessed by measuring GFP-expression in 
target cells by flow cytometry. Single-cycle replication assays were performed in 
triplicates (n=3; results shown as mean ± S.E.). Expression of FIV Env from 
CT5G8MΔpol4 was confirmed by immunoblotting with mouse anti-FIV Env 
antibody (vpg71.2). FIV Gag (p24) expression in lysates and in pelleted virions 
from supernatants of transfected 293T producer cells was assessed by 
immunoblotting using mouse anti-FIV p24 (vpg50) antibody. 
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5.3.4 Effect of FcaTHN on replication of cell culture-adapted, 
CD134-independent strains of FIV 
 
Given the high potency of FcaTHN in preventing the release of FIV in a single-
cycle replication assays and the absence of tetherin-counteracting activity in the 
FIV genome, it was of interest to investigate the ability of FcaTHN to inhibit 
spreading infection of FIV. Thus, CrFK cells stably expressing FcaTHN were 
infected with cell culture-adapted, CD134-independent strains of FIV-Fca (F14; 
Fig. 5-5A) and FIV-Pco (CoLV; Fig. 5-5B), and virus spread was monitored by a 
reverse transcriptase activity assay of the culture supernatant. Interestingly, in 
contrast to the marked inhibitory effect of tetherin on lentiviral pseudotype 
release, ectopic expression of tetherin did not inhibit virus production from FIV-
infected CrFK cells. In fact, syncytium formation following FIV-Fca F14 infection 
was enhanced significantly in the tetherin-expressing cells (Fig. 5-5D) compared 
with control cells (Fig. 5-5C).  
To confirm tetherin expression in the stably transduced CrFK cells, RT-
qPCR was performed. This analysis indicated that the cells expressed abundant 
tetherin mRNA (ΔCT = 8.95 ± 0.25) compared with the vector-only containing 
control cells (ΔCT = 16.68 ± 0.34). Thus, the stably transduced cells achieved 
levels of tetherin expression that exceeded those attained following IFN-ω 
treatment of control CrFK cells (ΔCT = 11.17 ± 0.17) (Fig. 5-2A). In comparison, 
when 293T cells were transfected transiently with either vector only or FcaTHN 
(see Fig. 5-3 and 5-4), expression increased from a ΔCT value of 23.43 ± 0.43 
(CON) to 5.97 ± 0.39 (FcaTHN), representing an order of magnitude higher than 
the level achieved in stably transduced CrFK. 
This observation suggests that, although functional levels of tetherin are 
expressed, available tetherin molecules on the cell surface of infected cells 
become limited as viral particle production increases. The antiviral tethering 
activity of FcaTHN is thus overcome by high viral loads and viral replication is 
able to continue. The findings presented here are also consistent with the 
presence of trapped virions at the cell surface promoting cell-to-cell spread, a 
phenomenon proposed recently for HIV-1 (Jolly et al., 2010).  
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Figure 5-5 Effect of stable expression of FcaTHN on replication of cell 
culture-adapted strains of FIV. CrFK cells were stably transduced with an empty 
retroviral vector (CON) or a retroviral vector bearing domestic cat tetherin 
(FcaTHN). Cells were infected with the cell culture-adapted, CD134-independent 
strains of FIV-Fca (F14; A) or FIV-Pco (CoLV; B), and virus replication was 
monitored by RT assay of the supernatant (means [n=2]). (C,D) Representative 
fields (light microscopy) displaying enhanced syncytium formation in tetherin-
expressing cells (D) following FIV-Fca F14 infection compared with control cells 
(C). Cell monolayers were fixed and stained six days post-infection with 1.0% 
methylene blue-0.2% basic fuchsin in methanol. 
 
5.3.5 Effect of interferon-ω on FIV production and syncytium 
formation 
 
Enhanced syncytium formation following increased tetherin expression would be 
detrimental to the host and counterintuitive with respect to the idea of a role 
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for tetherin in restricting viral growth. We therefore asked whether such a 
scenario would occur following upregulation of endogenously expressed tetherin 
by interferon. CrFK cells were either left untreated or were treated with IFN-ω 
either 24 hours prior to infection or 24 hours post-infection with FIV-Fca strain 
F14. As expected, treatment of cells with IFN-ω either pre- or post-infection 
suppressed virus production (Fig. 5-6), which is consistent with the pleiotropic 
antiviral activities of type I interferons inhibiting viral growth.  
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Figure 5-6 Effect of IFN-ω on FIV production and syncytium formation. (A) 
CrFK cells were infected with FIV-Fca F14, and virus production was monitored by 
RT assays. Cells were left untreated (CON), were pre-treated with 103 IU/ml IFN-ω 
24 hours prior to infection or 24 hours post-infection. (B) FIV-Fca Gag expression 
(p24) was monitored in lysates of infected cells and in culture supernatants at day 
four post-infection by immunoblotting using mouse anti-FIV p24 antibody (vpg50). 
Induction of tetherin expression was confirmed by RT-qPCR (THN ΔCT). (C-E) 
Representative images (phase-contrast microscopy) of syncytium formation at day 
three post-infection. (C) Untreated and FIV-Fca F14-infected CrFK cells. (D) FIV-
Fca F14-infected CrFK cells treated with IFN-ω 24 hours post-infection. (E) CrFK 
cells treated with IFN-ω 24 hours pre-infection with FIV-Fca F14. 
 
As expected, the reduction in virus replication was more pronounced in cells 
pre-treated with IFN-ω compared to cells stimulated post-infection (Fig. 5-6A). 
IFN-ω led to a decrease in viral production within cells, which also resulted in a 
reduction of particle release into the cell culture supernatant (Fig. 5-6B). As 
qRT-PCR analysis of tetherin transcripts confirmed that tetherin expression had 
been induced following IFN stimulation (Fig. 5-6B), syncytium formation in the 
presence of IFN-ω was examined. Indeed, a marked enhancement of syncytium 
formation was noted in F14-infected CrFK cells treated with IFN-ω (Fig. 5-6D,E), 
irrespective of whether the interferon was added before or after viral infection. 
These data suggest that the results observed in cells stably expressing tetherin 
are recapitulated in cells in which tetherin expression is induced by IFN-ω. 
 
5.3.6 Effect of FcaTHN on replication of a primary, CD134-
dependent strain of FIV 
 
It is theoretically possible that the stably modified cell lines expressed only low 
levels of tetherin on the cell surface, which were insufficient to block viral 
release and consequently spreading FIV infection. To control for this possibility, 
we took advantage of the fact that the primary FIV-Fca isolate GL8 cannot 
replicate in CrFK cells in the absence of the FIV receptor CD134. Transfection of 
CrFK cells with GL8 therefore does not lead to a spreading infection but allows 
particle release into the cell culture supernatant to occur.  
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CrFK cells or CrFK cells stably expressing FcaTHN were transfected with 
either FIV-Fca GL8 (Fig. 5-7A) or FIV-Fca F14 as control (Fig. 5-7B). In CrFK cells 
expressing FcaTHN, release of GL8 was blocked, whereas viral particles were 
released in control cells (Fig. 5-7A), which is consistent with tetherin preventing 
virus release. As reported above, spreading infection of CD134-independent FIV-
Fca F14 was not inhibited by tetherin expression in these cells (Fig. 5-7B), but 
was accompanied by enhanced syncytium formation in FcaTHN-expressing cells 
(Fig. 5-7D) as compared to control cells (Fig. 5-7C).  
To test the effect of FcaTHN on spreading infection of CD134-dependent 
FIV-Fca GL8, control or FcaTHN-expressing CrFK cells were transduced with a 
vector expressing CD134. CD134 expression rendered CrFK cells permissive for 
GL8 infection, whether or not tetherin was co-expressed (Fig. 5-7E). Tetherin 
expression reduced replication by about two-fold, leading to a delay of 
approximately one day in achieving peak virus loads, but tetherin was unable to 
block replication in a manner analogous to that seen with feTRIMCyp (Fig. 3-8). 
This effect was confirmed by analysis of the degree of syncytium formation at 
the end of the experiment (day 6). While the absolute numbers of syncytia in the 
GL8-infected cells were similar, the syncytia in the tetherin-expressing cells 
were smaller (Fig. 5-7F), which is consistent with a partial retardation of viral 
growth. 
Thus, two contrasting outcomes of spreading FIV infection in the presence 
of FcaTHN were observed. Whereas GL8 replication was partially retarded and 
syncytium formation was proportionally reduced, F14 infection was unaffected 
and syncytium formation was enhanced. 
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Figure 5-7 Effect of stable expression of FcaTHN on release and spread of a 
primary strain of FIV. CrFK cells stably transduced with an empty retroviral 
vector (CON) or a retroviral vector bearing domestic cat tetherin (FcaTHN) were 
transfected with molecular clones of FIV-Fca GL8 (A) or FIV-Fca F14 (B). Virus 
release into the cell culture supernatant was monitored by RT assays (means ± 
S.E. [n=3]). (C,D) Representative fields (light microscopy) displaying enhanced 
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syncytium formation in tetherin-expressing cells (D) following FIV-Fca F14 
transfection compared with control cells (C). Cell monolayers were fixed and 
stained six days post-infection with 1.0% methylene blue-0.2% basic fuchsin in 
methanol. (E,F) Control or FcaTHN-expressing CrFK cells were transduced with 
CD134-pDsRed2 and infected with FIV-Fca GL8. Virus release was monitored by 
RT assays of supernatant (means [n=2]) (E), while syncytium formation was 
examined macroscopically following staining (as described above). Representative 
syncytia are indicated (white arrows) (F). 
 
5.3.7 Intracellular localisation of FcaTHN 
 
In order to examine the cellular localisation of FIV and domestic cat tetherin 
(FcaTHN) in infected cells, CrFK cells were stably transduced with a retroviral 
vector expressing FcaTHN tagged in the extracellular domain with an internal HA 
tag. Confocal analysis of Env expression on intact (non-permeabilised) cells 
demonstrated enrichment of Env staining along the entire perimeter of syncytia 
(Fig. 5-8A). While tetherin expression was detected with the majority of single 
cells, where expression appeared punctate (Fig. 5-8B), expression on the 
perimeter of syncytia followed a pattern similar to that seen with Env, and in 
several regions, marked overlap of Env and tetherin was noted (Fig. 5-8C). In 
permeabilised cells, Env expression was diffuse throughout the cytoplasm of the 
cells (Fig. 5-8D) whereas tetherin expression appeared largely punctate (Fig. 5-
8E). It was notable that, in some Env-expressing cells, tetherin appeared to be 
concentrated at the periphery of the cell (Fig. 5-8F, lower left), whereas in cells 
lacking Env, tetherin appeared to be perinuclear (Fig. 5-8E, top centre). 
Occasionally, syncytia contained regions of co-localisation of tetherin and Env, 
possibly indicating the presence of intracellular bodies rich in both Env and 
tetherin (Fig. 5-8F, inset). 
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Figure 5-8 Intracellular localisation of FcaTHN. CrFK cells stably expressing 
FcaTHN incorporating an internal HA tag (FcaTHN-HA) were infected with FIV-Fca 
F14, fixed and stained for expression of FIV-Fca Env (FITC [green]) (A,D) or 
FcaTHN-HA (Alexa Fluor 594 [red]) (B,E). In merged images (C,F), nuclei were 
also visualised with DAPI (blue). Cells were stained either in intact form (A-C) or 
following detergent permeabilisation (D-F). Images are representative of at least 
five separate fields; arrows indicate regions where Env and tetherin expression 
coincided. 
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5.3.8 Electron microscopic analysis of tetherin-mediated FIV 
particle retention 
 
FIV-Fca F14-infected tetherin-expressing CrFK cells were analysed by electron 
microscopy for evidence of the retention of virus particles on the cell surface 
(electron microscopy was performed with the help of David Bhella, University of 
Glasgow). Infected cells produced abundant microvilli in the presence or 
absence of tetherin (Fig. 5-9A) with morphologies similar to that described 
previously for HeLa cells (Fisher and Cooper, 1967). While 0.1-µm-diameter 
particles were noted in the regions rich in microvilli, the resolution of the CrFK-
derived images made it difficult to distinguish conclusively electron-dense virus-
like particles from a cross-section through the tip of a microvillus (Fig. 5-9A). 
Previous reports have described mouse mammary tumour virus budding from the 
tip of microvilli in CrFK cells (Lasfargues et al., 1976). However, aggregates of 
0.1-µm-diameter particles aligned on the surface of cells were unique to the 
F14-infected tetherin-expressing cells (Fig. 5-9B,C), a feature that could not be 
identified in F14-infected control cells. The uniformity and alignment of these 
particles on the cell surface were consistent with the presence of trapped 
virions. 
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Figure 5-9 Electron microscopy of CrFK cells infected with FIV. (A) 
Microvillus-rich regions in FIV-Fca F14-infected control cells with occasional 0.1-
µm-diameter particles (inset, two particles [arrow] adjacent to a cross-section of a 
microvillus for comparison). (B,C) Aggregates of 0.1-µm-diameter particles aligned 
on the surface of FcaTHN-expressing cells infected with F14. Arrows indicate 0.1-
µm-diameter particles associated with the cell surface. 
 
5.3.9 Activity spectrum of FcaTHN 
 
It has been shown that human tetherin does not only limit the release of HIV-1 
particles from infected cells but also blocks virion release from members of the 
alpharetrovirus, betaretrovirus, deltaretrovirus, spumaretrovirus, arenavirus 
(Lassa) and filovirus (Ebola, Marburg) families (Neil et al., 2008; Van Damme et 
al., 2008; Jouvenet et al., 2009; Kaletsky et al., 2009; Sakuma et al., 2009). 
Thus, human tetherin exhibits a broad spectrum activity and specificity. 
The data presented here show that domestic cat tetherin (FcaTHN) 
prevents FIV, HIV-1 and SIV particle release from viral producer cells. However, 
expression of tetherin has little effect on FIV spread. In order to characterise its 
activity spectrum, control and tetherin-expressing cells were transfected with 
molecular clones of the gammaretroviruses FeLV-A and RD114 (Fig. 5-10) and 
viral growth in the presence or absence of FcaTHN was assessed by C-type RT 
assays. Furthermore, infections of the same cell lines with the spumaretrovirus 
FeFV (Fig. 5-11) were performed and FeFV growth was monitored by titration 
onto FeFAB reporter cells and LacZ staining. 
Firstly, CrFK (Fig. 5-10A) and FEA (Fig. 5-10B) cells stably transduced with 
an empty vector control or a vector encoding FcaTHN were transfected with a 
FeLV-A molecular clone. As observed for FIV-Fca GL8 (Fig. 5-7E), in the presence 
of tetherin, FeLV-A growth was initially reduced by up to two-fold resulting in a 
growth delay of about 24 hours in CrFK cells and 36 hours in FEA cells compared 
to the control. However, peak viral loads were comparable in the presence and 
absence of FcaTHN, indicating that FcaTHN is unable to exert a potent block to 
FeLV-A spread. Next, the stably transduced CrFK (Fig. 5-10C) and FEA (Fig. 5-
10D) cells were transfected with a molecular clone of the endogenous feline 
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gammaretrovirus RD114. RD114 did not grow in FEA cells but, notably, tetherin 
expression prevented RD114 replication in CrFK cells completely. 
 
Figure 5-10 Effect of stable expression of FcaTHN on replication of 
gammaretroviruses. CrFK (A,C) or FEA (B,D) cells stably transduced with an 
empty retroviral vector (CON) or a retroviral vector bearing domestic cat tetherin 
(FcaTHN) were transfected with molecular clones of FeLV-A (A,B) or RD114 
(C,D). Virus release into the cell culture supernatant was monitored by RT assays 
(means ± S.E. [n=3]).  
 
Finally, the ability of FcaTHN to prevent spumaretroviral release and spread was 
investigated (Fig. 5-11). FeFVΔbel/bet (devoid of bel2 and bet) and a wild-type 
FeFV molecular clone were transfected into 293T cells in the presence or 
absence of FcaTHN (Fig. 5-11A). Whereas the amount of virus-encoding plasmid, 
that was transfected, was kept constant, the amount of FcaTHN-encoding 
plasmid was varied. Virus-containing supernatants were titrated onto FeFAB 
reporter cells, which express lacZ in the presence of FeFV Bel1 (Zemba et al., 
2000). Bel1 is a transactivator of the FeFV LTR, which is stably integrated into 
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the genome of the reporter cells and drives expression of lacZ. Viral titres were 
determined by LacZ staining.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-11 Effect of FcaTHN on release and spread of FeFV. (A) 
FeFVΔbel/bet and FeFV wild-type particles were produced in 293T cells co-
transfected with empty vector only (VR1012) or FcaTHN expression vector. 
Whereas the amount of transfected virus-encoding plasmid DNA was kept 
constant at 5 µg, the amount of FcaTHN expression plasmid DNA was varied. 48 
hours post-transfection, cell supernatant was titrated onto FeFAB reporter cells 
and the activity of FcaTHN was assessed by measuring FeFV Bel1-driven lacZ 
expression in target cells by LacZ staining. Viral titres are expressed as mean 
focus forming units per ml cell supernatant (FFU/ml) from duplicate wells (n=1). (B) 
FeFVbel/bet and FeFV wild-type virus stocks were prepared by transfection of 
293T cells with respective molecular clones. 100 µl of virus stocks were used to 
transduce CrFK cells stably expressing a control (CON) or domestic cat tetherin 
(FcaTHN). Viral growth was monitored by titration of cell supernatants onto FeFAB 
reporter cells and LacZ staining. Viral titres are expressed as mean FFU/ml ± S.E. 
from triplicate wells (n=1). 
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FcaTHN blocked FeFV particle release in a dose-dependent manner. When low 
amounts of FcaTHN plasmid DNA were co-transfected, FcaTHN prevented release 
of FeFVΔbel/bet and wild-type FeFV to a comparable degree; however, at high 
amounts of FcaTHN wild-type FeFV titres remained up to one log higher than 
FeFVΔbel/bet titres. The data points towards a role of FeFV Bet, which has 
previously been shown to prevent dimerisation of feline A3C proteins and their 
incorporation into viral particles (Lochelt et al., 2005), in FcaTHN antagonism. 
Therefore, single-cycle replication assays using FeFVΔbel/bet in the presence of 
FcaTHN and FeFV Bet were performed. Bet expression did not rescue 
FeFVΔbel/bet titres if tetherin was co-expressed (data not shown). So far, the 
product of bel2 has not been identified.  
In order to investigate the activity of FcaTHN to block not only FeFV 
release but also spread, control CrFK cells or CrFK cells stably expressing 
FcaTHN were infected with FeFVΔbel/bet or FeFV wild-type (Fig. 5-11B). 
Independent of tetherin expression, titres of FeFVΔbel/bet were about 4.5 logs 
lower than that of FeFV. Indeed, the bel2/bet mutation has been shown to 
result in reduced particle release and possibly in reduced infectivity of viral 
particles (Alke et al., 2001). Tetherin expression reduced titres of FeFVΔbel/bet 
in the first 72 hours of infection by a maximum of one log. At later time points, 
FcaTHN had no effect on FeFVΔbel/bet replication. In contrast, in the presence 
of FcaTHN a constant decrease in wild-type FeFV titres of up to 1.5 logs was 
observed. Thus, domestic cat tetherin efficiently blocks FeFV particle release 
and partly limits FeFV spread. 
 
5.3.10 Identification and characterisation of non-domestic cat 
tetherins 
 
In addition to domestic cat tetherin (FcaTHN), non-domestic cat tetherin 
homologues were identified and characterised, and their antiviral activities were 
compared to that of FcaTHN. African lion tetherin (PleTHN) shares 95% 
nucleotide and 89% amino acid identity with FcaTHN (Fig. 5-12). Puma tetherin 
(PcoTHN) possesses 97% and 94% nucleotide and amino acid identity, 
respectively, with FcaTHN. Both PleTHN and PcoTHN adopt the same protein 
topology as described for FcaTHN (see Fig. 5-1). The double tyrosine endocytosis 
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motif at amino acid positions 6 and 8, the three cysteines involved in tetherin 
dimerisation at positions 59, 69 and 97 and the GPI anchor attachment site at 
serine 161 are conserved among felid tetherins.   
 
 
 
 
 
Figure 5-12 Identification of non-domestic cat homologues of tetherin. 
Alignment of the amino acid sequences of feline (FcaTHN), lion (PleTHN) and 
puma (PcoTHN) tetherins. Amino acid residues are colour-coded as follows: light 
gray, hydrophobic FILMPV; dark gray, amphiphilic AGW; green, hydrophilic neutral 
CNQST; light blue, slightly basic H; blue, basic KR; pink, slightly acidic Y; red, 
acidic DE. 
 
To assess the potential of felid tetherins to limit viral particle release from 
infected cells, single-cycle replication assays were performed using FIVΔvif(VSV-
G) pseudotypes in the presence or absence of FcaTHN, PleTHN or PcoTHN (Fig. 
5-13). Human tetherin (HsaTHN) was used as positive control for restriction of 
FIV particle release (Jouvenet et al., 2009). Pseudotypes were produced in the 
presence or absence of FIV Envs to determine whether they are able to 
counteract non-domestic cat tetherins. As shown for FcaTHN and HsaTHN, 
PleTHN and PcoTHN potently restricted FIVΔvif(VSV-G) pseudotype release from 
293T cells. Neither FIV-Fca GL8 Env, nor FIV-Ple B or FIV-Ple E Envs antagonised 
the felid tetherins or HsaTHN.  
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Figure 5-13 Felid tetherins restrict FIV particle release and are not overcome 
by FIV Envs. (A) VSV-G-pseudotyped, GFP-expressing FIVΔvif particles were 
produced in 293T cells co-transfected with empty vector only (CON) or tetherin 
(FcaTHN, PleTHN, PcoTHN, HsaTHN) expression vectors. Assays were 
performed in the presence of empty vector only (CON) or FIV-Fca GL8 Env, FIV-
Ple B Env or FIV-Ple E Env. Pseudotype-containing cell supernatant was then 
used to transduce 293T target cells and tetherin activity was assessed by 
measuring GFP-expression in target cells by flow cytometry. Single-cycle 
replication assays were performed in triplicate (n=3; results shown as mean ± 
S.E.). Statistically significant differences relative to the empty vector only control 
are indicated by asterisks (*, P<0.05, Dunnet’s t-test). (B) FIV Gag (p24) and Gag 
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precursor polyprotein Pr55Gag (p55) expression in lysates of transfected 293T 
producer cells was assessed by immunoblotting using mouse anti-FIV p24 (vpg50) 
antibody. (C) FIV-Fca GL8 Env expression in lysates of transfected 293T producer 
cells was confirmed by immunoblotting using mouse anti-FIV Env (vpg71.2) 
antibody. 
 
Because of the clear difference seen between the ability of FcaTHN to prevent 
FIV particle release and spread, CrFK and canine CLL cells stably expressing lion 
or puma tetherins were infected with different strains of FIV and virus growth 
was monitored (Fig. 5-14). CrFK and CLL cells stably transduced with a construct 
bearing a FcaTHN mutant lacking the double tyrosine motif (FcaTHN-Y6/8A) or 
HsaTHN were also included in the study. 
All CrFK cell lines were first infected with the cell culture-adapted, 
CD134-independent FIV strains FIV-Fca F14 (Fig. 5-14A) and FIV-Pco CoLV (Fig. 5-
14B). In agreement with our findings for domestic cat tetherin (FcaTHN; see Fig. 
5-5), none of the tetherins was able to prevent productive FIV replication, with 
PleTHN and HsaTHN being the most effective tetherins at limiting viral F14 and 
CoLV spread. CoLV growth was in fact enhanced by expression of FcaTHN, 
FcaTHN-Y6/8A and PcoTHN compared to the empty vector control (CON) (Fig.5-
14B). This enhancement is especially noteworthy in the case of FcaTHN-Y6/8A 
because it indicates that prevention of tetherin endocytosis from the cell 
surface and hence increased tetherin surface expression did not increase the 
antiviral activity of FcaTHN.   
Moreover, tetherin-expressing cells were transduced with a construct 
encoding feline CD134 and infected with the primary, CD134-dependent strains 
of FIV-Fca GL8 (Fig. 5-14C) and PPR (Fig. 5-14D). Interestingly, similar to our 
data obtained for FcaTHN (Fig. 5-7E) all tetherins modestly limited FIV-Fca GL8 
growth. This effect was less pronounced for PPR. Expression of FcaTHN-Y6/8A 
and HsaTHN led to the highest reduction in viral growth. 
Next, CrFK cells stably transduced with felid and human tetherins and 
CD134 were infected with FIV-Ple E, which, like FIV-Fca, uses CD134 as primary 
receptor (McEwan, 2009). FIV-Ple E growth was not affected by tetherin 
expression with the exception of HsaTHN, which reduced viral growth 
significantly (Fig.5-14E).  
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Lastly, FIV-Fca GL8 (Fig. 5-15F) and FIV-Ple E (Fig. 5-15G) growth was also 
assessed in canine CLL cells stably expressing tetherins and CD134. Again, none 
of the felid tetherins were able to prevent viral spread. These data indicate that 
the inability of felid tetherins to restrict FIV spreading replication was not 
limited to CrFK cells and seemed to be cell type-unspecific. 
Infections of both CrFK and CLL cells with FIV-Ple B were attempted, but 
the virus grew only to very low titres, insufficient to draw reliable conclusions 
about the antiviral activities of tetherins.  
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Figure 5-14 Effect of stable expression of felid tetherins on replication of cell 
culture-adapted and primary strains of FIV. CrFK cells (A-E) and canine CLL 
cells (F,G) were stably transduced with an empty retroviral vector (CON) or  
retroviral vectors bearing domestic cat (FcaTHN), lion (PleTHN), puma (PcoTHN) 
or human (HsaTHN) tetherin or a FcaTHN mutant lacking its N-terminal double 
tyrosine motif (FcaTHN-Y6/8A). To enable growth of CD134-dependent FIV 
strains, cells were further transduced with the construct CD134-pDsRed2 (C-G). 
Cells were infected with the cell culture-adapted, CD134-independent strains of 
FIV-Fca (F14; A) or FIV-Pco (CoLV; B), with the primary FIV-Fca strains GL8 (C,F) 
and PPR (D) or with FIV-Ple E (E,G), and virus replication was monitored by RT 
assay of the supernatant (means [n=2]). 
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5.3.11 Characterisation of the feline tetherin N-terminal region 
 
In this study a domestic cat homologue of feline tetherin was identified and 
characterised. Its genome locus and the sequence of the corresponding cDNA 
were analysed. This cDNA was predicted to be 504 nt in length; however, the 
genomic sequence upstream of its start codon shared significant homology with 
known tetherins. Interestingly, the upstream sequence encoded for the double 
tyrosine motif involved in tetherin endocytosis from the cell surface and tetherin 
turn-over in cells, but was missing the thymidine in its start codon. Thus, a form 
of tetherin 561 nt in length was amplified from Mya-1 and CrFK cDNA with a 
forward primer containing an intact start codon. This tetherin (FcaTHN) was 
used throughout this study. 
Recently, two groups have independently performed 5’ RACE (rapid 
amplification of cDNA ends) PCR to characterise tetherin’s 5’ terminus and 
identified the shorter cDNA starting from the downstream, intact start codon as 
the coding sequence (Fukuma et al., 2011; Celestino et al., 2012). In agreement 
with our observations, Fukuma et al. (2011) found that domestic cat tetherin, 
which was termed FcaTHN-WT in this study, was indeed IFN-inducible and was 
able to restrict RD114 particle release. Surprisingly, Celestino et al. (2012) found 
that, although both forms of tetherin were able to dimerise and were correctly 
expressed on the cell surface, neither of them prevented FIV wild-type particle 
release in single-cycle replication assays. However, FIVΔenv particle release was 
blocked by the short form of tetherin and rescued by expression of FIV Env in 
trans, identifying FIV Env as an antagonist of domestic cat tetherin. 
Due to the conflicting data on FIV Env antagonism of feline tetherin, 
5’RACE PCR was performed. Moreover, the downstream start codon was verified 
for both domestic cat tetherin and lion and puma tetherins. The upstream 
sequence resembling the 5’ end of known tetherin cDNAs formed part of the 
domestic cat tetherin transcript, but was lacking an ATG start codon. Then the 
domestic cat tetherin cDNA (501 nt), which encodes for a protein with a shorter 
cytoplasmic tail (wild-type domestic cat tetherin; FcaTHN-WT) than FcaTHN 
(Fig. 5-15), was amplified and cloned.  
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Figure 5-15 Amino acid sequence alignment of domestic cat tetherins. A 561 
nt long domestic cat tetherin cDNA was amplified from Mya-1 and CrFK cell cDNA 
with a forward primer engineered to contain a functional start codon. This cDNA 
(FcaTHN) encodes for a tetherin with a cytoplasmic tail that resembles those of 
other known tetherins (see Fig. 5-1). A 501 nt long domestic cat tetherin cDNA 
was amplified from Mya-1 and CrFK cell cDNA that encodes for a tetherin with a 
shortened cytoplasmic tail (FcaTHN-WT). Amino acid residues are colour-coded 
as follows: light gray, hydrophobic FILMPV; dark gray, amphiphilic AGW; green, 
hydrophilic neutral CNQST; light blue, slightly basic H; blue, basic KR; pink, 
slightly acidic Y; red, acidic DE. 
 
5.3.12 Comparison of FcaTHN and FcaTHN-WT antiviral activities 
 
In order to identify possible differences in the abilities of FcaTHN and FcaTHN-
WT to limit FIV particle release from producer cells, single-cycle replication 
assays were performed in the presence or absence of both proteins (Fig. 5-16). 
Both FcaTHN and FcaTHN-WT were able to block FIV(VSV-G) pseudotype release 
from 293T cells (Fig. 5-16A). In agreement with the findings of Celestino and co-
workers, restriction by FcaTHN-WT was more pronounced than restriction by 
FcaTHN (Celestino et al., 2012).  
Next, the replication assays were repeated in the presence of the FIV-Fca 
GL8, C8.1 (CrFK-adapted GL8), Petaluma clone F14 and 34TF10 Envs provided in 
trans or in the presence of KKS Env (Env of in vivo readapted FIV-Fca Petaluma) 
expressed from construct pEE14-Env. The latter construct is identical to that 
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used by Celestino et al. (2012). Expression of all Envs was confirmed by 
immunoblotting (Fig. 5-16B). In stark contrast to the observations by Celestino 
et al. (2012), neither FcaTHN nor FcaTHN-WT was counteracted by FIV Envs, 
confirming that FIV Env is not a functional tetherin antagonist.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-16 FcaTHN and FcaTHN-WT restrict FIV particle release and are not 
overcome by FIV Envs. (A) VSV-G-pseudotyped, GFP-expressing FIVΔvif 
particles were produced in 293T cells co-transfected with empty vector only (CON) 
or tetherin (FcaTHN, FcaTHN-WT) expression vectors. Assays were performed in 
the presence of empty vector only (CON) or envelope glycoproteins (Envs) of FIV-
Fca GL8, C8.1, Petaluma clones F14 and 34TF10 or Petaluma clone KKS Env 
expressed from construct pEE14-Env. Pseudotype-containing cell supernatant 
was then used to transduce 293T target cells and tetherin activity was assessed 
by measuring GFP-expression in target cells by flow cytometry. Single-cycle 
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replication assays were performed in triplicate (n=3; results shown as mean ± 
S.E.). Statistically significant differences relative to the empty vector only control 
are indicated by asterisks (*, P<0.05, Dunnet’s t-test). (B) FIV Gag (p24) and Gag 
precursor polyprotein Pr55Gag (p55) expression in lysates and p24 expression in 
pelleted virions from supernatants of transfected 293T producer cells were 
assessed by immunoblotting using mouse anti-FIV p24 (vpg50) antibody. FIV Env 
expression in cell lysates was confirmed by immunoblotting using mouse anti-FIV 
Env (vpg71.2) antibody. 
 
Furthermore, it was of interest to assess whether FcaTHN-WT, unlike FcaTHN, 
would be able to prevent FIV spreading infection. For this, CrFK cells stably 
expressing FcaTHN or FcaTHN-WT were infected with cell culture-adapted, 
CD134-independent strains of FIV-Fca (F14; Fig. 5-17A) and FIV-Pco (CoLV; Fig. 
5-17B), and virus spread was monitored by reverse transcriptase activity assay of 
the culture supernatant. Importantly, ectopic expression of FcaTHN-WT did not 
inhibit virus production from FIV-infected CrFK cells. These data validate the 
findings obtained with FcaTHN and indicate that its prolonged N-terminus did 
not interfere with its ability to limit FIV spread (compare Fig. 5-5). 
Figure 5-17 Effect of stable expression of FcaTHN and FcaTHN-WT on 
replication of cell culture-adapted strains of FIV. CrFK cells were stably 
transduced with an empty retroviral vector (CON) or a retroviral vector bearing 
either FcaTHN or FcaTHN-WT. Cells were infected with the cell culture-adapted, 
CD134-independent strains of FIV-Fca (F14; A) or FIV-Pco (CoLV; B), and virus 
replication was monitored by RT assay of the supernatant (means [n=2]). 
 
0 1 2 3 4 5 6
0
1
2
3
4 ACON
FcaTHN
FcaTHN-WT
Days post-infection
R
T
 a
c
ti
v
it
y
 (
A
4
0
5
 n
m
)
0 1 2 3 4 5 6
B
Days post-infection
178 
 
5.4 Discussion 
 
In addition to FIV, domestic cats harbour gammaretroviruses such as exogenous 
and endogenous feline leukaemia viruses (FeLVs) or RD114, as well as the 
spumaretrovirus feline foamy virus (FeFV) (Reeves and O'Brien, 1984). Whereas 
FIV is highly prevalent in felids with 21 of the 37 known species of felids 
harbouring antibodies to FIV (VandeWoude and Apetrei, 2006; Troyer et al., 
2008), gammaretroviruses are, with the exception of sporadic cross-species 
transmission events, restricted to domestic cats (Benveniste and Todaro, 1975; 
Reeves and O'Brien, 1984). This suggests that they entered the Felis genus after 
it diverged from the main lineage of the Felidae approximately 6.2 MYA (Johnson 
et al., 2006). The high abundance of different retroviruses in cats necessitates 
the presence of potent and broadly specific anti-retroviral restriction factors. 
However, as discussed in previous chapters, feline TRIM5α is non-functional 
(McEwan et al., 2009) and feline A3 proteins are, at least partially, overcome by 
FIV Vif and FeFV Bet proteins (Lochelt et al., 2005; Munk et al., 2008; Stern et 
al., 2010; Zielonka et al., 2010).  
In this study a homologue of tetherin has been identified in the domestic 
cat genome. Its coding sequence and predicted protein structure shared high 
similarity with known tetherins (Fig. 5-1). For the main part of this work, a 
protein termed FcaTHN with an N-terminus, which resembled that of other 
tetherins, was used. During the course of the project, however, it was 
discovered that wild-type domestic cat tetherin (FcaTHN-WT) most likely 
possesses a shorter cytoplasmic tail than FcaTHN. Consequently, the activities of 
both proteins to limit FIV release in single-cycle replication assays and to block 
FIV spreading infection were compared and were found to be similar. 
Feline tetherin has been shown to be IFN-inducible in different feline cell 
lines, Mya-1 T lymphocytes and primary macrophages (Fig. 5-2). In agreement 
with studies on human tetherin, FcaTHN prevented FIV(VSV-G) and HIV-1(VSV-G) 
pseudotype release from infected cells in a dose-dependent manner (Fig. 5-3).  
Primate lentiviruses have evolved diverse mechanisms to evade the 
antiviral activities of tetherin. Pandemic HIV-1 M strain isolates as well as SIVs of 
Mona monkeys (Cercopithecus mona), mustached monkeys (C. cephus) and 
greater spot-nosed monkeys (C. nictitans) (SIVmon, SIVmus and SIVgsn, 
respectively) encode Vpu proteins with potent anti-tetherin activities 
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(Courgnaud et al., 2003; Neil et al., 2007; Neil et al., 2008; Sauter et al., 2009; 
Yang et al., 2010). In contrast, SIV of chimpanzees (Pan troglodytes; SIVcpz), the 
nearest ancestor of HIV-1, uses Nef to counteract tetherin (Sauter et al., 2009), 
a feature it shares with SIVagm of African green monkeys (Chlorocebus sabaeus), 
SIVmac of rhesus macaques (Macaca mulatta), SIVsmm of sooty mangabeys 
(Cercocebus atys) and SIVsyk of Sykes’ monkeys (Cercopithecus albogularis) (Jia 
et al., 2009; Sauter et al., 2009; Zhang et al., 2009a). Furthermore, HIV-2 and 
SIVagm.Tan (SIV of Tantalus monkeys [Chlorocebus tantalus]) Envs antagonise 
tetherins (Abada et al., 2005; Gupta et al., 2009b; Le Tortorec and Neil, 2009). 
This diversity of tetherin countermeasures points towards an ongoing struggle 
between hosts and lentiviruses. In search of a tetherin antagonist encoded in the 
FIV genome, FIV pseudotypes were produced in the presence of domestic cat 
tetherin (FcaTHN) and either FIV OrfA or FIV Envs (Fig. 5-4) neither of which 
rescued FIV particle release from producer cells.  
In contrast to particle release, tetherin was unable to limit spreading 
infection of cell culture-adapted, CD134-independent strains of FIV (Fig. 5.5 and 
5-14A). Indeed, tetherin expression promoted enhanced syncytium formation in 
CrFK cells by a mechanism that is likely to involve trapped virions on the cell 
surface. Rather than being released into the cell culture supernatant, their 
enrichment on the cell surface may trigger cell-to-cell spread, leading to 
syncytium formation. Interestingly, enhanced syncytium formation was also 
observed upon infection of IFN-treated CrFK cells with the CD134-independent 
F14 strain of FIV-Fca (Fig. 5-6). These data indicate that IFN stimulation 
upregulated tetherin expression favouring cell-to-cell rather than cell-free virus 
transmission and leading to syncytium formation.  
There is evidence that suggests that Vpu-deficient HIV-1 can replicate in 
cell culture with the same kinetics as wild-type virus (Strebel et al., 1989; 
Terwilliger et al., 1989; Klimkait et al., 1990) by shifting from a cell-free to a 
cell-to-cell mode of transmission. As a consequence of this shift, viral replication 
was not inhibited, in direct contrast to the effect of tetherin on viral release. 
Furthermore, it has recently been shown that in T lymphocytes infected with 
Vpu-defective HIV-1, but not wild-type HIV-1, virus envelope glycoproteins 
accumulated on the cell surface due to the action of tetherin, promoting the 
formation of virological synapses (VS) and direct cell-to-cell spread of virions 
(Jolly et al., 2010). Depletion of tetherin using small interfering RNAs (siRNAs) 
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impaired cell-to-cell transmission (Jolly et al., 2010). Strikingly, prior to the 
discovery of tetherin, studies reported an increase in the size of syncytia in 
HeLa-CD4+ cells transfected with HIV-1 devoid of Vpu (Klimkait et al., 1990), 
while enhanced cell-to-cell spread and the formation of giant syncytia in Jurkat 
cells infected with a mutant virus bearing a frameshift in vpu were noted 
(Gummuluru et al., 2000). 
What is the significance of the enhanced syncytium formation seen with 
cell culture-adapted strains of FIV? Cell culture-adapted strains of FIV are similar 
to, and are frequently derived from, CD134-independent strains of FIV that arise 
during chronic infection in vivo. They may be considered to be analogous to the 
X4 strains of HIV-1 that emerge in the later stages of infection. Initially, these 
viruses were thought to be the consequence of cell culture adaptation, a 
selection for adaptation for growth in CD134-negative cell lines such as CrFK. 
Indeed, FIV-Fca Petaluma clones F14 and 34TF10, the prototypic molecular 
clones of FIV, bear mutations in their V3 loops consistent with CrFK adaptation 
and CD134-independent infection. However, it has also been shown that CD134-
independent viral variants of primary isolates of FIV-Fca can arise, either during 
culture in CD134-positive peripheral blood mononuclear cells or in vivo in 
infected cats (Kraase et al., 2010). Thus, it appears that there is selective 
pressure in vivo for the generation of CD134-independent strains of virus. Such 
selective pressure may be exerted either by the humoural immune response 
(Willett et al., 2010) or indeed by tetherin, both of which impact on virus-
receptor interaction and receptor usage. While IFN-induced tetherin expression 
may prevent particle release from infected cells, it may also, as an unintended 
consequence of its antiviral activity, enable efficient viral cell-to-cell spread.  
It is noteworthy that infection of CrFK cells stably expressing FcaTHN with 
the primary, CD134-dependent GL8 strain of FIV-Fca led to a modest viral growth 
delay and a proportionate reduction in the size, but not number of syncytia that 
were formed (Fig. 5-7 and 5-14C). 
How can the discrepancy between enhanced syncytium formation seen 
with F14 and reduced syncytium formation observed with GL8 be explained? It is 
likely that the switch to CD134-independence facilitates a more efficient cell-
cell fusion mediated by use of the abundant co-receptor CXCR4 alone. Assuming 
that CD134-dependent strains of FIV rely more heavily on cell-free transmission 
than CD134-independent strains, it is notable that a mutant of FcaTHN that lacks 
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the N-terminal double tyrosine motif involved in tetherin recycling from the cell 
surface (FcaTHN-Y6/8A) reduced GL8 replication significantly (Fig. 5-14C). 
Deletion of this double tyrosine motif has been shown to increase tetherin 
surface expression (Hauser et al., 2010). It is therefore likely that FcaTHN-Y6/8 
is more effective at inhibiting particle release than FcaTHN, which leads to the 
observed reduction in GL8 growth in FcaTHN-Y6/8-expressing cells.   
In addition to FIV, the ability of tetherin to limit gammaretroviral and 
spumaretroviral release and spread was investigated (Fig. 5-10 and 5-11). 
FcaTHN was able to reduce FeLV-A growth modestly. Moreover, RD114 
replication was completely blocked by tetherin. The high potency of tetherin to 
block RD114 spread may be facilitated by low viral loads or a strong dependence 
of RD114 on cell-free transmission. FeFV release was inhibited and its spreading 
replication in tetherin-expressing cells was reduced in comparison to control 
cells. Although RD114 and FeFV infect cats without causing apparent disease, 
their expression and replication could sequester available tetherin and limit its 
activity against FeLV and FIV, thereby potentially contributing to disease 
progression.   
In order to compare tetherin sequences and antiviral activities within the 
Felidae, lion and puma tetherin homologues were amplified, cloned and 
expressed transiently in single-cycle replication assays or stably for use in 
productive retroviral infection studies. Both tetherins resemble FcaTHN with 
respect to sequence, predicted structure and their ability to restrict viral 
particle release and spread (Fig. 5-12 to 5-14).  
The final part of this study focused on the characterisation of the 5’ 
terminus of domestic cat tetherin. In recent publications, a tetherin cDNA 
encoding for a protein with a shortened N-terminal cytoplasmic tail (see Fig. 5-
15) was identified as the naturally occurring homologue of domestic cat tetherin 
(Fukuma et al., 2011; Celestino et al., 2012). In disagreement with our data, 
Celestino et al. (2012) found that FIV-Fca Petaluma Env is a potent antagonist of 
cat tetherin. To rule out differences in activity and susceptibility to FIV Envs 
between the tetherin used in this study (FcaTHN) and the tetherin used by other 
groups (here called FcaTHN-WT), single-cycle replication assays were repeated 
in the presence or absence of different FIV-Fca Envs (Fig. 5-16). Under our 
experimental conditions we found no evidence of an activity of FIV Envs against 
either FcaTHN or FcaTHN-WT and were thus unable to confirm the key finding of 
182 
 
Celestino and co-workers (Celestino et al., 2012). Interestingly, FcaTHN-WT 
restricted FIV(VSV-G) pseudotype release more potently than FcaTHN. As 
discussed above, deletion of tetherin’s N-terminal double tyrosine motif leads to 
enhanced tetherin surface expression (Hauser et al., 2010) and possibly to a 
more efficient restriction of particle release. However, despite its higher 
activity in single-cycle replication assays, FcaTHN-WT was, like FcaTHN, unable 
to prevent FIV spreading infection of cell culture-adapted, CD134-independent 
strains of FIV (Fig. 5-17). As discussed above, these viruses are capable of cell-
to-cell spread, thereby overcoming the action of tetherin. It can be assumed 
that FcaTHN-WT will behave like the tetherin mutant FcaTHN-Y6/8A in retroviral 
growth assays with primary, CD134-dependent strains of FIV (see Fig. 5-14C,D).  
In this study we showed that felid tetherins inhibit virus release but not 
spreading infection. Thus, there may be other roles for tetherin that do not 
involve the inhibition of viral growth, in particular that of a regulator of innate 
immunity. Tetherin has been identified as a specific marker of type I IFN-
producing cells (IPCs) or plasmacytoid dendritic cells (pDCs) (Blasius et al., 
2006). These cells circulate through the blood and infiltrate lymph nodes that 
drain sites of infection. While they were initially thought to have a primary role 
in immunomodulation resulting from the secretion of large amounts of type I 
interferon, subsequent studies indicated that pDCs were capable of presenting 
antigen to both CD4+ and CD8+ T cells and might have a potential role in antigen 
capture, processing, and presentation to T cells at sites of infection and in 
lymph nodes (reviewed in (Villadangos and Young, 2008)]).  
Viruses trigger Toll-like receptor (TLR) 7/9-induced production of type I 
IFN and proinflammatory cytokines that activate antiviral intrinsic, innate and 
adaptive immune responses (Colonna et al., 2004; Liu, 2005). A chronic 
activation of pDCs and continuous IFN production caused by lentivirus infection 
leads to immune dysregulation, T cell anergy and apoptosis (Tompkins and 
Tompkins, 2008). Tetherin has been shown to interact with the orphan receptor 
immunoglobulin-like transcript 7 (ILT7), which is expressed exclusively on pDCs 
(Cao et al., 2009). This interaction induces a negative feedback loop on the 
production of type I IFN and proinflammatory cytokine production and adjusts 
the magnitude of immune activation upon viral infection (Cao et al., 2009).  
By trapping virions on the cell surface tetherin may mark infected cells 
for destruction by antibody-dependent cellular cytotoxicity. Moreover, virions 
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tethered on the surface of dendritic cells may facilitate interactions with B cells 
bearing compatible surface immunoglobulin. Finally, tetherin is known to target 
virions for endocytosis and degradation, and internalised virions may be 
processed for antigen presentation in conjunction with MHC (Major 
histocompatibility complex) class II to CD4+ T lymphocytes.  
The elucidation of the role of feline tetherin in controlling replication of 
feline retroviruses in vivo and in regulating the antiviral immune response may 
lead to the development of promising new approaches for the prevention and 
treatment of viral infections. 
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 Concluding remarks 6
 
Throughout the course of evolution, lentiviruses have invaded a broad range of 
mammalian species. However, their host spectrum is limited and successful viral 
transmission events are rare, even between closely related host species. Cross-
species transmission is dependent on the compatibility between the virus and 
host factors that are either beneficial for viral replication (viral host dependency 
factors) or that protect the host from viral infection (restriction factors). Thus, 
transmission often requires adaptive changes in the viral genome to occur. 
Newly established lentiviral infections are characterised by high viral virulence 
leading to apparent pathology and rapid genetic diversification of the virus in 
the new host. During prolonged periods of host-virus co-evolution, the host-virus 
relationship eventually becomes balanced resulting in reduced viral virulence 
and/or improved host antiviral immune responses.  
The HIV-1 M (main) group pandemic in the human population started in 
the early 20th century and was caused by a single successful zoonotic 
transmission event of SIVcpz of West African chimpanzees to humans (Gao et al., 
1999; Korber et al., 2000). This transmission was, among others, facilitated by 
molecular and functional changes in the SIV accessory proteins Nef, Vif and Vpu 
(Mangeat et al., 2004; Schrofelbauer et al., 2004; Sauter et al., 2009), known 
restriction factor antagonists. Because of the as yet unbalanced host-virus 
relationship, HIV-1 infection in the susceptible human population leads to a fatal 
immunodeficiency syndrome. In contrast, natural SIV infections of non-human 
primates such as sooty mangabeys, African green monkeys, mandrills, 
chimpanzees and others are mostly benign due to host-virus adaptation (Silvestri 
et al., 2007; Pandrea et al., 2008).   
The non-primate lentivirus FIV infects a wide range of non-domestic felids 
as well as domestic cats. Similar to lentivirus infections in primates, a difference 
in the pathogenicity of FIV infections can be observed between non-domestic 
cats and domestic cats. FIV has been endemic in non-domestic cats such as 
pumas or lions for hundreds of thousand or maybe several million years (Antunes 
et al., 2008; Pecon-Slattery et al., 2008b; Poss et al., 2008; Troyer et al., 2008) 
and infection is not usually associated with disease. However, FIV is a relatively 
recent introduction into domestic cats and infection leads to the development of 
feline AIDS.   
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Restriction factors form part of the mammalian antiviral intrinsic 
immunity, a form of cellular innate immunity that allows for a rapid restriction 
of viral infection and replication. It has been shown that the genes encoding the 
well-known restriction factors TRIM5α, APOBEC3G and tetherin evolve unusually 
fast (Sawyer et al., 2004; Sawyer et al., 2007; McNatt et al., 2009). Their 
diversifying selection is undoubtedly driven by frequent encounters with 
infectious agents such as viruses. Alterations in the specificity and potency of 
restriction factors, in return, necessitate adaptive changes in the virus genome 
to occur in order to ensure sufficiently high levels of viral replication. 
Because of the apparent importance of restriction factors in limiting host 
susceptibility to viral infection and in preventing cross-species transmission 
events we hypothesised that differences in restriction factor activities may 
account for the differential disease outcome seen between FIV infections of non-
domestic and domestic cats. These differences may have arisen as a 
consequence of long-term co-adaptation between non-domestic cat restriction 
factors and FIV restriction factor antagonists on one side and the lack of 
adaptation between restriction factors of domestic cats and their only recently 
acquired lentivirus FIV-Fca on the other side.  
In this study felid restriction factors were characterised and their 
activities against FIV strains of non-domestic and domestic cats were compared.  
As previously shown, feline TRIM5α bears a deletion in its B30.2 (PRY/SPRY) 
domain essential for lentiviral capsid binding and hence does not contribute to 
FIV restriction in felids (McEwan et al., 2009). Here, a synthetic domestic cat 
TRIM5α-cyclophilin A fusion (feTRIMCyp) was generated based on naturally 
occurring simian TRIMCyps. FeTRIMCyp was able to potently restrict FIV(VSV-G) 
pseudotype and FIV productive infection, indicating that the feline TRIM5α RBCC 
(RING-B-box-coiled-coil) domain has indeed retained its functionality in the 
absence of capsid binding.  
No significant differences in the activities of domestic cat, lion and puma 
APOBEC3C (A3C), APOBEC3H (A3H) and APOBEC3CH (A3CH) proteins against 
FIVΔvif(VSV-G) were detected. However, especially feline A3CH proteins differed 
in their susceptibility to FIV Vifs. Whereas cat A3CH was potently counteracted 
by FIV-Fca Vif and FIV-Pco Vif, lion and puma A3CH proteins were largely 
resistant to these FIV Vifs. These differences in the susceptibility of A3 proteins 
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to FIV Vifs may be a result of disparate degrees of host-virus co-adaptation that 
has taken place between domestic or non-domestic cats and FIV.  
Felid tetherins were shown to block FIV(VSV-G) pseudotype particle 
release from transfected cells efficiently. Unexpectedly, they were unable to 
restrict FIV spreading infection. In fact, we found that domestic cat tetherin 
enhanced syncytium formation in CrFK cells upon infection with the cell culture-
adapted, CD134-independent FIV-Fca strain F14. These data indicate that 
tetherins may force lentiviruses to change their mode of replication from cell-
free to cell-to-cell transmission in order to circumvent the block to particle 
release posed by tetherin. As an unintended consequence of restriction, viral 
propagation may thus be facilitated. 
Differences in the feline APOBEC3-FIV Vif interactions seem to offer the 
most likely explanation for the sensitive phenotype of Mya-1 T cells and the 
restrictive phenotype of primary lion T lymphocytes with respect to FIV infection 
described in Section 1.3.4. It has been shown that A3 genes have been evolving 
under diversifying selection since long before the emergence of modern day 
retroviruses (Sawyer et al., 2004; Zhang and Webb, 2004). Here, we compared 
the coding sequences of A3C and A3H isoforms of African lions, in which FIV-Ple 
is endemic, and Asian lions, which are FIV sero-negative. In agreement with the 
ancient origin of cytidine deaminases, we found no evidence to suggest that FIV 
Vif poses a selective pressure on A3 genes. Thus, it appears more likely that 
lentiviral Vif proteins have to adapt to A3 proteins for the virus to be able to 
successfully replicate in a new host species. This adaptation may then lead to 
the observed host species-specificity of lentiviral Vifs (Mariani et al., 2003; 
Hatziioannou et al., 2006). Given that cat, lion and puma A3 proteins were 
equally potent at restricting FIVΔvif infection in single-cycle replication assays 
and that FIV Vif was able to counteract cat A3H and A3CH, but not lion A3 
proteins, it would be justified to propose a scenario in which A3 proteins 
generally possess a high anti-lentiviral activity in the absence of Vif. In contrast, 
Vif proteins may be very potent in a new host but over time adapt to allow some 
degree of restriction to occur. Incomplete neutralisation of A3 antiviral activity 
by Vif may be beneficial for the virus because a low, optimal level of viral 
genome mutation could enable viral escape from host immune defences (Simon 
et al., 2005; Harris, 2008; Jern et al., 2009; Kim et al., 2010). Notably, within 
human and non-human primate populations, some degree of variation exists in 
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A3 coding sequences, activity and expression levels that can modulate natural 
lentivirus infections (Jin et al., 2005; Biasin et al., 2007; Land et al., 2008; 
Ulenga et al., 2008; Zielonka et al., 2010; Cagliani et al., 2011; Compton et al., 
2012). In principle, increased A3 activity and expression correlated with a lower 
viral load and preserved CD4+ T cell numbers, but not necessarily with higher 
levels of A3-mediated hypermutations in proviral sequences in vivo (Jin et al., 
2005; Pace et al., 2006; Land et al., 2008; Mussil et al., 2011; Kourteva et al., 
2012). This indicates that deaminase-independent rather than deaminase-
dependent A3 activities may be responsible for the inverse relationship between 
A3 expression levels and viral loads (Kourteva et al., 2012). 
Conversely, there is natural variation in Vif function in infected 
individuals that can result in partial neutralisation of A3 protein activity, 
thereby promoting viral sequence diversification, or host control of viral 
replication (Alexander et al., 2002; Farrow et al., 2005; Simon et al., 2005). 
Interestingly, inactivating mutations in the form of premature stop codons in the 
Vif coding sequence occur at higher frequencies in individuals with lower viral 
loads (long-term non-progressors or patients receiving anti-retroviral treatment) 
than in patients with high viral loads, where viral replication selects for active 
vif alleles (Simon et al., 2005). Again, these observations point towards a direct 
correlation between A3 activity, viral loads and levels of vif hypermutation. 
There are also polymorphisms in non-hypermutated vif sequences, but these are 
rarely associated with a reduction in Vif function (Pace et al., 2006).  
A recent study has investigated SIVagm.Ver (SIVagm of vervet monkeys 
[Chlorocebus pygerythrus]) vif evolution in individual infected sabaeus monkeys 
(C. sabaeus) harbouring either of two naturally occurring APOBEC3G (A3G) 
variants, Asp130 or Asp130His (Compton et al., 2012). Variant Asp130 was 
sensitive to all SIVagm Vifs, whereas mutant Asp130His was resistant to 
SIVagm.Ver and SIVagm.Tan (Compton et al., 2012). During the course of 
infection an adaptation of SIVagm.Ver to Vif-resistant A3G Asp130His was 
observed. The Vif adaptation enhanced viral infectivity significantly compared to 
an unadapted control. All virus isolates obtained from the sabaeus monkey 
expressing the A3G Asp130His variant shared a common mutation in Vif 
(Tyr46Cys) that is not present in naturally adapted SIVagm.Sab (SIVagm of 
sabaeus monkeys) Vif (Compton et al., 2012). These findings demonstrate that 
Vif evolution is driven by naturally occurring A3 variants. Vif adaptation can take 
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place very rapidly and can occur via different evolutionary routes (Compton et 
al., 2012). Overall, the A3-Vif relationship seems to be delicately balanced and 
may be a crucial determinant of the outcome of lentiviral infections.  
Genome-wide screens have been performed to identify additional host 
factors that act as inhibitors of lentiviral replication. Particular attention has 
been paid to interferon-stimulated genes (ISGs). ISGs are genes whose expression 
is upregulated upon induction of the innate type I interferon response (see 
Section 1.5.1) and whose products exhibit antiviral, anti-proliferative or 
immunomodulatory properties. HIV-1 single-stranded RNA has been shown to 
induce IFN-α production in plasmacytoid dendritic cells (pDCs) (Heil et al., 2004; 
Beignon et al., 2005; Meier et al., 2007) and expression of several hundred ISGs 
in primary human PBMCs and macrophages (Woelk et al., 2004; Solis et al., 2011; 
Berg et al., 2012). However, the validation of ISG product antiviral activity has 
proven difficult due to their high number, their possibly selective expression in 
certain cell types and the fact that they may inhibit viral replication at different 
stages of the viral life cycle. In addition to TRIM5α, APOBEC3 proteins and 
tetherin, ISG products with confirmed anti-HIV-1 activity are IFITM (interferon-
induced transmembrane) proteins, IRF1 (interferon regulatory factor 1), ISG15, 
PKR (protein kinase R) and TRIM22, among others. IFITM proteins interfere with 
HIV-1 cellular entry and affect viral Gag expression (Lu et al., 2011). IRF1 is a 
transcription factor of the interferon pathway that regulates expression of ISGs 
(Schoggins et al., 2011). ISG15 is an ubiquitin-like molecule that inhibits HIV-1 
release by blocking the ubiquitination process that normally enhances HIV-1 Gag-
mediated release of infectious virus (Okumura et al., 2006). PKR reduces HIV-1 
production by suppressing protein translation (Nagai et al., 1997) and TRIM22 
disrupts Gag assembly (Barr et al., 2008). The apparent wealth of (potentially 
yet undiscovered) ISGs with antiviral function raises the possibility that 
restriction factors other than APOBEC3 proteins are, at least in part, responsible 
for the inability of FIV to infect lion T lymphocytes.  
So far, this study has taken into account two explanations for the 
observed difference in disease outcome following FIV infection of domestic and 
non-domestic cats, namely higher antiviral activities of non-domestic cat 
restriction factors compared to domestic cat restriction factors and reduced 
pathogenicity of non-domestic cat FIVs compared to FIV-Fca, both a 
consequence of prolonged periods of host-virus co-evolution in wild cats.  
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An intriguing third possible explanation has emerged in recent years and 
looks at differences in overall levels of immune activation between host species 
in which lentiviral infection is pathogenic and those in which it is non-
pathogenic. A feature that distinguishes pathogenic lentiviral infections (HIV-1 
infection of humans and FIV infection of domestic cats) from benign lentiviral 
infections (SIV infection of non-human primates) is the high level of chronic 
immune activation, which is positively associated with disease progression 
(Giorgi et al., 1999; Sousa et al., 2002; Silvestri, 2005). In contrast, limited 
immune activation, in particular during chronic stages of infection, seems to be 
the key factor protecting natural SIV hosts from simian AIDS (Silvestri, 2005). 
The immune dysfunction seen in HIV-1 infected patients and FIV-infected 
cats comprises cytokine dysregulation (Clerici and Shearer, 1993), immunologic 
anergy and increased apoptosis of CD4+ T lymphocytes (Miedema, 1992), and 
inappropriate activation of immune regulatory cells (Ascher and Sheppard, 1990) 
(see Section 1.2.3). Because the high state of T cell activation is associated with 
enhanced levels of viral replication, viral loads are usually high in treatment-
naïve patients and an indicator for progression to AIDS. Exceptions are long-term 
non-progressors who show low levels of immune activation, preserved numbers 
of CD4+ T cells and can control viral replication (Silvestri et al., 2007). Immune 
activation also induces ISGs and leads to the expression of high levels of 
restriction factors. However, high-level ISG transcription is positively correlated 
with viral burden (Sedaghat et al., 2008; Rotger et al., 2010), indicating that 
restriction factors cannot prevent viral replication in vivo. Notably, elevated 
tetherin expression in untreated patients was reported to contribute to disease 
progression (Mous et al., 2012). In agreement with our findings, tetherin was 
unable to control viral replication by cell-to-cell spread (Coleman et al., 2011). 
Indeed, accumulation of tethered virus particles on the cell surface may also 
enhance levels of immune activation (Tokarev et al., 2009). 
Curiously, in natural, non-pathogenic lentiviral infections (SIV infections 
of sooty mangabeys [SIVsmm] and African green monkeys [SIVagm]) the levels of 
viral replication and CD4+ T cell depletion during acute infection are similar to 
that of HIV-1 infection of humans (Gordon et al., 2007; Pandrea et al., 2007). In 
fact, one study reported that 10-15% of SIV-infected sooty mangabeys showed 
significant T cell depletion, but these animals remained completely 
asymptomatic for more than five years (Milush et al., 2007). In addition, 
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humoural and cellular immune responses are either similar or weaker in natural 
SIV infections (that excludes experimental infection of rhesus macaques with 
SIVmac) compared to pathogenic lentiviral infections (Hirsch, 2004; Dunham et 
al., 2006). However, T lymphocyte proliferation and turnover rates are normal, 
immune cell functions are preserved and levels of pro-inflammatory cytokines 
are not elevated (Kirchhoff, 2009). Thus, despite high viral loads and some 
degree of CD4+ T cell loss, simian SIV hosts can prevent immune hyperactivation 
and its deleterious effects. It is important to note that type I interferon 
production was shown to be transiently induced in pDCs from sooty mangabeys 
and African green monkeys during early stages of infection (Diop et al., 2008). 
However, this interferon response quickly diminished and T cell activation levels 
and expression levels of ISGs returned to normal (Bosinger et al., 2009; 
Jacquelin et al., 2009). 
FIV replicates to high titres in domestic cats and elevated viral loads are 
associated with progression to feline AIDS (Diehl et al., 1996; Goto et al., 2002). 
FIV-Pco proviral and plasma viral loads in naturally infected pumas were 
reported to be comparable to FIV-Fca viral loads in domestic cats (Blake et al., 
2006). These findings indicate that the benign nature of FIV infection in pumas is 
not due to an efficient control of virus replication (Blake et al., 2006). Moreover, 
CD4+ T cell depletion occurred in a proportion of FIV–infected lions and pumas, 
but was not associated with severe clinical disease (Roelke et al., 2006).  
Immune activation is not only dependent on host factors but is also 
influenced by viral determinants. Specifically, the ability of viruses to reduce 
the level of T cell activation and depletion and to suppress innate immune 
responses may help the host to prevent chronic immune hyperactivation.  
In this regard, the differential expression and activity of the two lentiviral 
proteins Vpu and Nef in HIV-1 and SIVsmm/SIVagm are of particular importance.  
As discussed in Section 1.5.6.3, HIV-1 belongs to a primate lentiviral lineage that 
has acquired vpu (Cohen et al., 1988; Courgnaud et al., 2003; Sauter et al., 
2009) in addition to nef, which is present in all primate lentiviral lineages 
(Sauter et al., 2009). SIVsmm, SIVagm and other non-human primate lentiviruses 
use Nef to counteract tetherin (Jia et al., 2009; Sauter et al., 2009; Zhang et 
al., 2009a). The switch of pandemic HIV-1 group M strain from Nef to Vpu to 
antagonise tetherin was most likely forced by a deletion in the cytoplasmic 
domain of human tetherin that has been shown to confer resistance to Nef 
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(Sauter et al., 2009; Zhang et al., 2009a). In primate lentiviruses that do not 
encode vpu, Nef is multifunctional and acts as a regulator of host immune 
activation (Arien and Verhasselt, 2008; Kirchhoff et al., 2008; Kirchhoff, 2009). 
It down-regulates CD3, a component of the T cell receptor (TCR) complex 
(Schindler et al., 2006). This blocks activation, migration and apoptosis of 
infected T lymphocytes, and prevents formation of the immunological synapse 
between infected CD4+ T lymphocytes and DCs or macrophages (Kirchhoff, 2009). 
Additionally, it reduces cell surface expression of CD4, CD28 and CXCR4 (T cell 
surface glycoproteins involved in T cell activation, the induction of cell 
proliferation and cytokine production), and down-modulates major 
histocompatibility complex class I (MHC I) (Bell et al., 2001; Swigut et al., 2001; 
Schindler et al., 2006; Kirchhoff, 2009). 
The presence of a functional Nef is not always sufficient to prevent 
chronic immune activation. Whereas SIVsmm is non-pathogenic in sooty 
mangabeys, it is highly virulent in rhesus macaques (Silvestri, 2005). Hence it 
seems that the lack of host adaptation to a virus results in disease progression. 
In HIV-1 the acquisition of vpu has resulted in the loss of the protective function 
of Nef. In fact, HIV-1 Nef is a virulence factor (Kirchhoff et al., 1995) because it 
increases the responsiveness of infected T lymphocytes to TCR-mediated 
stimulation and enables effective viral transcription and production (Schrager 
and Marsh, 1999; Wang et al., 2000; Fortin et al., 2004; Fenard et al., 2005). 
These data indicate that lentiviruses play an important role in the 
regulation of host immune responses. Although FIVs neither encode for vpu nor 
nef, there are differences in the levels of immune activation that FIVs of 
domestic and non-domestic cats trigger in their respective hosts. What causes 
these differences is incompletely understood and requires further investigation. 
Overall, the clinical outcome of lentiviral infections appears to be determined 
by a complex interplay between host and viral factors.  
The observation that in natural SIV hosts efficient viral replication and 
depletion of infected CD4+ T lymphocytes generally does not correlate with a 
negative disease outcome poses a serious challenge to any vaccine development 
efforts that aim at controlling viral replication. It seems that the disease 
outcome of newly established lentivirus infections is rather related to the nature 
and magnitude of the host response to infection (Silvestri et al., 2007). 
However, if viral replication was blocked early in infection, induction of chronic 
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immune hyperactivation could be prevented. Further research should thus focus 
on the development or improvement of therapies that avert immune 
hyperactivation and progression to immunodeficiency. 
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APPENDIX 1 List of Primers 
 
Primer name Primer sequence (5‘-3‘) 
Chapter 3  
feT5a-1 GCGGATCCATGGCTTCTGAACTCCTGAAAT 
feT5a-2 CACGATGGGGTTGACCATTTTTTTAAAGGCTTGTATTAT 
fCypA R69 5’ Nde AACATATGGTCAACCCCATCGTG 
feCypA 3’ Mlu AAACGCGTTTAGATTTGTCCACAGTCA 
feCypA-1 ATAATACAAGCCTTTAAAAAAATGGTCAACCCCATCGTG 
feCypA-2 GCGTCGACTTAGATTTGTCCACAGTCAGC 
feCD134-Fwd TTGGATCCAGGATGAGGGTGGTTGTGGGGGCT 
feCD134-Rev AAGAATTCTCAGATCTTGGCCAGGGTGGAGT 
Chapter 4  
FeA3Ca F 
ACTGGTCGACACCATGGAGCCCTGGCGCCCCAGCCCAAGAA
ACCCAATGG 
FeA3Ca R ACAGCGGCCGCTCACCTAAGGATTTCTTGAAGCTCTGCAGCC 
FeA3H F ACTGGTCGACACCATGAATCCACTACAGGAAGTCATATTC 
FeA3H R ACAGCGGCCGCTCATTCAAGTTTCAAATTTCTGAAGTCATTC 
LiA3C1 F 
ACTGGTCGACACCATGGAGCCCTGGCGCCCCAGCCCAAGAA
ACCCAATGC 
LiA3C1 R ACAGCGGCCGCTCACCTAAGGATTTCTTGAAGCTCTGCAGCC 
LiA3H F ACTGGTCGACACCATGAATCCACTACAAGAAGACATATTC 
LiA3H R ACAGCGGCCGCTCATTCAAGTTTCAAATTTCTGAAATCATTC 
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LiA3C2 F 
ACTGGTCGACACCATGGAGCCCTGGCGCCCCAGCCCAAGAA
ACCCAATGG 
LiA3C-Ex1-Fwd ATGGAGCCCTGGCGCCCCA 
LiA3C-Ex2-Rev CCGAAAAACTCCCCAGTCGCTGTCATT 
LiA3C-Ex2-Fwd-1 CCTTCCATTTCCAGTTTCCA 
LiA3C-Ex3-Rev-1 GTCACGGAACCAAAAGAGGA 
LiA3C-Ex2-Fwd-2 TGGGCGGAAACTCTGTTATC 
LiA3C-Ex3-Rev-2 ACGGATACTGGTTACGGAAC 
LiA3C-Ex3-Rev-3 TATTCATCACGGCATGGATAC 
LiA3C-Ex3-Rev-4 TCCTCATCACGGTACGGATAC 
LiA3C-Ex3-Fwd-1 GTATCCATGCCGTGATGAATA 
LiA3C-Ex1-Rev-1 TGGGGCGCCAGGGCTCCAT 
LiA3C-Ex3-Fwd-2 GTATCCGTACCGTGATGAGGA 
GL8 Vif F ACTGGTCGACACCATGAGTGACGAAGATTGGCAGG 
GL8 Vif Rev HA 
ACAGCGGCCGCTCAAGCGTAATCTGGAACATCGTATGGGTA
TAGTTTTCCCGACCATAACAG 
LLV-E Vif F ACTGGTCGACACCATGAGTGGTGAAGATATAAGTCAGG 
LLV-E Vif Rev HA 
ACAGCGGCCGCTCAAGCGTAATCTGGAACATCGTATGGGTA
GCCACCTTTCCCTATTAAATATAG 
PLV Vif F ACTGGTCGACACCATGGCTTCAATCAGACAGACAGAACAG 
PLV Vif Rev HA 
ACAGCGGCCGCCTCAAGCGTAATCTGGAACATCGTATGGGT
AGAATGATAATGTTAAATCCATCCA 
FIV-Oma Vif F 
ACTGGTCGACACCATGAGTGGTGAAGAGGATTGGCAGGTAA
G 
Oma3 Vif Rev HA 
ACAGCGGCCGCTCAAGCGTAATCTGGAACATCGTATGGGTA
ACTCTTCATCCGATATAACACTTCATAGGGTACA 
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GL8Mya Vif-Fwd ACTGGTCGACATTGGCAGGTAAGTAGAAGACT 
GL8Mya Vif-Rev ACATGATCAGTGGGATTTGTAATGGGTCTGTAC 
GL8MyaVifSeq-Fwd GTGTCTTAGGAACTCACCTCCA 
GL8MyaVifSeq-F_1 TGAGACTATAACAGGACCATTAG 
GL8MyaVifSeq-Rev ATCTCTAGTATGAAAGCTCCAT 
GL8MVifMut-Fwd CCTGAAGGGGATGAGTGATCGACATTGGCAGGTAAGTAG 
GL8MVifMut-Rev CTACTTACCTGCCAATGTCGATCACTCATCCCCTTCAGG 
qPCR-FcA3C-Fwd GGACAGGATAGATCCTAACACC 
qPCR-FcA3C-Rev CCACTTGGAAGCAGAGATAAC 
qPCR-FeA3C-Pro FAM-TTCCACTTTCCAAACCTGCTCTATGCTTCT-TAMRA 
qPCR-FeA3H-Fwd CAAGATCAAGGCACTGACGC 
qPCR-FeLiA3H-Rev ACAAACGCAACCAGTTCC 
qPCR-FeLiA3H-Pr FAM-CGAAATCATCTGCTATATCACATGGAGCCCCT-TAMRA 
qPCR-FcA3CH-Fwd TCCTGGCTGCAAAGCTTCAAG 
qPCR-FcA3CH-Rev TCTGGGCAAGAGGAAGGAAACC 
qPCR-FeLiA3CH-P 
FAM-CAGGAGGTGACAGAGCCTGGGATAAACACCAGA-
TAMRA 
qPCR-LiA3C-Fwd GATCCTAAGACCTTCCATTTCC 
qPCR-LiA3C-Rev ACCTTGTTCCGAAAAACTCC 
qPCR-LiA3C-Pro FAM-GTTTCCAAACCTGCGCTACGCTTCT-TAMRA 
qPCR-LiA3H-Fwd CAAGATCAAGTCACTGACGC 
rDNA 343F cat CCATTCGAACGTCTGCCCTA 
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rDNA 409 R TCACCCGTGGTCACCATG 
rDNA 370P cat FAM-CGATGGTAGTCGCCGTGCCTA-TAMRA 
12S-UP-F AAAAAGCTTCAAACTGGGATTAGATACCCCACTAT 
PAN-16S-Cy-R CAGAACTCAGATCACGTAG 
L12S-Cy-F CTTAAGTGACTAGCCCCTA 
Chapter 5  
FcTHN-Fwd-2 ATCGGTCGACACCATGGCACCTGCTTTTTTACCAC 
FcTHN-Rev-1 ACAGCGGCCGCTCAGGCCAGCAGAGCAACGAA 
HuTHN-Fwd-1 ACTGGTCGACACCATGGCATCTACTTCGTAT 
HuTHN-Rev-1 ACAGCGGCCGCTCACTGCAGCAGAGCGCTG 
FcTHN-SP1 GAAGCCAACAGGGTTACCAA 
FcTHN-SP2 GACACCGTGACACTCCTCCT 
FcTHN-delCT-Fwd ACTGGTCGACACCATGGTGCCAGGTCGGAGTCTT 
FcTHN-Y8A-Fwd GCACCTGCTTTTTACCACGCGTGGCCTGTGCCCAGGAC 
FcTHN-Y8A-Rev GTCCTGGGCACAGGCCACGCGTGGTAAAAAGCAGGTGC 
FcTHN-Y6/8A-Fwd GCACCTGCTTTTGCGCACGCGTGGCCTGTGCCCAGGAC 
FcTHN-Y6/8A-Rev GTCCTGGGCACAGGCCACGCGTGCGCAAAAGCAGGTGC 
FcTHN-Fwd-3 ATCGGCGGCCGCATGGCACCTGCTTTTTACCAC 
FcTHN-HA-Rev-1 
ACGTAGTCTGGGACGTCGTATGGGTATTCCTTTTTCTTGCTC
GAG 
FcTHN-HA-Fwd-1 
TACCCATACGACGTCCCAGACTACGTCGTCGCGTCTGCCAGC
TCCTTGA 
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FcTHN-Rev-2 ACAGGATCCTCAGGCCAGCAGAGCAACGAAG 
qPCR-FcTHN-Fwd GAGAAGGCCCAGAGCCAGGAG 
qPCR-FcTHN-Rev GCAACGAAGGCCAGGAGCAG 
qPCR-FcTHN-Pro 
FAM-TGCAGAACGCTTCGGTGGAGGTGGAAAGACTGAGAAA-
TAMRA 
rDNA 343F cat CCATTCGAACGTCTGCCCTA 
rDNA 409 R TCACCCGTGGTCACCATG 
rDNA 370Pcat FAM-CGATGGTAGTCGCCGTGCCTA-TAMRA 
GL8 orf2 Fwd ACTGGTCGACACCATGGAAGAAATAATAGTATTATTC 
GL8 orf2 Rev ACAGCGGCCGCCTAAGCAGTACGATGGATAATGTA 
GL8 Env-Fwd ACTGGTCGACACCATGAATGAAGAAGGGCCACTA 
GL8 Env-Rev ACAGCGGCCGCTCATTCCTCCTCTTTTTCAGA 
PET Env-Fwd ACTGGTCGACACCATGGCAGAAGGATTTGCAGCCA 
LLV-E Env-Fwd ACTGGTCGACACCATGGCAGAAGGAGGAAGAGTA 
LLV-E Env-Rev ACAGCGGCCGCTTAGGTATTAGACTCATCATTCAC 
LLV-B Env-Fwd ACTGGTCGACACCATGGCGGAAGGAGGAAGAGTA 
LLV-B Env-Rev ACAGCGGCCGCTCAAAGATCCTCATCAGACTCCCT 
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APPENDIX 2: List of Buffers and Solutions 
 
 
 
 
  
Name Composition 
CHAPS lysis buffer 
30 mM Tris-HCl, 150 mM NaCl, 1% CHAPS (w/v), pH 
7.5 
DNA loading dye (6x) 
30% glycerol (v/v), 0.25% bromophenol blue (w/v), 
0.25% xylene cyanol FF (w/v) 
LB agar 
10% Bacto-Tryptone (w/v), 5% yeast extract (w/v), 
85 mM NaCl, 1.5% (w/v) agar, pH 7.5 
LB broth 
10% Bacto-Tryptone (w/v), 5% yeast extract (w/v), 
85 mM NaCl, pH 7.5 
PBS 
137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4 
PBS-BSA-azide 
137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 2 mM 
KH2PO4, 1% bovine serum albumin (w/v), 0.1% 
sodium azide (w/v), pH 7.4 
SDS-PAGE loading dye 
0.25 M Tris-HCl, 2.5% SDS (w/v), 10% glycerol (v/v), 
1% β-mercaptoethanol (v/v), 0.02% bromophenol 
blue, pH 6.8 
TBE buffer (10x) 890 mM Tris base, 890 mM Boric acid, 2mM EDTA 
TE 10 mM Tris-HCl, 0.1 mM EDTA, pH 7.6 
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